var title_f25_40_26240="Hands in acromegaly PI";
var content_f25_40_26240=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PI%2F79214&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PI%2F79214&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Hands in acromegaly",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 232px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCADoAWgDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwDqPKOBv5HP4U6G3+T5R8w6Z6flVhA2N0nAPIJHP5VZTbxnPTqeRX1B4NyqIX464Pf9KUwxhVyDvHX0rQWNtydSWOV78+1LJEFBJJ35INCYrldLfLAj5kxjIqeO3BJD4x6+lSwx4bKk57+o/wAasqhdsnAH+eM9qdyWytHCu8qc564xUix7X5BB7elT+UuBtPHbAp5SSPpt29AxGR/+ui4iq0A2/dXKjBHapVhJYMrZO0ZAGBUzQgKWcLwc85z+VSxxqAMcEn8qTkAyOE4G44GcHIpTEoYh87cYz6fWrOzKZJOF9sHp3pcJtynIP51nzgVvIYYP4cU5odq5PUcZHarGGKgjcFHHHvT9hRzvGW9Oxpc7ArCFSAGwMdQOh/8Ar09LdUK88Y3AD0z61OsSsw24Bxndjj8amjhBO75OOgB61DqDK6oVOexPXGPyqyiqEABKt/dI5/CnqCN4Awc8j29Kd5eQC64IPPcVm5XAaFwGC4yeoz1wP1poDkKszbxjuP5VYMTNgpyACAO+KekTKDnBj9PXpUcyAqFQq4VmPQZxz7//AK6eLR/MGAd2D0POBVpgoV+cdCrDnb9aGjO3lsr97Oe9LnYEbLtAEqbmycGo3BcHjAB5UngfU/4VZnKSR4BZgGHOcY/+tUMjJIQB8g7AdAMUosCGKHDEowJHTH+FP81mUnAAHJGKk2eXySHcdh0FOQySAu7gqxIOBkHj9f8A9dNu+oFb5Q3Xn1HPPuaidCoLREsqg4z1FXHEeAW+Qknp0qGZw6sqKAoyc1UWBnkfPvkJ+bI9/rUYRc4IJHU981ZdWWQjBII5GeKjZ8t8igrjgKOv4VumIjaEl+o9Pmbj6VDcnbH8uN5OFqSVhuYkcn169aYCA6n7yxngMeATWiuBGE2qFOcA9cfepnlgKSMBmOQN2RU7y/w7wozk+5/rUMgHY8n+LHJqk2BV8lmwq5UjoOnHamzKmzBAdxjPp+NTneHKZIUY56A/j+FRbtjdPmxkcY/DHpWiArsI2zk7OuB2H4UjRKoLbtxPHHan7dxLE7TjGe3akKxiFdhHHUkcVQFVoyXYD5j6fy5qrJ1IdckHt1zV14iBg9Pr1565qpPtZtowf4ic8f8A16Y0QSDfgscIOM9qjYKQRGTjGAB1NWmjBx8wBqNljHyr8zEdh0HvQMrES4OR064FVHIXcpz/AI8VdmYn3HT24rOnmVXyy7ieg78CpZSKc43AkcEDFFRXM+9V5UL3HriioZojt4UwAxOR6dc+tWI0TPA+bsMVDHGw5Dde4PNWFI3DauQPfANSZMkKs2ABg/1qUBujxlj2aljTccrkkcgH+lTxIRkdumDRckrxjy87CwPTPepYcgENwAM/WpEjUsRkjP8AEKUREAsWAx/FngCi4ChBlstgH34p2GIx0XI/CpbWa2ucxxzwvJ1IRxkj0qS7HlWc8iAKyRM4HowBNZynbcLO5yGueL1tLmS30uza/uYTiVycRqeuPc1V0zxzIcHU7LyYhw7xAhk7ZIPUfSs7wMI7jSIJHYM8inew67s8n88mrvxBi/svRreGzZG1K9/dxoByueNx9u9cEsXO+iVj1lg4KNjvYNsiLNBIskbgOGU5DA9CPwqUAbD8p47jvxXFfDS7liS50K/bMsA82I+qHgqPYNz+Nd+OOQoPrnt9a6FUU0pLqebUpunJxZAAzJ0AX16U77gbJPHJz/SnOilyTlT39PwpZPKgieeV0jROSzthVHuaLmYfKy4UBFzk0bPmGHBOcc9/pVWx1fTL6byLTULOeQ/N5Sycn/GtGRVAOF5B4XpilK8XZqw2mtxIt2MKQST+frzUqhCgKng9D/gKiETsFKkgcfjVhBl28wdDyQMVlJiBclmEQwcD60gJxkZwSTgdKftAG1eeMg9gc0eWy8KRkdTU3GI0qkbcYbvjqOajdCrgbht6k5/nUrEhd4wrnimmNSVBbIJzg9qE7ANcqMDb0H3iP8impG0udw+UjIYDHepGDKWxymBjPIpCzH/WMQuMgAYz/jTv2EMRUUHa+9xkgH7v40yNpSclWyOc9Mc//rp42uvzAhc5WolMpkCx7sNluOB71SAWZlAG4ZcYyy9wPX0qvKQUbbkeg7DpUzNGOh3AHnIwM+gFQsokY/e+Ucntzn/P4VcdAIsIpVscjPy9zULMcsXZdp4JXipZBtRc7SAPu+/rnvVYK2Mdz1yPatorqIaAoYZlPsB3FMYAN0ODwM9fyqTAZjt3huhC/wAye1MMbKD3A55rVAR+YNuXweec/wAqGkVRnac5+83Qf401osDOMjGcZ5/KmAc/vNy49eoq7IBm5Wfg8rxgtUDykMfuEgd6kMIDKSCwprYwRtBIGRk9fpVqwFZPmkLyMec4XH9KfKVc4JOQemeDSyEK4MgXnJ3A844qI7ckKcgYG71qkBXYFiQBkgdSfWoeA+FX8+v0qVlwrEHMh689BSBtjfN83HU0xieWCDkhRjPPTFRzoiJlD85HPp9KHbIJdh0+7jgmo7oqwbbkN096GCKMqtnDZXHOSeKo3jLjIG4D/wDVV2YOVbhio454AH9aoMPnLgZI4BPcfSobNEUGAlbrjjr2FFTvGfKzwoxtGelFRYtHbCMBiS3Az2/Dp+FWYm8s5I4P96qiMDyzZOcg/wB72qypdcgjKgcD1oMi4oEmD9weueKnVPlB79MZ5qojGQgHAHfHYVaiTZt2kbj2zSZJKvPCxqfQZ5rzvXtTn8Qa1c6faXDw6dbOI22dXbua9ELlI5HZSXRGO7p2NeVaIktvqUV1bp5i3CjzVzyDknP61xYqq4JJO1+p3YGmpSbfQ2L3w2bazE1nczRSgZRj1rpvBuuP4h8MXn2vBvbTzLadh0b5SQ2PfkfUUeLrq/n0azh0y0jVjHgtIwyD3NYvw3sjpWr3Omu24XNk0kh/vSBuT+TGuSnVal7Nu9/wOrFUk6fMuhzfhXT7pLWH7PcGOKX95tx0JAziuzh0dZbhbu6JmuSP9Y5yRxj8KxPDMirp1uhyGjQAnvkcEfpXQrNI0RZPlHcZ6VzNvls3od0Y3M8BbHxnpM33BJKbeQg9Vcf4ha9LCbAQBjYOh59q8i1suLzTySci6iIb/gYr2ARmN25zn3yCK6cPK8LeZ5OYRtUT8hixbwpwQSevXJ+leeaxdjxF4qudKXB0/TCI3TPDzEZZm9cdBXo00xhtprlgEESNIc9BgZrxTw1ZTzajNfxXMkM1yTLIFXIJJ706tVwVu5OCpKUnJ9Db13whFLZtd20XltB8wmi4KHtyK3/h14hk1Wyez1B2e9hjEgkJ/wBYnTJ91P6GqurRXV3ppsYb+VI3wJdke0uO65rH07ydB8WaRJD8tuW+zOuf4WGOfxqKVTlfItU/zOvE0OaDdtj1ZISBlWBGcbgenNPAUrl+T3Hp06U1Y9gIjztUkE4qSOIRhgfvd8/Q1q2eOMAUlBnBHXPRqkEZEgJOCD2+tK+1jhU65we2f6U1FJJ2nIXtnv1/pSuAp2jLeWGz17YPtTBGSu7PIzwakA2qxPGOT6nmkl3YUnABPPtSTAQjKsuO/TPGfeoy2QC2G45HtUqIdu0HI5+bpSqu/DKCE75p3SArq0KkNznsD2FVjnfnJycgDPH4ValWPLfMxUDkdMf41WdNzsFOR1JJ6DPf0rWIiF5MMyyLkgZH/wBb3pDITvP3VHGO1K20rtbDDHJY9PxpiSxznCNGzDjCEcetapBYikUtgAjPoeKrzssUU0k0m2OFS8hHG0AZJrTXywFGN7Yx+lc/8Qcp4U1EkFQ3lqRnHVxR7TlVyoR5pKPc89vfEGpa5dzw6bJJBEhxwdqop6Z7lvbtTraHXtMUTwajNJs/5Zy8o/qMdvrVLRZ59H1mSa7tPPs7hi+9F5Qn29K3tf8AEVhHZicTBhnBjA+bJ9q5IV6tT34y0/D7j2lRgo8tjp9A1KHXdLi1C1Vk3ExyR9fKcdVJ/l7Ve8nDP8hB6YNeefCC+mj1DUrScbFvS91GjcYI/wDrV6dNIcp9xU9B/jXfSre0ipLqePWp+zm4mU0TIoXbgcbT1wKruvGV5PIyRVbxhrseh2iOV3zyttiX17E/qPzrkmvPEk+J0u44cj7jAfkRWk8TTp6TZdLDTqq6O0WEO5PA55J6f/XphVNgPPA5LDr7e1c/4c8TTT6gun68iQ3MmfJnQ4WQ/wB32OK6kojcc8c1vCcZrmi7oyqU5U3aRnpCu0bztXBAApGGCCCDsHU1aaAKxAx1wDULD5mG05APXvzVkFacBmPG3nqRUExVcAfePcirdwmDh8Bj071XmQEjDFSOMk5//VTGjPmBkXOWz3B7VSlJBAK5Yc9emK05IghZmOwH05NV5SXZmAVcDAz1qWWjMkUh39eeO9FWpEUHaTj1oqbMdzpoxGVIHbHb+X51aiYRqwU/e5I68VV8ojLFsuT+H5VYjVicIc88AjmoJLUZSRAp+UAY46CrSIgXJfI/pXO33iPS9OuBaXExe4U5eGIbmT646Vs6PfafqkMjWcyNjBMbcMv1FJuxTpySvbQuT/8AHpNhMnyn6jttNeceGvKNvG0hAYAYNepxqd7KVI3Dbx0ORivGrIG2nlhc7fKkZCPoxFeZjHsd+XbyR6bDNDPBGPlDKOMVi2s0dt440lskJKZIWPplT/hUOncxKqAgZ569M0phUeMNALcKbnr77W5rkjL94vU9GvFOlL0ZU0yLybi6ixyk8iY/4Gf6V0trb4iY7wWA6AZrERTHr+qQDJAvH5P4Guos1zEoRgR1yKiatoh0neKZx3iWE2z21w4ykdxE5z0wHFeuJIiyEIPlY5znk/8A1q838ZwGXSpwg+coSPr2rvPD9yt9oWn3UXPm28bn1BIGa1w7XK1/X9aHnZjHWMiHxZI0HhTVMj7ts446jjFcH4biIs0jgOyTYvzkZHSu88WxM/hbVVY8eQ5Jb865zwjbg6fC7JncgbcPpU1nqrF5dbkkW5ooRF87AnOSR6+tcH4wYRXluVIJWZGGP94V6Tf2h8jIGFOcelec6patdeI9Lt05L3UakH03DNRDSS9TtqtezbPZpEaQnOAoOPw74oXeMA4KgjPOcfjVggM2c+4BpAqqzHcCTwf1rp5j52wxR5kWVQruFKIsOT3FPUdvfOB2o+UoAD8vtSuFhcncQBnHHPWoWxtOfvDoKmGWIwcY6cZoZRg7sjsSKE7BYQKC4K9ccDH51GVLhhITsHU/0qfcMALz2puxi5JY5/SkmFijNGHbj7pGCCfeoJ7YBhuKjPBDHHHr71oyEoqkIobHJPasfxPIbTRdTmZv3q27snH3SQQPpzW0JsFG7seeard3XizVn0/T3lj0u2Hzuh2tKeeSewODgegqOTw/b2MHmWxktpVBYSxsdwPY+9U7ayvLFoLnTWBIjWOSJjgOoOQfqMn86fruu6ndWbQwWIWQkgkHgelc8sTKXvKVrdL2Pdp0Iwjy2O38Baz/AG/pkyXTIdTsHMFz5YwG4+VwO24c/nTviLZ7vB2osRkpsl3Z64cf4mvMfhnPc+GvGlr9vkzHqbG3uCf7xGUP5jH417f4g0wajo+o2YGGmgdF54JIJH61p7b2sOZdf6/4PzPMrUvY1l23PNbOOGWwRiRyo61Qu9Ph3ZEag9elVtAleXTYNx5A2n69K2rmFmjj2jIYck9K4FJPc9/kVrnKx3I0bxBpt+uQIp1Dj/ZJwR+Vex3KBSR5e5FbKr2x1BrxjxbZmSxndMhlUsPbFez6PM95oGnXIwfOtopGLHvsGf616OFqaNdjxcxglKMjy74mRvNrtosCF2t4kn2e3mZIH4Cui0ltN1DR2MTR+dkfKeGGO1VvFiK3j2AR5ANmp5/32rQk0YRxNKI495XOdozWVSX72Tkjswq/cxseX+LsS6pax23LQOZWYfwsB8vP15r1jTpvtumWl2u1RPCsn5jp+dcBrVqFLkBQM54GK634c3S3HhKCF8k2sr25I9ASR+hFdWCqO8kcuYQ0UjUkjAxlcDp0qAhhIEHUnA4ya0pY1VCxYcHAGTnpWe7SEnaxGcjGPf1r1YyueWVmxj5iSx7A8j3qo6q3AwPY9/xqxNLknzFz6kdaglkL4VQFQHBA+nerGVZbYlh3I4GTy1V1Uluoxz+HNWnTO4jGR0FMKyYOT93k4GTSZRSfaygOwXnPA60VIkJJ54I7k0UrDubzS3EUuWtw8fco/wAw/wBojHP4VJrVx9h0y8vfuNBCzqPVugH5kVdhXaM7QR6Z6elZPjdseGL4KNqsUTB5Jy4P9DWE5OMWxwXNJIwfBunCe183GZZAXY45Y98ms22vX0jxbPcQx7Y4AhlHYgnDDH05rp/AFiLWAJvlcFSu3dima1oSJ9rfbjzMhj1zXhOTg1OO57/IpLla0O4Td+7aE5jkwUPY968uFsW1/UwRl1uXyCK73wdJJe+HLCaQ7njHlHJ5JU4rlhEyeK9WUjBFyTz7gV2YlqUVY87BLlqyTNvTbUCNA0YWTGcDqeaqa8q22raNcNlVjvI8n2J2/wBa6GwUsu8AHYO/1rK8c24l0C4li+9H86n0I5B/SuL4ZKR6cvfi49zIuJkg8Vaqnb7UffoozW9Z38MQESABF6EdFz/WvP8AUr43uoz30J2faXMynuNw/wAK09MvCI44GZ5GPzYwBSqSV2goxtFJ9jrNcWOaxYqchhxWn8MH+0eELOMMGe2Z7dgeCNrHv+Vc8lyZISjqQORgnPNaHwlnP2bXLZf+Wd7uUH/aQf4Gig7SaOfMIfu0/M6Txk5h8K6rJKcBbZ16dzxWF4VB/smCP7vyLn16Vc+I8z/2CLNMbru4SI5P8I+Y/wAqytNnl4jiXgDHDYqqj95EYCNqbfdnVXsatZbXLbT+FeeXUSweOdCZOA10p575rpn1MrEyN5wUZyx5H0Nclqc3l+KNBlZg226jPHGRmlGzkvU6KyahJeR7FxzxtwT9DSbFbkYJ449OaVVbdk9MnB79aRuevXjtWx4LFCkkg8jFBRN5YnjpilUsQARhupFJnPPJGcccUgHbe3b2ofCr82ce3Wk6D5T+VKQQcYJPfJpAKMNjGR9adtx1NMQEDkfMO9KVJznqDxz1oGhpY53KBkDr3rn/AB9tXwbqbL18sfluGa6LLAY/L3rO8SWI1HRbyzJ+eaFkUD1IOP1FBUXaSb6HC2DolojA8ntj2q19jMi7pFABzjjrWX4WT7ZptuzZ3EA496663tm8pVcFwBhQT0rktc+l0seWePLT7Pby3NuSsluRKh9GU7h/KvcNPnF9Y2N2uP38SSZ/3gDXmnjjT/N0i5+X5ijAD8K7jwBJ53gnQJC2c2cQz9ABWlB2Ul/XX/I83MY3UWebaLbAXuox4CrHdyoFHQfMa6OW0xAvBOeOKytOjI8QazH1/wBOl49Oa6P7MxGVZsdcHtWSXvM9GD/dr0ON1aBfIlSUklsqQR7V1Pw6uBeeA7FZeTbO9s3flW4+vGKydYttqs+d2BjJHWl+EbMYPENhkqIbpZVGezrz/Ku6g+WX9f11PNx8b079iHx6BD4j0q5xxJHLETnkkFT/AFq8t/KYQMDaVxg+lSfEqBTa6a+wiVL1VB7fMrZ/Mf0qeGz/ANEAYAtt7is691U0NsA06KT6HG+IUE0UhjGDjpU3wgcm11uBukd0j8deYwP6Ve1eJUEgKgAg4x3rJ+GLeTrviCHdhXihl2++WFa4a/tV5kY9XpM7q6ZeQTk54A4/OqMwdzJgbjjt/nir03zpjAIbjnrVG8Vbbc80gC4LHJ5AHtXtwdtDw0ilcyQWsYe7cAdM5xkjsKoRanp93IIFuUV2biNhtJ+meprktWv7i4t5rxuS8scSZ/5ZxlucehIrpfFWkpDbxI0Plkxh1yMcdjXE8wXNaKuj0o4D3feepsPGqAhEBx3NVirBODnHXA59qj8J3Daj4eglmlLSJI8LOeSdpwM/gRWhJFs5Zh06ivQjJSV0edJcrsZpZdrh1APOfeipLpw/YHPGSPfP40UMaOnhAT5RlgeueelYHj1nTwlPkEbZomOBwBmuiXHGzJGcA9xzVHxJatf+GdRtlDEvAzLn+8vzD9RXHW1gyqb5ZpsyvB86/ZFYnGO9amtXWYCABsPBxXJ+DJFktIgz8EV2clmJLUqB/wDWrxpN2PpUluRfD1TJ4bZAwPl3Eo68jmsS6kjj8W6r5pADSrj3yorR8Ft9lvdU05zjDLcRr6g8NzWB4siZfGeoLGu7zBHKv0xj+ldE5fuos8yjG2JkmdpBIPs6eWRsU9hnNM1ho7vRbleDuXb056VhabcNHbhEyX67cZwa2JojFpLCUBmcEgA88j9K5JyvoeooJbnnfhy3W8tI43HCZjJPYg4/pXSWuj267WEiBxwOcH86wfCkhg1O+tySkkcxI9CG5H9a7eS5i3J5cZLH+IKP1NRyXSYk7MyNTkjtbfau7DEb5NuAPQCrnwjOdQ8QwuzLukhkH4gj+lQXsL6ncJu3KiHJB747VY8AFYPG2qWy5CTWav8AirEf1q6Gk7HPjleiy38UZJI7vR40OMeY2B17DNULS3WOJGiZgze2c/jV74jIH1bR0ySdkhH5imaeqDiVpE442jPNFW/OGC/goo3PmRBpA7RMcjB6EH1rnH86fXNIgIDO15EFIHT5hXXzyowdZWfcDn5lx/OsLT4ivjjQ9wwWuQwH0BopX5ka4l+4/Q9o3BmO5e9ICMAgZ44oxnrkgH8abu3RnH3+QN3HNdFj54MkHPI5/wAaQygc7S3OOP1oUZBL8H60w8YG0ZBwSaaQiRdzc8BccAU8sVXPGKi3BSCeOeQacJByRyee1JoEyTdkDHTFNIz7DrkcUwO3AAB/SnFwoyMkk459aLDvccxbOBn16U1SFIXOSOpNBy2QSR04zTHJXBZQxz09qEgPOPCrYvtRiAC+XeTpgdsSNwK7lYytuOmf5V5/o8vleJ9cQ5J+3S8fVs8fnXWSaukahWcJg4B9TXM92fR0rygit4jhWazlDAcAg0nwjmEvgy3t3Pz2c0luR6bWOP0xVa/1GDyz5b71P3iQcfhVD4eTpZ+JNW0pmzBfRC7hwerD5XA/8dNOi/fce6/L/gXMMfTbpX7EVjGp8W64DjAvG6fhW7eyCKHCltp5PNYM4a08Z69HkZaVZR9GUGodTnw4WdvMDD5lzis78smdVFc1ONuyIr/UYyWV5IznhQD0FQfDe4Fp42u7ZiQt9bZA9XQ5/kTWdqUEd1J5gUGPbwOmKydGuZdM8ZeH2cna115anPVWBUj9a2o1LzSf9XOfF006cj0j4gv5iaKgVVDXueDzwjn+orYtYc2qDtgDpWF4+lA13w/bnHDTOQPYKP610SSi3s0K8/L93vWlTWZhgtKKOX8SxKsMgQ8AdR2rj/h67L45v4xkiSyO4eu1x/jXU6rLuZ2ZVUkHIP8ADXIeDpBB8SLMEkGa3mi47nggfpWlHSaa/rQeLV6TR6cx5AjQZ/n+Fc/4xcW2gXbJkyS4jLccZPTP4V1DDy/lIQq2C2O9c548jhOgbckO1xHge/POa9GrO1OTXY8egr1IrzRz2naKtxpBSSMOj4LDHWm+LZL1bWPbcu3lx7FE3zYH1rodFnWCBI2JYAVheLbiJ4mkB4IPFePTvFaH0co33IPhY8p0K/ilOWjus7scZYV0F1A7BmAyc5wOtc18J5vNtdaXIBW4Q59PlNdZdx7vunGOeOte7hXekj53EK1WSM1EKxLncznJ57UVadiqoo5AHHNFdKRjc6CNDztJB6DJ4Aqwqs5BkP7snawzyQeKjyGQAfczgHHSptu3BBJyTXJJjPLPC4a21Z7XosMrxnPsa9VtyksPHHFeXa7K+l+N9SRVx57rMhxwQwB4/HNdjptxLKgVXbKjOOpNePOybR9DQfPBMpaxKdK8RWOoKdsW/wAmY/7DcGjxtbrF4jsZw20y2xjLDuVPcfQ1Y8TWn23SJVkG1mXt2rH1m/bV/Cui30pAurac2lxtHRsY/XAp03zU3Ht/X9epnWhy1ozXob1nZSyxo3mDav8AdFaDRqcBznPQdzWP4alaSIbs7yORnpWxcSwxyY2fOAMEd6zcUjrT6Hnl7F9m8W3Hlk5liVgB3IY/411+mcRAfMQVz7tjsKwdat2HiCKdl2gxED35FbmkyDhjIVVQAMc8+lKCuhS0ZfO22jO0ghsfLn7ox3rH8OOYPiLasThZ7SVOP4sFSK25QZA4ZRzk4+prGvrO9gurfUdNKi8tmLLkZBU8EH2xTi1GSb2JrQ56bitzW+IK/wDE10TbxxLg9R2qOHLQ4BVHBywxn8qw9V1a9vfENompiLbBGSoiXGC1dFBGpjV1ORyTziidnJ21Iw8HTpqMiIRo6ESop5zyK52Bs+P9BVcnbPwM9sGugum2Fwy8kcE8/SuWsGKePNDkkJ+abAHpkEYp01aSDEfw36HtW4o4Lcoe/pSKST8wAJ7elRuXVW2jIA4HemNPncPpkjtzWyjc8EeRtYBiuOAMdck03DszBhgZ6L3H+RUCyEsdvKk4JPT6/pVfVdRi02ze5vZ/LhUjLDq3oAPWtFBt2QrX0RqAkfKWBYnICjJxUDn5eHxk9DxXmuqeKtXv/N/s1VsLU5+Y8uR6k9qx5PE+r6ayTwz3t8igEiSPdGf6/jUp007OX+X3/wCVzq+qTtd6Hs8KBADJJufr14p+Qu1cdecd6xvCmt2+v6JBqNugiZiVkQ87GHUVtqN33ex61Mk09Tmas7DgAB9OlDDgY6DmhVbI3Y4HP1p3Iz3qBnlF2DZeOdcQk7pJVmX6MgqwY/3YmY4Y/KM9/ernjmDyPGNhchQRc2pRgB1KN1/JxVpAjKCCWIFctSLbPocJO9OJntBujBPIx0PH1Ncw93/Y/irS7yHJWC6WN/8Ack+Vh+eK7vyXkVCqJEhBJJOSfauO+IVnFaaLPJbsWmGJSfQqQ39Kmn7s1I2qrng49zofGVr5XjWCfJRbq1xn1ZG/wIpHtEmAaWIOVGN2al8Xyme38OanH8yyHbn/AH0B/mKkhuSwKvCnzKMYP3jWtWnaTRzYGd6Kv0Me7twYiViRTjglgce9cTr0JttU0i6MmWjvoSG9PnFeiX0SvBiLg4wy+g9a848bYiso5FyfLnjOfTDinTjaSfmjWvrFo77x9KZfHWgW5kB228zkY6ZZf8K0tQvNkcaKybAuN3WsLxq4uPHlkTxs09Tj6uf8KdPCHtfMM23bwgc449M1dS/OzDB2VGNzP1S9Nzu2YGByc9q5DSp3j8caDM3AN0Y+mPvIwxW/dSAQ4lWRSMhmxXOW7fafGnhuGAYP24OPU7VJJNFKT54+qKxKXs36M92Uu7bFRWU84boOfWuN8ZTfa9VtNMhK+XH++k9QegFdhPJn5dyrHnnb0x35rkNH8q/1S6vmKkyyfJkfwDgV3YiXLT9TyMDT5ql+xJc2TRWuY/THTrXFeJyIbd489Byc5A9q9R1SNVsWQHaT0weleLeOpmUyck4Bx9e1cHLoe25+6dX8KLL7N4Vku3wJL6d5R/uL8o/UGurmVduG69PXPFReH7D7F4e02zIKmK3QMT/eIyf1NT3DBYMrgk9R36/4V72HjyU4xPmak+ebl3KV5N5bOwPOMHNFVJ2aRyAc/hwPr+dFdAkkdYCHbAO1em3t0qRGKk5bbx0FVwqMA2SD068Hr/n8KeiFicnkHhQclq5WkM4P4kW//FQaZeElI5ovJO31U5/ka3PDsiRIscbAZ6nOWPtVP4lQmTQoLpCQ1pP8w9m4P6gVkeHb1y6DcAvFeZXppTZ7GClzU7dj0W+jS4t8AADGMV5zfE2c+s6aTiGVUvIx/to3zY/4DXe2t350mGAORz7VynjLRke9t70M3mrkAA9V75rnvySudkoc0bFrwwGjkkZSCP4cnrW/a2zyyCad/nAyR2FYWmDy4w4VRuUcelbFlcO2ckGID5iOlORUdiHVoVnkluMALEqID6ZyT/Sqem3CrcSRtEQ5BYEdCR61bJe4sEDDaJmaQk+nb9BTbewlhAkdlHOMH9anRB1NCP50Lfd4yR71bt2WON95Thc+9VbQsygREFM5I9DU13DiRHZcxjOcHnPrUPU19Tl7y3a51qWeNCwePhe+a2rPMcarMhyy4K+lJIiwt50KlizYz3B9qmhllKsVjKHGC5GcGpWgrXGXSq0O2NTl/lAP864fU2Np4o06dCwEV0hXd6Zx+FdvMWwV3qQeQVH51x/ixHaJpRwYyHBbuQelawdmmZVoXTR7TKpLcHnPBqMhjg4AGc7QOv1pLOf7TZW84PMsaOfxGadgKoY7k3Dn2zXTtofOlK+vbbT7J7q53CGIEt6Y6Yx6k8V53/pvirU47i5QpCCRDB2Rc8Z9W96u+Nr9tX19NPh3fZLXBlH9+Xrz9B+prrvClitoqs0aDHADdT6msK9V39lH5/5f5nrYPDqEfay3exyHjXTBZeGzHEPvMvmEcYXILfpVjW7i3a0jhiePyVUEBfpXXeKtOW8iOQQgUjFeMeIbO9tri302zkJW9mW3U9Wj3HHHrUQSjodUmrczN7wV4vsdF0mWK2s57y5url5JBFhVjHRck9+K7HT/AB3YyBY7yCeykOAvmjKfUsK8r8LeHvs0E0MU80dzG7ITuyNykg8V2Giwf25oLztFtuInaFxjoRwfzrR4iy1irfO/52/A5nhIT16s9Ojn3gMCGDAEFeVI9c+lSo4bABNeVaTrN34TuxFMsk+ksfmizlof9pf6ivUrSeC4t4ri1dZIJV3K6Hhh7Vd4yXNDY8+tQlRdmcX8T1a3j0fUBuLQXRiY5/hdD/VVqpp7rqD28pRkkZSOvBrf+JUAm8F6gwX5oQk49RtdST+Wa5nwwpMauC3zeh6+1YyPSwMvct2Ogfyo7UsVJccA8jA9a5PxUPtOnzQqMmRGXPXrXXRS4+Qq2QCrHGcAVzmrKrFtuBn5mVRyKzlHQ9C5XEhvPhNo9yG/eWbRbs+qkqR+taFnKW2OcLwMA9D7VwsUV9Gt1Z213MlpNcK5t85VlJyf1FdjbLKZhGyqVGGBxg1pOpGbTX9M58LRdJST7mxcxZjUMxwevH3h6V5j8Q4hJp11tAyBlQvbFenzndG3ltnII6VwfiK3W4Rx1XHT9MU2tNC5gl7Hqvi2S7L5ijsbaMHOcHaWI/8AHhXQfaraSxaKSEtMpJDAZDGua8I6S1jpKyW4EmGZHXuD7/hitnTrtUDFSBtJ425xmlKfPJytuKlDkgo9jJ1u4dUA2DaRjHTJrmPBcZn+J+lgHd5MU87Y6DIC/wBa6bxRfx3ED/ux5ijdkdAaxPhVj/hOdTuZHCCPTwSzHAUFySfyFXSjerFGGLdqUj0jxjqsmmaRIsSgzzkwW6kY5I+ZvwBqj4YtEt9OjBPzqAevWsAXb+IdZe/IIs4h5Vsrdl7t9T1rflmS2to40XAB27q0xNTnnZbL8ycFQ9lC73YzXdVVfMjIOMcEdjXll476r4s0mxOStxeIpHqAcmur8SSl9xR8MAcqxxXNfDS2m1Tx6brH7nTY2kd+wdhtUfXvWUG5TUS8VJRptnsF3P8AOSWOcngfXpVRwxUHAD/3asyRpvYnAx37niqzkFvl6AfeNfRx20PnSkJGdXdhiPGOmPw/nRSuzEl9xJxtwKKZSOkQltpY4QDkg0oSL7yyd+/0qNZCoXcDgfd4xUrPGHGc5YdGHQ56fWudpiKWvQm/0S9s3UEywsobHOQMj9QK8r0F33JtySOG+vevZEZiVZWOQwwAO9eOhxY6zqEIOClxINo781xYqOzR6GBlZtHeWF55MW5jwozk0+acXsJmk6P8qAnoP/r1ydtdtcMFywiHX/a9q2oZW5DAgYyK4d2evfQ0YrYDMSZbAyTnjH1rYg8mbTrhYhhY1xtJwSelY0lz5FqzYz8o4H61c0wNwJFx5nzmlbUVi6kO1IyeVUYVevaoZ5w15IsykfICOODnvUt/Kw8sIh2EfMwGTmse7muEuIlV9wYBckZI9v0oehUTc0dJVds/LuBO7HAqxsd12Ak4zgjoKi08yTwCNh1bBCj9a1WV9qyKArSHCjFQkVKWpUFqq2wLp5kuckg4/CpHjZod5QRD1Bqe4iUxLhunHoR+NVlXzh5UbsVB/iOOP61LiVEzkib7Q4Rf3YPXtWF4ls/tazxwtlYYyzt2HtW6ytJLJFG7CNTwfU96reIoRa6MVgBFxcjGBySDxmmlczqOx1HhN1uPC2kNhubZM56cDFWtb1C20nTpL2/b9zGRhRyzMegUep/xrI8GzPa6Z/ZhG42TCME91IyCf1rlPHl+2qa9Dp0J/cWfzSe8rDv9FP6muqclFOb2PEp0HUq+zZX8LwyXV8biUMWmld2PoCc8/wAq9NtI0jiQsGOTzz0rlvDVoILYbRnBwcV0V4dtkRDIRuBIOehrghdtyZ77SSsiLVtRfY0aOGH6157ZE3fxD0KNifkmeXHuqn/GtC4vJPtqqzEE+9Z3gsfbviirxjelpaySOQeFLEKPx610J3scuJtGnJoPGzjw54taaMBYL1ftAXoNw4f8+tbnwxMxt7+Z4SsF1MZQrDkD1pvxQso7i90GWdAwEkqgn6A1v6NJ5cKrbIpG3kZxSmtfIjCScqSuVfFekRyQs6DIYcYrm/h1rTaVrh0K+YrbXTFrbcf9XJ/dHs38/rXcarPCloDcPsj5BY9sd8V5D40VlnjvrMlJIGEiNjupyD+lZwl7Kd+j3/ryN61NVYOLPcNWthfaXeWpAYTQPFz7rivL/B146WFs0pO51G09gcfzr03Sr2LVdGtNRtyNlxAJRz0LDkfh0rzTwbErabb+YcqIwdpGRjFbT912ODAJrmXp+p1d5dm3gcbXKlcbVON31/SsDVrg/aDIkaL+7x5SHODjv61sQsVjkiG1vRmGc1kNYi2upJ5JEdtwwG7/AOFYyl0PXUdCnYfYTGszuVkyFweoP09K3JUJlVxhCpxkdCPesW5sXuL7zY3AZPmAA4xWha3JJRZg5UHaB3pRSJbL1yxkhlDHbhcttOAP/r1yN00UfmvNJ8oU8Y6V2htkmjKNgqo6MO/vXGeJY/IyWiPzZX/ZI9q05lchq6G6dOLdElg+ZZPlZV/iXsw9xVkwCTdJGuc8jHesKKdYJokDnaBhW6c57V0dlFcC1lkikXn70eOMd8USjfUSlY5HXTgOrDGTznjNY3hvTZbrU7+JJWjW5iVJFU43qpzj9a0vEMMs1zscFWPQr0xmpdMj8psnKPGflYDkHFJNp6OxLtJ6nR2Nn9kt1hVThew71alm+zWnlzRCQr2c8D6HvVWy1lZRi5iYTJjco/n9Ko+LLwBWeBwFxgJ/hV01bcqfkcV4m1Jmed438pckeoxXd/CPSjZ+DILgoRPqDtdSNjlhnC5/AfrXlyabc+I/EFrpCOENy+ZH/wCecQ5c/lXv6QJDCkFuAsMUaxoP9kDA4rtwcOafP2PHx9TaCIrgLyhyWHccVVmUEDBwSM1LNywyDn65qFipQ/ImQMDJxmvXWh5xWm/dnJ+XHOF6/jRUV2flyArcdB2/x6UUx2OhV9wZCQw7qf4vp6fWn708zJUkEcDr/wDrqj5zZG4tg9RjryOatx3GBkpx7HPNYtDsOcNkybssBgFTx1/SvKPGMJtfF9+C37uXbMD/ALw5/WvWGXKkhgM9QeDXm3xOgKaxYTLz5luUZh0yrVy4pXgdOFlaoVdHuFkiUKoyGxnPP411tnA7uu0HbkEnPNcLo4VJFUkjd0Br0G1kVYIgjgEDAGefpXmqJ7Cehdu7USWxJIWLkH1aq8d2ILuyii5d+VwcgkY4+laLtvtjGByMD1rMisB9qjmLlGi5HPQUbPQaempv3ayrazbJVjmZs4b09BWbHBHNIhUEOueSOvvV+STzVBUljLgHI/KrBtfKQzOwLY2gdOO+PzpNXZSegthNNAmfL3Mo4PTIrTH2ubBihChFDIW67j/9aqOn3S20e6cEO7/KuOgzW5Hc+YoCjahAwMck07NivbUrzR7LcySRguBhvQVnQwSLGuUB7KRyMVNfQ3UlzKYwDAxGecZPvVXSIZbYupmeXLfOx5CnuFPpU6M2irrctrYZDPJ82MZGOtQS2n2zVICwyiHcVz2HQV0EmwW6op5659KgaBIpiwz8xyMd+aVraGMm2cL4t1C88OardXVhDG4mhWNy5OIyWO18d8ZrG8L2TlhLMWkeRi7yN1YnqSa6rXkivtSvracho57Qp9CTkH8CKt6VoJi0eOVPnUxhvrWNec7KL2RVKMYty6s09NhEVrlR84GG/wDrVm6ld/ZEcffhY4PqvtWsYDb2MbuCHABds8E1xHifVYUjJdvmBI47/X9K0hHTQrm6mJ4l1KC2heZJMEc4A5H0rr/hZodxpuiTXl/D5Wp6hIZ5EIw8adEVj645x71xvw88OSeJNUXW9Q3DR7SXdbRn/l5dT97/AHFP5mvYuZXJDbR25xk1tGK6Hk4zEc75EcX8R0nzo08mfLEzqTn7rFeOB9Kb4cvDuGM9eeOtbnjPS3v/AA/MlqoaeAieJRxll6j8RmuS8JXUHl73Y7CefU+1RU8jry+acOXsd5dwrNZSElRu5346H29a878YWO6xCFf3pTDlRgdOv516LA/noVACjHyj0rnvENkHtmQHPfdjrXLUVj0Iq7Mn4Pa0smnt4dkAW608b0bd/rombk/UE4+hFQaDpcsdhuRvmiLxNgehIx+lcZZXcvh7x7pV5BHvZ3a3ZOzB1IH5HB/Cuv8AB0txafb9Pu5G82OVmLN1O4k5/Ek1sqiqRT6/1/X3nHGj7KpJrZmjpkE6yypLIW3nO1v4RjoKjubZwx3klI+Nx43AVpMkaAGMsCRuBB5OO1JdQyPDGXRjEwOOOTUNPqd0ZdxdIXz49q4AI+YEdP8A61OutNMUaSYLhmPGOlXtJQQwANuyPukHnHvVq72rGhyfKXG8Ecn3q1HS5m3qZk/yLHvyfXnv7VxviNZSHVC0jEn5cZAr0O7igkQOH3rt3Ejr9MVxOroZJ5nhkfbt4HY/hQ0wUjjrx2kihQhcrjJxzj3rV0nU5Le3lh5ZHQ8N2NXHhRo44woaQH6HnmsXVLd4ppcAxrn72f0pxbW5myLUb1ZZVXZnC/L6io45tiM1wsglTHAHB/8Ar1Stw814zD5lU8n+tdFbRLbxSFxvVvvj29RQndi8zKup2lhikjYeZnC7uPl9KzNZ1BUyrJtfGM5zg1a1ENbXhdW3278rkf5xXG6tcO18yFsAjPJzT2IlLQ7H4PxtNr2uagcfuYkt1JGfvfMcV6czZVvc+uBXnfwVVk0rW5ymUkvEjH/AVr0Ivw2eTnqfSvbwcbUkeFiXeqxkwYFUUBjj8qryMu5uP4iCMZJ/wFSOTvYjsoGKpyyKAQ5OeuRz+FdaMCtKA2BCVyOo/CimvK0jBVQquPbJ4ooKNVOCQucZPB43VcEgTG1QCT69apLJHuClgQeQCOKnjYtyNmQNy/T1rOwF8/dAc556DBxXEfEuEf8AErlToHdOnTjNdesj4OWCe9cp8Q5w1tp4wdqzH5yOD8tYV17jNaH8RHIRRMHUrxit6B8pH5YPmfdUgnpVCONViG05YjP41o2srW5SdVGxeSBjpXls9mOh0aahNaG2t4ULyzAhn7L7mnTNPBIsMpVyUPznvVWwlRpA0ijbnJ57HpSXObzUVBI6529OnSpk2i0dJpwX+y1Ea7pmbgsegq3DOZY3SVWJC4Xjpj+lZGliedzBx6Lz0HpXQBWtLUmbAx1Yf1qUtdBooxwyGWOXIMWBhc9K2YLl8hSmQDkgkZJrKs7hZldiCqHjB44q5Y2pcockMWyWzjOOlJtrYq3cvWMkkssnnBhHksC3Q+1WGsEliIU7FOHAB71KimMCMANGeWb396ZZut0JNoZfKbaST39qdrrUSdtUWXXEUbxoGbgHmmO2ZwJV+ZeFx9KiE8sbCPOd3QelV5blILpklcZA479aaQmYtxa+brFw2Rnbn8K3/BVyx0ZY5v4GZV913GsuYN57OrYbnA/vCmaNdfZtIlDEAxTyp9Rn/wCvUyhfQlss+KNWiit5Y2+VCD8y8YryLWEfXdVsdJt3bdeyiInuqdXP4KD+Na3jDXFeZkaQlB8wA+lJ8GNOfUNavtZnGYrRfs0JP99sF8fQbR+JqlFIyr1OSm7HrVna29haR2tpEsNvCgjRFHCqBwKnDqzDBAY8D/GoxHtYjkLn1zTHBaM7sKCcHjj/AOtWiSPGJ8pFtDku/ueteUnT20LxTcWROLeQmeEdirE8D6GvTFJRRhgWH3iB1+lct8Q7Fn0yLU4xiexkDMe5jJww/rRKB04Ws6dRdma+mBmA3kgHuD2q1qMQe2bjLdvesjw9fLPCoHOQBj1roLiIyAhc7e/oK46q0PfjLueRX2nibxXYSbeIJVbnpnPFdRrtobXXYb1M7Zots2PY9aZJaA3M8mAW84HA9Acf0NdPJHHcxqjIS/BHGfXippQ5Vdk1HzPQli0mC7skKyBX49wR64rKMT21wI5fmBOFZV4xWpZRNaH7NJvKrnYw9KuSQ/d8wh4zyCBitbdhxbRBFCvkY5LNwGU028Sfy12YMjDad3TFQ3SyREeWpWMkkZOAPr/jV9wt3arvZlCjOc4qraaEuXU5treeBSvRye7cAVlXTAod6kFuAQRXQ33mHeqbSyrwcnkiudnUyRZiGHJ5AHP4UWstSr3MuWQRSgiAFe/P4VT1fdLFcGQJwMhO/wBf51t2MAa3d7hdr8k7uDxXO67PGsMk6s/mDovQH86EQyhprhZFWP5QSBuxkGrt1M0chw65UdMZB+tZ2mqoLyZYHGcdgfemXs7rhiSOOeKlNBbQyda1EGEo2eWPI4xXG3kpN0JF5yNo9TW9qE4nIVUBIBGT/OufliKvIVbJ6ZptmEj134Q26r4LglJI865mlYnoecCuwbAjITOSeSR/nNcn8LAD4F05QNxDOOe/zV1Lg4bjAHY9q+goK1OPoeFV+N+pXdWJZhjAPXPWqU6xrzhmwc8dCannXcRuYB8jj6etVmG+UAZAwc4HStiCAxhlY9OOFPb/AAoouwPnBCgkjJ7UUFI10WMSEqDg8DjirCxnK/MM46AcfWqsWFOWXkHgg8irARtqgHA9zgisxE+BsYO2T/exzXMeP4hJ4faVCQYp0cgjqORkmulIKrhRzj7x/pWV4jtpLrQL+JUw/lM2fpzWdVXg0VTdpJnH2LFkXqcjt2rZk2QwI5wM8EgZFc5oVyWjTGMkce1aeo3DyrCsSkOOGz2rx3pqe5HUlE80r+TjGT8zL3FOjuQZyUJJLYznnjpUNk8NtCW5aQnaQTj8akNvEWaSM43N03cA+tQ72uWt9DstBedbRtkYaUg8jt9K21n+0xLBLCxXb8xPWuS0fUVgtQHbj+HH8q1UuJJLvzI2eOHAAZuABRfTctJ3Nt4g1psi/d4HG6r9tzHEhLbk+97n1+lZ0GpRSRdCexLDr71YMkcduCsyNIBkFW5X296aQrNFuS8AlKqMLjA989ao3939nWPyDtZu/qKlba1nC0gAYjPFY9/MrnEkR8wZ2H2ob0uCJxqsxkDBVGw/eJzVKfUHlug5OOM4PU1Qt4pBKCWBwc4A4anahZybN4PzdQR/KpTckVdI3EulYnawyoB5rmL/AFU2kFzH1V5S+PQ0y4vRFGeWA6YHXpXKa3qBG5m4DdyegrdIwbszH1R5bmULApmupHEMMY/idjgD9f517z4P0SHw74fs9MV98kS7ppO0kjcufzP8q8/+E/hpppF8R6jGQgyLGJx0B6ykep6L7fWvV1kBUEAAnseR0pJdTzMTV53ZdB7OwDFCNueuOhqMyPvwwbk5APr60/8AhbPDYzxwKaSyBfMGQOc5qkcoodHHO5ST36Gqt7bi7sLmKYNtkRoyG6njtVvOT8vyg8nnOKRoi8u7cBzjHTPvmmB5v4DvUMCwSHEkTlT+Bx/SvUPPRbEt2C5Jx2rxbUmbw/4w1KBlIi87zkz3R+cj8c16LY6rDd2QAORsyfpXPKNz6GlNSimZ2nAy2+9gf3jE4x1JOf610+jMgYq4JYj9K57SriKKwtSwy7KMevetYXccLxMMYztIz71PKWtTduIkWVRIACTlWHb2pjh1DrjKn7vHSnxSm4iCsNy92xik3rho5mPndMfTsaaQJle3RJIjkliOi9c1QvvnHkx5hY8grngVoQPGsuYs/KvP1pcLmSWQkNjI/iwKGn0LWhjXdlLLtZpflQYbavJ+lYRs3tX/ANKHlORwN2c+gNdRNepskKKVxx7/AJVhXaSSMX3R5ByM84p2sTZrcx7q0juI/MMxV2GAATgHvXN6zp5FnNM8pZ4+AeoI966a+ZktS8MQlfOABxmuYuUlcvG52OfvIT29KlpPqJyZlfaovsflBGV8Y+vvVEpKys0i71Ix+NWNRjeKEEJmRTgg8YqjGbm4A2DrwecCpYubSxlTxiOVyhycc5/lVR4wtuDsCnccmulOmr5bAsCcZz3FYOqRJa25COS2M8nmnGLMpHoXwuITwRZHJ2+ZLx1/irqpnLKvyHBxjPSuX+Fq7PAemsygeYGfP1Y9q6abcMDBYk557V9BR+CPoeFV+N+pVuNpYgBt3aq3MbFRkADoBzV05XlRyT39apTq5dsE5Pv/AErYgoZOwkDcO+e/GKKUuCTlSMA+1FKxRqxT7VO1V69e9WQwZCHcbs4PfFZ8TkyHbtHv/FmrCfKjMD82eRUA0aCuY1PcYyfQil3htxk/1eMEHofb3qBWz9wEZGG75GKc338HDHHAIwRQSeZtbf2VrV1YuQQj74yRjKHkVacGQuY5CCRyD6+1afxBs/3dtqcGS8LeVMcfwnpn6GsezUyLGFI7ljjvXkVocsnE9jD1OeCY9EuEA43q+A3HFaNnZ75HZ8xgDJPYmktmEZ3lcgZAXpmnzzmVQUzHzx71zSjbVs6ovUt2SGFTjmPnGe1bsF8GhjjljDleMZrnoZGCqGfIB7Vp2IdiGGNx4Oe/0rNOxsjdsQf3gU7Ebg8cD/69WVCKQpCnpz2/Oq0MpCjYiruOMjufWnNIHwpGSDlu2OaA3NzcqqFwu3H3Cec1Tinto0eO4VWYjCg9jVOaUlnfo38JPQCqslyGRgQobrnOeKpyT6C5RYwi3Su7DCtkDsAT1pdQnTLK0g6/KAelYGp6kMSLC6gqM5H8qwri7dsSM+NnAUHvWlPTRmci/qV2nzKh+VSTn1NZnhjRR4s8SC1nU/2fakTXb9jz8kWf9o9fYVmzyXF7dw2Onxede3bbIox6/wB4+gHUmvaPCOhWvhzRI7CFt0pO+ecj/XSsBlj7dh7VvbojzsRW5VZbmysTDHlhU+UDp8oHHAHpUzKsbDCEgcEZ/nTFR2I3k4A5weMHHSpY+FUfePqT1obPPEKlshW+U/wk0xwUiwTv7deDTpI48FgxAJJwT/I+lKY8HamDu6nt+FFxEPmYUAptA9Kd5wzkku4GQAOMe9SogYAcEA4z6Uh2c7WHX5fl4H19aLoDi/iD4an1q0S/tULahbAgRjjzY+6j3HUVwvh3W3tibeYleqgN147fWvawhL8sTg7g2e3rmvPPiL4WSXzNW0qJjKnzXKKPvjGfMA9fX1FJo7MNiOR8r2LWmTh7aMKB+7zj1H0pJbl45hvYleuAK4nRNUe3mTed3y4Vs9RXXreRyiNlUFnON3ocf/WrKUex60JnSWetPFCqqCyN1DHketavnCUGUnCgADsXFcVIpkjBWTgc5U4+tadpqSibyfJ3OBtXccge4pX7mi8jq7ZUEhMJzHjGwnnNSXRTanA4GW9qwop5WnAmChB94oed1TSX7AJEy5wcAnuKEPVsma3WZJXQqDjJJyaxPNlS4ljUEpjrjr+Na93epHBu85igx8mMk/TFY19dw20OUJkO3cCx9e1J6ArsRUQo5JDMBnHaucvWhmDHKtKrcMP0FXW1EXEexiRKRyFHWsu8S0dfmEsZAwQvHNK6JcbPU5rUZXlleCUZI5De1XoGtodP3SxZ4we3PqKhvhHu82Fsk5wCf51maiyfZgSSCD0U8ZqvNmTKl7qSJKRGCM84B6Vyet3Y+z3Enmjcqkkdc8cVb5knkcvkqMA1HpOmDWfFOmaYFzFJN50+P+eafMfzOKSbk7IznJRi2z2bwnafYfDOmW3AZLdAV9yM/wBa1mO3Jd+nXninMoZSylUOcAdqa8TAEKAeOtfQxSikjwm7u7K877NoUFcH7x9Kosm3IZwRnGQelaDRncMgHHHNUnEahvmye3FWBUkYnblMkDv70UsgY7RnK5wCOlFSMsQPwO56Z9vWrasvCtgHdziqqrIpwoGAOee1TpgN8qlj3z161mNlxGA2hPudyDyeKm3KBltpHXDdarIq7cqCv+znoal8tAQ7LvYjoTTEVPEEUN5oV/Cwfa0TFTnPQZGP8a820x5jaxOhAJUDBH6133i+9Nn4duygUO4EaYHTcccVxWjRqSjOG8scdOvtXBi7Jrud+DTszRs42Hz3AJBODnt71oWsvl7422CBlO3jofrUCTQvd5RiEHygOOlaxtlMQwq5bgqeh968+Uj0UihbzyJ8zgMdoOAvate3ljCPIkbBvbsfpWVboY5pFjU7M9PTtW3a2xkjLYXO3A5wazNLlhphGu1WdgBux1AqdNrlGHX+8O9V3iSNFEZbcMEnIOR9ap3DOqu0YwFbjbxQy4smvp2UuhYEgknnriuX1XVHUfLId3Tk/wAqfqt4wyZOc5BastSsgA2hn657EUIUpaFaNbiVcv1PINQzySPdw6bp8Ul3qE5wkUfJPufRR6mrusagbDTo1t0Ms0r+XFCo5ZyeAPxr0X4f+F4fDenGS5O/Wrobru4xnrzsHoo6V0U4P5nn4muqa03LHgPwlH4bge5uZEutVuFxcT44jX/nmnovv3rq45CeFjC8A9c8f5FMQp1VwxAzx2pHmPzqAuD1Hqa6FE8pycndkikDkEggde3f9elPeZht37Sx4GBUKyKzBWfagH3QOTT1kI5QAAcDik0IezKV+c5/CnKzDmLPzD0waiaT5mGSM8DjmnCQYzs4x3xSsBKHdkBccE8DGP0/rQkqk4Kkg9OajLg8RDJJ9cnFIr5H7raQO4OaXKA5l2uV3jOPTofpSurEHgKBwAOc1DxjO7Prn/GiNnUHyixJODjmqsB5b498Mvos39oWY/0Cd/nTH+ocn/0E/pVDRtT8ttshBQ9D2r1+5t4Z4HtrlBLHKu2RG5GD29+teQeKfDk/hu6M0O+XSpW2pIeTET/C39D3rNo78LiPsSOltyskiyRbCerc/wAq1ZVlSATRFVZedwHB9s1wumX7WoDxPuj6kGuw07U47rTytuFKHH4Dvx3rNx0PTTLtnqe4BJo1ffyTnH51Ncv5+EiIDKdxBOcfWsbYrZkRiFZQxUev92rGnzCOViykZG3IH3R6e5rDnvozoS6oluHlRGAD/N8uDxn1xVLJZ1HllTnJYnIrpFa3nQqxwYwDuJA4qpJb25jUKoDFvlOc8+9JpjTRzl+SzgpGqkDJYDFZsro8BD8jFbmoCElvNkXA644rkda1SG0DJZ/vWI+9ilysmdkUtRLwRLKoGCeg/rWHexme2kcEhWOMdBmq1/qV1cRuhKRpnJGM4rDnZpAFllkdfQtx+VWrLQ55MsXk8MK4EiZHVR3rrPgxp3n6lquslSQmLOHI49Xx+JxXBXFuYdrMhXeNy+49a9G+EGshWn0ecqAxMsXOOe4967cLBSmmcGJb5Gkekt99MPyM5oJJOI859e1Oypk/erxycgYxTJpwCEQYY+leueWVLnzDtY7gvfPFVD8ysccdOasyO/BXHXk9TVQ3ABYBFDnnr0/zzV2GitJC6ldp46Nk449T+dFMusupzJ8xGOfX1x+NFSUWEJPOckjPWrCykbiy8/r+NFFQxluJi4BY7dw4BPJNWgccrxgduaKKOhDPOvH2tG51iOziYiGBQ0ig8M5/wqvptxM8XlqAFPcUUV42Lm/aNHtYWKUFY3BGG+5hvlw4xVxZVYERlUMY+6570UVyrex2JD4EeQrKhBUZDL3xWtHDIXII6gbccY+vaiilewkEjyxKTNEZAvGRUaIrxsyMyxKvAb3oopx956lPRHNa1EpuPLEi4HqO/es8KlnE7LIC2Oc9B9DRRW8aa3MJNmh8MtIl1rV/+Elvos2NuTFYRkffb+KXH8q9ZRW2kuxIwcHPNFFdcPhueHWk5Tdxsar1UKXHyg9OKkVH6sSAOpooqpOzMxQwUjDtwOQP88UgLkYDqSOhHpiiigAl/iGAx6cUuVYgMm04xgdKKKQiZCFJBK57YPeo2kcqQqqM9cd/xooqUuoxwKjJCtjrtGDmlUFm3N8o29QcUUUMQsZZEQdVznB9f84qK7jS/tpYLlBLbSDa8bdCPeiilvqB5H4p8N3nhm4ee2WS70YnIfGXg9nHp7j8apaVqzWdwLiDLxkfNj0oorJu1z1MJVlKOvQ3/wC1Y7i4jmXaoZRkgdQO1aAnjZFaSeNBzhmb+neiiudxTlY9WL0JrPUoZXPkNKwY4OxDkj6Vqf2TdXaDyklhjx1lbLH8O1FFVypNIxnVlcytW0iO0RmnfzCB3PH5VwWrlXdxldqDkA4/IUUVc4pEp33OdmVFcEoCgIJDd6qtHHc3sjQW5VSeI0BIUelFFc0tNRkh0K+vCFWMqAON3YVQFvf+HtXsbiFGmdZ0G1Bg8nH5UUVdGtOL510MqsVY9+3KxA6kjJAI449aYzIxUsAp64zwf8aKK+mSPCIZVVcsWC854qm7DzC20ENwT3oopPYaKrpHgHIHGMH1ooop2Qz/2Q==);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Swelling of the hands in a patient with acromegaly, which resulted in an increase in glove size and the need to remove rings.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Verna Wright, MD, FRCP.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_40_26240=[""].join("\n");
var outline_f25_40_26240=null;
var title_f25_40_26241="Permanent teeth identification";
var content_f25_40_26241=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F82290&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F82290&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 541px\">",
"   <div class=\"ttl\">",
"    Conventional identification of the permanent teeth (United States)",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 521px; height: 407px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    By convention in the United States, general dentists identify the 32 permanent teeth by the numbers 1 through 32, as depicted above. Different identification systems are used in other countries.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Redrawn from: Dentistry 2000 - Human Teeth Numbering Charts. file://www.dentistry2000.com/dentalhealthcare/teeth_numbering.html.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_40_26241=[""].join("\n");
var outline_f25_40_26241=null;
var title_f25_40_26242="Hypertrophic osteoarthropathy 2";
var content_f25_40_26242=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F61526&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F61526&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Hypertrophic osteoarthropathy - digital clubbing",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 324px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAFEAbADASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwAYKo+tQu69BjpU7njpVUrknFescIFsnjmmcZJ7mgJg9DUhXpimtBjVOQRS496VE59KRwafMAg9c9KmU8HmoH49KRXAPWm1cC1xnABp6pn8arrJ7/pUyTgDrzUagTJFlulTpHhar/aRwc5+lPNwBwT+tJlJk+2mnaCaYJQTjIpy4zk9aQXG7c44oZQqgAVISM9RTTwcnmgbI1TJ96k8vjmlBB5FOU8YpijsNMYFNYYUe9Sg5OT0pu0Hkn6Uiiu4JfGPwp6dKs7AV9SRUZXtzz707iSIv4uePQ1MCpGAMCgpn3pdqgYBoAZLt9aFG4DmlZBmlVOcLSC4gix3pHUfeIyelThc9Mmgpxz1oGVwmTwMEVOI+AKcsYByenWpCoABzQTYqlQGqFlyRgEc1dK5GR61EAA2PemUTQqdmO9DKR1FWYUyoNDKScYxioTEiBVx70rJ61Mid8/hSEE4BwM80wuVJIcgHFRGE9hwK0lQDPGT2zTZTGByMH6UxMyihQnIxSMwC+/cGpLl8t6VUwTyTVCHud/v7UFePYUi4UUqnJ+tAhu0jkU7Bp3IGCM1JFEznOMUrgRiIZOBS+QT3Jz71oR2ZY84NW4rIcZFJyK5TJjtie3NTpbMRjFbUdoqnO2rEcCnkrUc5agYkVm2M96lFoVx+orb8pFAC4J9aZInBwBxRzNj5EZDR7UK4qLYQBnvWk6ZznJNNEQ+lUmNKxQEZJwCPen+Quepq0YDu6U7yiD8wxRcDlOvI6ULFwSRipzilU4GCKZhYiMOcYpPJKnmpwrMwz0HapWUMPTFFwKHl5PSniPAxzVsrkAAUKuDk0agUXtstzmmm2x0H51fbA5FIo+UmndjsUjaNk4HBpv2Yrx1NaQAIGKQjGBSuxWMkwEHqwqQQuTzmtER5FSFe5p3YWKcduSec1IYiB1NW9uF464qFyT0AH9aQyPlRtPPvSqOM8Gn7C+ew9KfHCSe/FMZGq5xwaeFCr1555PWnuCvPSqznOcUg2JVwQKfsG3rUcWadgsSB0oCIo5FIcgggVIsTYBpQmBigdxgzmgoSc5+gqUDbgLwT1p454PSi4XIVQ7eRzShcduanXpxRjk0riIwSMYFNPJqcAdD+dROVXkkUIGxCxOFqVF4OTyKqvcKvpkehqjdavFCgLOPxPSqsLmNVj2pilNwyQOa4y+8XW0KnMq5z61lJ45tDJtEoNDt3DmfRHrMYUKMMKRpFBwSK4Wy8XW0kYIlGPSnyeI4SdwkqUgUmt0duDGB/wDXqJyuc7uK8/fxlaruHnjI96pnx7aByomH41WgnI9KLqy9RVaQ9eRiuOsfFNtcj5Z1z7mtqC/EpUhwy+ooSvsLm7lyZC3TrUYjPQ9asxukh4qZLcljxz9KNh7lBY9x2kVKluTjtWlBaZIJFaMNjkDjge1S5FKNzHgsywBKkjPGa07eyA6gYrTjtlAA2irkcACYUc1nKRoo23MyO1IPy5xU8UO1gzntnp0q4VC9uTxmnbV2gkgAVN7lIgEYOOcfSmuuDwDx3FSl4o87j7VTmvokXbuH50JNibsPye9G3OfSsq61i2hBLSKPqRWPd+LbKFTuuUGOuDWii7Cc0dUQBndUUhReSa84vviLpsJc/aV49DWBc/FWwYkKXP4GhpdWTz9kewPNEDnI496glvo1UkEEfyrw2++KYIItomJPQniuX1Lx/q1yGCS7FPpSc4RW4Xk9ke+soHcU0cdWwf51KACRzTWAyOOatMgVc8c0pxjDEgeoox8o96f6/wBaAFCjrmggY4xSn65pAB0oRTfQicjGCM0xQfwzjFPYFiaakZ3Z5x+dUSSoBwT2pxVTySaI1IPPNPdcHnpU3KQ1QAMDpTW4PXj3p4GBRjLYPNFwYzeW6DFGBxxk9ae0fHA/KlCk9KdyRAcHkfhT9/p1prJz15oXrz0pajvca8TOxIHfmnR2/JBAqyuGQAH61PEFGBj2oeg+UgS2GAOc09bcD0zVoAZBx+VDYJxip5r6FJIrGMFTRsVV56mrBHHH8qiKndgHrTQc1nYgWPcvPrUiwrgZHJPapEXOcDgVJtIGABSbsVcgEQ5HBx3pRBnnrVqJcjHSlkAiQmhSuGxUkjVEJOM+1c7rGox20bM7hQO1XfEGqwWFq8s0mAB3rw3xPr9xrN26oWW3BwBmlOpGmrsyUHUdkbmt+NjvaOy+YjqR0rnJ9Rv7wZkmbnsDVC0tRwcZNbcNmdvQflXFLETk9Dsjh4xObu7eQr8xY+xNU7WzfzQQDgdq7Ce0O0/KDVe1tCJFO3FReTZbikWdPs9sAyOcdMmodUJgjPzHPpntXTQRpFabpDwoyK43XLvzpWWP7vTFaRulc55JXMOYs7EoSePWqhjYc81pRxEHI+970jQnOTU3uFkUYZJYWyjsp9jXR6P4uvLF0EzF4xx6msgwgjBIqMwAqQw59PaqhNxejCUE0e3eFvFNnqSApKA/dSeld5ZXkLYywr5St3ntJfOt5CjDuK6Ky8banbxld25sYzXWq6kveMXScXdbH06txbxr94Z+tSjVLdU+8APrXyrJ4y1ozE/aiB/dFRS+L9bfObpgD2qfaQGuc+qJtetYx/rVB789Kqy+LrKLH79APUtXyo+s6nJnddyZPXmqzXdzJkNcSn6tml7WC6Fcs3ufTt34/wBNj3A3KAj3rn7/AOKunQblWXeR2FfPjB2JO4nPWlEZPI61Ptl0QezfVnr2o/FrIIt4mbPPNcrf/EzU5kZYgEJHGTXG+ScZprQjf0yal1pB7JF+/wDEeq3nE13Jg9gcVnSXE7th5ZG/3mJp4gXgnIpXjCyAFM5HBJqHKT1K5UisVJ4LAZoe2YgFRk57VoIqHI8sZ6ZFOkVUhIGd2M5FK/cozTbyhgGXLDjApWgbn5eRwQetXYVZwhVsEnls5q7DaSSI+CoHUknrUjXc+kQvPSj+IdsVMoGOcUm1SWAxxXo2ZykZGRkEUiDOc8VKoUntipAq87aQESp1pHG04A5qZo9vU4pp6c8igqxFtz7CpEjz/MU+Ncn2qwqHFHNYZCEwpzimFS3tV4JlcECmOoXqePrU812BUI2sAentSmIbQEHAqUxZJGM0oQr2NMCIp8p/pTlwBg07nkmq084HCYzVJA2kSSuF54qAyr06GqNxc4JyRmsPUdegskLTzKuB3NVy2M3LsdUs6qTlqe2oxhuXH0ryDU/iLaplYCXK8cVhP8Q53fiPg+9Tzw7jtLse+HU4yfvgCnrqUJ6sP8a8Qi8ZSSWokGQx7Z61Yi8aKY8sshbrihuHcXvdj2c6pCCfm6frSf2rDkHeMmvFP+Ervbmby7eMKT0LtjFU73xHrNufm2bCcA81HtILqack2e9x6pAx+/8AhV2K7jbuPrXzlB411GJ8tGG9ecV0emfETbtW6jZPVu1CqU5bMHGpHVo9yVwwOzFZes34t4HdmwqA81zGleLbW7gzFOpJHQnmuX8d+I3Nm8EbY3cGqsoq5Lbk7HLeMfEU2r38kMTEwKfpmsaC3Yr93J6daNNti53sOvXNdNaWQIxtFeVWqc7bZ6FClZFCys2yDtret7QhAW6Ve0/T1xnbW3DYr5f3efTFZxuzp5DlZrX5cAAnNVEt9jZPbr7V2x00N1XFZniEWmn6cdnzTvwfaumnF7mVW0Tl9bvSkXlIcDHpXJlWeXcRnNaVxKbiU4bcKWC0Z8HbzVOTb0OJrUrpbnaMrlj09qieA5AI5zya3EtnXA2n8qje3IDAdRzWb0NEjGMQzjAyOKidTGpBXBPetYQ5BfA3fypktu5ALEbT0ojK4NMxpoPuoFz3NRyQovLgqO3FaCxySSNIQAtQSDzn27CFHGatCvczGjI54OeRQISxG7gVppa+aSufl7ZGKmjs8soYAbhU7AkZCQEfNxUgttp7Zxk1q/ZB5m3GFHUmnpbgA7gSegouCizINuc8Cnrbccck1ri0ZVBbufSkWBmIbGFqXIqxmCEMnIwR0FIlsWyRjcO+a0fJ2yfMMg9OKcLc+Y2F+UinzByszxF8qsVGKtLa5TzCFx2qyIG8rIAYDse1PgikQgp88TdQfWqBorPaRABlcbyOhFV5bPexUhdxH5VrDfLEY0t8uDlc8VHHHNLKXNuGboQO1VoSULfTWU7YU8z1PpV57AQnbMUHAIAOc/4VftxtZUkdIhnDDuakkgRpGEUO5h0YnikM9Qj1cZGTn16U/wDtheOefpXiU3ijUwc+YmMYPFZcniPVvNJS6YjPT0rs+sQ7HIqcj3/+113YzViHV0HOf1rwKHxRqasC024DqCKs/wDCZ36sAUQ570/bwD2cke9nVIjg561LHqMOB8wrwqHxxcqCJYQwHoaur47URgtE+70oVWDEoyPbY9Qg2jnipl1OHOCwx9a8JT4ggPkwOF6ZFOX4gLu4hfB96fPDuO0j3VtQjyBnjFRvqEQOdwz7mvFn8foGXy4pCPUnpVa6+ISggJE59eafNDuJKR7kmqQDkN+ZpZdViwOR+BrwL/hYjgMBbsfTJqEfEG5JA8rj60vaU77j5JnuN3rClcI1ZF7rUVrC01w4VR68V5HdePJymII8E9zXO6nrt9qY2TSkqOwodeMVoNU5N6nZ+J/iJJNJJFpy4HTea4C91G6vnLXMrOT6mq6odxyDUqQllYgggVyTqymbxpxiVyaQ1aMBIyCOfaoZExjis2WdL4bEV3bPC+0MORnqTXSWungrtWMY78V5vbzyQNujYg5zXpXhjVm1C3ClAJkABx396q6aJSswutGKr5gBB9jirSaQkmhtPNJuwcBSeRWncQTPESTVO2ttrFZiSD2rJbnSkc19iiPORTzYxkHGDW9NYxlvk6DiohZqMAc59qyLtc502k1u++CQq3qDVe4ku5ZB5zFhnqea6G6s9rEg4yelUGjYH5lGD19qpVGla5Dpq9y7oyqwXoCB0ArrbC28zG0Z+tcjYsYH8yMZAHSuq0LWbec4kITHXNRy3ZrTkonUafaKgG7HvxW3DBFgDiucGpQFC3nqdvPBqhe+JY1hKwEs/qK0Vkbucd2dTqtxbWsJJkRT0ya8Y8Va21xdS21q5c9C/p9Kfreo3d8TudgPSsjTdNdrnc/ODnmtFUv8JyVVzam/4c0hriJA6Zc9PWu4sPDPCrtw2OcCpPB2nAhOSAe9eoWMNvaxp5Ue5wMZNbQSSObluzy650DyyRuLZPcVi6tonkqZIWLDoRXqniGKIKJT8pz0rhL6Tf5ybgVzmlNI0jFnDS2owAnHXIFV5F3KdwyqjpWrftmYCFMEng+tDWkUULAyF5G5K4rFbhJHNLMyq8WPnP3farUNmFUtNy2OeBVy301FzM5DMe3cVp29mGDRbeSM5IrTVozUbHPxWbSc4wuc4HpVpYBv5xgcDNbBt1lkEKhVWPlj6mmGJfPLEDKcCocepojLktmY4CgKDlmNL5HlndjKdq3hAHVlOMnn2qJbYsASu3B7elJxaLRki35HmA85P1qIQ5UqRjByMd630gQxMxyR0GKaLTaUJXJPr1osM5uW3LjAwpHI9aFgOBj/AIF71vS2jcvsw68HFVoIAZAO/Tn0osS9Hco+Qox8uF+tMSIwB2cN5IP4itdomRto2uDyCKiklQSMW+XAw+elVYhu5VSAE7hIeeVINMh02VbgFyzI+TwTyael1bRhwkqeWEx7g1Wl1+2tRsV8kYwQatJJCuacVjB8z7FHrvPep1gwmElG7HzgdBXLv4othuZRmQnJY5IpJPFwkiCFlVCP4FIqlYVzClhQDLJg1SeBy+VA9sVti2ldvlVcY4qGexnt9pdcBv4utYXFYzk4B3AHnHTmmEbgAdoI5rR8s7PmUHBxxUbwYck459BT3FYrqgPGeTTmh3IOACDUxi6bA2BxzTwhxtNGwXMyaHLgcYp0cfOAo5q6YgW6nilWAB8+nNK47EAiCjbnn9KzruPY3Xr2rfEe7qevSs6+iYsT1xxTTvoFjKA5qSOPLkH6fjUkEDOzdiOxqwIWIEiHLimkBXKNI5KJgDrin20P+kbGIB7VfQfZ3VwgaJ+CPSp7y2EbwypjDcHHeqs2BU+zN574wrY596bDCxV/mwD2rXvofLEcjcjGORSW8AZNwAA6ZPrUPQpGeiDgDGRUdzEC3bOKvi1ZmbHryRU66bMIfN2Extxk0J9QZzU0DA8EEVs+EdUWw1BTI2BjH1qX7CGO3gEmsu8sXgl3LnIP0q7dUQ3bQ9lWT7VEuwjbgEc9ailiPT8q5LwbqTlVinb6e1egtbxiIMXXI6VLhfVG0J20McQ8A1G8QHJHArWk+zxPiSRQeuc1Tku7VRnzF74zWLi0bcxlXYCsdo+X2qixAJJxWhfXsIhJU7sjovJNcze6i/kmSGJigbac8EfUUvZylsiXUjHc0vMUcLgN1xVKSUJNtIxu4rC/tdhy2VfpUU+qJIOWIPritPZtbmXtE3od3p8kW0Z5PpVyWNWTK9PavP8AT9VxIAJST6ZxXRW+rhk++PpUWZqpplu5iw3Bx9abYu6ygNjbmqk2oxuOeQO/FS6ZcoZfvDp3pXcWWrNHqvhu+hijjLFRgdDXWf29bLD/AAo23PWvLdP+aMNGeT27VpGeMvtlO0r1NdEauhnyHSanrYuoWDMuO2a4C/mkWVgMFW5PpV68ugOI2GKxbpiGJzkVE5X2DlsIJI2O3uOtQ7Q4KjdkHIIp8L/PhR8p5OK2XezitjggcdT1FVBXM5STKq+Tb2gDwuJT6jiobmchIwgIboT7VW1DWoo4MvIDIOAKx5dejAYDaW9c4q27aEHRQeXHGcPuJ/nSPMudrj5ycscVyh8QxhWBxgHK4qjceIHc5QEKegqL3HzJHcJOixkHr1p0+oJ5eR1xjFeeNrF2wKqMDuM1A15eMQS7L6+1Go1UR6LFfRhcMyr3wKdLrVsiq7SDcBzXmc0srLnzXIzwM9arfOXO9uOnWhITqnpl14itQCY5BhlJwa5+bxMiF0jO4j7pHOK5vyQ5Uqu5jwpxkVEUAiAI+VuSQeSKdkS5XNS48TTNgRjZx1Y8VW/tG7ufnmuCqD5SFHX6VVjSHAUq+WHI449KsGCHYzLuMY75I4+lVYl7EU7QeZzJKDgEgnO76YqoxgSWX+IKfkGM5+pq7Z6bcTr5kayiEE4kPAqvb2fm3DLI20feUgZJ5pX6AiEXKiQOIFAxgAdPyqRZF5HzMB/dX9PpVxbRbW43rNiPaW6c59Pxp5WdHDBWywwFAIJ/GizQNnUXUyeYzxxefGjZLqNoqk7yXs5jhXyoiffbmtO4S3Vd0cMq85AyoGP8arfadkREFmxHJYs2AefQVLsiylPZG1QIWLbyCOOtUmUPO5VMY4wORmtdIZL2QyeYMQkZUD19BS3FuEhkdoygOG5GOfapdlsO1zJ8nEZ37h35qxDZsSvAAPRhU9xb+XHAUO4NgkGr7ws8QMT7toORnGKktRsYcEJd3IweowxwamaFlBjbAIPA9qvwRMsEYZS6E5AzzUlvApjmV1bbvwMnBFMfLqZ0SDy2jZAwz1HUVQ1C1BjwMNt7rmurgsW80KgByn3W7ms+5ttshXaUSYcc9CKFclq5y62MsUgZlOXGV9DVqOFkbdsyvQ7a6CKyjMkUU0UmHBXGehqJbdbd3G4mBn2+hB7VSE0Zk1hhjGACsgyhBo0sC5lSxnyJFyVyOTWnJbuIJIomw+Q/zD37UlzFC81tdwK0ZK5V06q49a0WhBJdW6W1ncLNA3mEbRu7H1p+nQeYGV0LlgD06Cq17eTagqQ3km2YMWxjO73rQ0lPLXKStucHk88Cs5Nc2hUUyaHQlNrHIMqXc/KT2rb0nS/ti+UpO4HG1VyPzrW0Lw8skSz3DkRTn5QT0Peu1FzoHhLQ3knlEUh5Hct9K2jFbsJt7HIx/D9Pscs85KSDpg8Ma838V3VtBI9qipJOp24HUVqeJfGOp65K6Ws0ttZE4A3YZh71gw2KAk7Mv1LE5yaU60FpEmNGUtTGsorkP5gZgfRTgYrYafVJAE85gg6DdWhBayHACAD6Va+wvjgAD61zqozdUjnntbqQ/NMxqSPTpu8p/wAK3Vs3B4p8dk/RhkDmhNhKFjMtbK7DIsLFjuzjGRmp7yGSxllmmtl2pGY3XOMk55/OuisrV4huBA9CaxPFk8sFslvLk+aRKwzztHTNbxk7HNONmcBMokkYRoVXPXFQ3ELYyBxWwX3ttC4+opotMyZYFc9N3+FZ3fUa7GJBGTIgPGT1rW2MsYVvTjnpUgs9snXBz6cVeWBtpQgZx8pxgGmnYJK5g3bzRhcSNtHtipNO1R4ZQJDkHvVy/t90JBA355FYscDG5EXBYHHXiiVmUm0eo6NrWyBSpU4Aq1Pri5d3ZQT71xlrbusahAfUUTRlVwy8MeCTzU8ovas3Z9djDEhxj0qjPryugDMxPsKy5ISirnkHrmoVTDEED24pWsP2jZovrTLGBGjZHcniqc+rXc25S4VTTSmM5Clh2oMYwOAMHqaq5JSk86Ylndnb1zSLCe4Yn3q6IyhLD06Yp0cWDgrnA5OaLlWKqQkZAJ4659aekQblTnHJFW0iIbGTk5PTrUjxbAzc9cH/APVSFYorDhs889SelPWEbDsbIYgHAJqcKu0EnBPGCKEXyxt9+3AFAWIHiJl2YHy8Y9KctvH5XznDnoCOAe/NWBbmRywDPkZPFNWH94UHufXFO6CxVKzrGPlBQDCjHTHvSxRGQEwglQTzg9Kv28b7ioLAqD1XIx+NQBRbRukhxhs4AzwfSi4WIQpjVGJ2HOckYB/woPliQB/3g77DgZq9JDDOIikTnJBPzAsTjsOlNNu0MSMY4hM/3VwcqPU88fSncW5TuXeRo03yMcheTwo7YodYo23wsryIwbdgc+2O/NWmtpbk+XKMoo3OiqFJ+lPltIxtChV+fbwpIPqc5pqQWKV3JHJLFI7SXEjksVbhAcYBwOgFJGjk4+V1U7irkqo49M1qjTjHK6oQ2AG5GCF9ePX61PZ6Q0zOCxjdOCG+YDHbijmbY7G7cNbTJbwywyQkgEgEMP8AOay7qVtkcSIomZtqsnbnvWPezXZUPM8ZMhwMnGP8OaoWeqTm9YInmSYKqoPAPqKWgkzvtNt2jSKCFUVm4Bzk/jVa5hkur8WuNxQmQrnPA65rnINbuIB825VA528kn1z/AEp9jr6RW9xI5zcytye+KOVS0GpWNeSBJJyASUT5lPpVllRLUxICGc9cc5zwKydM18RkZEYkfIwcYxV+TVUa9UuRtjG7JHGetS4q9zRVEy79lI3KwJjiwvPXPWp7axJDgttjxnnkHA9aZBqMMwVdyh87sj+tW3vITZlzIS23aqfjk1VkVzoZDEJEgO3BXK7h1BzUENvBJvW8XGZCVatJHtvJjAHzKQx55JPNNnmtlIEzhgULKmMgZ6/jSQKRAlo8olcFGdIzvXrn3HvUlnpyz2+JREQyhsMKg028jgklLo2WTarY468E1Pp955UkuXGNpKexNaaXVyZFGCE+aIp4wJCpUEDgjoDTI9LitEktSQ8UpBw/BVvXNO1GVSIpA0hkRuDngjHIqaSdLhPMYO2Tgg+w9KeiI1ZnPoU9xE3lxjzopNpfOBjPFatxJGkSB4xCUi2AYqWM3UZBQko6jeCvQdj9aztV/wBEglln/eCQEAA8UpW3KWhf1HxUmnWcUdmzSqc5jfkKcdq4y4ubzVphJcyO+OFBPCD2qhawGdy8xI579q2YiEXagzjnPrWE6jasi4U76skgs1UAyN8uOlWY2ii+6Mn1IqqHBPQ1MMY45rJNs32L0MxZAFx9MVNG7ujHOAOvFV4VkyFUfjU6QyswGfbFMRH+8HOe30qeHeQGJyD+dSrZyEA/geKsRW0i9QD34FaRiyZEunS5lCSAbOpz6Dk1wfjK5a+vnnYlRKchOmFHQfkK7nWIGsNE+1SMF+0ExoPbPJ/SvNpY3uLstjHoMHpW0tFY5G7sm06xZiuwfMW6Hj8uauzQYv3VFcY4I6jPp9PetPS7KVookcBR0XK8kf1q5c6fLGoA27tvTd1B7UmtNBxV2YH2dmlDu28E5bA4FXnt454U8pcckBh3/wAanNqyhhhVcErnkHnv6VK8DRRAAfOh3FW6H6GpKdmYN5ayGFlRBuU4O/rnH8q56yiB1Jy3ABCniu+vYw6ySz4Vgvyv64Gfzrk9AgW8luZZGwzHd+H/AOqrEzpbSBY9gUbW24IJOfrVbU7fMscagBieeOMDmtTRYy0TyNkrk4OOSOn9KqyKJ5nkwWVSUHNDXKZWMu+jVUUKN3zBcnj6VUAAlXPKgHB/Sta7hX5N2QPT2FVVgLMXK47AdPes22WoshSDLSAYCkgD1HFEVtuYZ6Bcj0zVqGIqoZ+rvnBGcirSxhZXJ6hflyOai5oomaYQx68h+wp5gCqDtyRxVwQkOFXIcHBz71IEG3awyQ2AQe1FzTlM8QHy9y9SMfSjyRg4OWHzAnrWjHb+bvQKAScAE9KFtsANt5OckHqBSbDlMv7MHiZgCecnjOKsJbq8ZBVsnByvQ1aFuQzbjtUDcvvn+dSW9uyuFymCN2WXOMUJ2DlK8cLKylVbYR8wUYx2780w2kobEO4KvKksADg+v1rRigCM8b/Mspyoxz15qOWICRlYSBs5TIz7dqq4cpnPbbz5qnJU/OXOf06VLNYGKNjNFjeQvHYHt7cVd+zm3bz96m3dQHDrxzxmrduPJtzbymeK2nHyyIQQM9mPcZ9qaVyeUzNNspElaCTaygbwy9GB9D6+1W4NLuJJo442EajLMsoyyrwPx/CnTQt9jy4aCWFyQwPBK9iB6+p9ati+TULRZb2ZhhdoSBAW4PQtnIHP0NWrW1Fykstla6ZY6gt80a37KVSMZIbcMDGagstPW3igivEM0Lx5HlMFwMfxHsc+tQ3MtreXSz3EzzrgKkbK2IhjgZPJI6Vav54ZVVNOeeLT8bLhpZOTk5289AMUc1xcpFZI63eo6hYwMlogG135wR05HrjpV2+sRbWUdvtuP7SkiaW48zC+VnPJHb8eetbcUcWoaFHbwzrZR2b/AHbrPlkZ4csBgt7VBrd1AY3kkvYrto4Vgd5osvcMPmHXkYBAz7UXtoUlrqePyllWTcodWGOeCD65qH7Zbr5SmAhh1y2Qfpitq9hklj3+Y0igAZBBxj19KwJrcG7WMZG3kn0oTMbGj5gaAHzlA6eTtJyPUHFRmRFh3DA44XYD+ZpAqgcoxXHOO9SoisgXZGwz3GTQDRWMSMAeARzwef0oHneWQshBPYmp1hZmYx4XHB+tNZWKNkYPcdadxJFGC/uEdl37WI6n/Iq3FqFwMZU5XP8AFUsUWVAVv3nPBIwcD9KiWBkmO4EMcbiOMGpKNCLXJ1RuD5nXmop9fb92S5JXqAOtRNEN3Gcj1rIvE2M2eg9RzVRt1DU3ovErPGY/7xDc+1aVlrRCbZHBXGRmuISJim9lIQcZqRBlSVGPoaNx3PQH1O3lmGGGFHBIIB6UQajDFMyt8wkO7AbjNcIJbgYKucYpyXcysCclgepFG4rnrGkaqftRVUVcgBjgsBVbxgfuZAKyYxnj8q8/tvEFzDN5vnSdMHbxmjUPEd1doik8K27nrVtpoLs3ZAqbVXG0dqfGTjaMAGsqDUY5cbj8p55PetS0kRgMEHtXJJWOmE0XIo9x45rRtrRjjavB9qLCNDnoSBxW9ZRgsuB0xnHFLU0G2WmOQCflB68VqRaQHZQxOav2saCMHIz2961LYRFpG5+UY4raELhYzLfS0EOxi2M54OD3qxLo3lIqozgv93/JrbsprGFh9tnihiA3O0mBxXFfEH4naSTJDoZ89lXYkqjgH1z/AIVtGKRhORzvxD1H7VcLBAB9mgURoD3wcE/nWL4d02S6cAKsaFsGUAkj6VyuqavLdXJd5Cqp91QvB/8Ar1UGvajG2YLuaI/7JxRK17swV7HuOm6HaOoEscsit0ONjA4689ai1rRGsEE9u/mxgZZHQ5Cg/lxXjMfijXBt26pcnaOMSEYrc0jxV4svbj7LZ6ncTO4yYpCGHvkEVXNFq1gUnHVnbx2UV68LWw2lwcoTwCOw/Ckv7YJ9hm+QrkJMvtnqf5cVn/8AEw0W5DSalYyzQsHaNk27mxnGASKgufEourO5je0aBy26NAQy4Jywz6Z6VDRXMmP8XOLewuURdkZBCyLgg4GOffmsWOyj0zSI5yUJkjB478ZxUXiTW57rPkwOkDBPMj/vFR/jWbceIZry2ltzZKiuy4IJ/djuB7U1bW4SZ22kEJocYUgEqACCCSxH8qVLZbZVDcqASxGP0/GqOhajbRxQ+YrLsXarN29T9a2pri3ubtYIpjLaxnAZm+85HXHXApXujNbmG0KyM7upWSRtkYHOOmamuLfeqRR4RnwMHquO5rYjhDOTEweO3A2HGPmPU/nRdwusqJtZrmb5t23Hy4IwPrzWUlY2jsY0VqhjDSZ2gcD1A9PfinCHzJHfbtVSAFIyef8AOa2Rb4V8qFiRQqKB949en9ai+yMGG1TGijLse2Tzj6DipsaqNzGhQhS5Ulm+QFvX1+tW/JAbpjAOEBxyBV+CyMkasiska7ipPUjOSfyqx9mKrHJFEFC8lSMFvqf1osVYxGjYBthBIX52I6fjT/J3Rlchedy4HLe/+fWtYWW35pd4BADZGfmNJBYytGjADeh24LAKMHp9DipaZVraGYYipifucfewMA9zUs1oUHAaXYQ25Rge457VoJbq3lF4zmQFJHYcKeoH60LCIiis5Hy7lZujDj5en1oasFihdQPc2xwFRseZHGowR+OPSmRwNK0EsSlyuACi4z/smtyO2Nm8rFMQSLnCjHlk9M89KsXGmyK9xNFE7WxxIQjYIx3Az04os2KyMBImCTNCkcquSHU8bcc9PSq4RoUYShTZJ8qSL8wIJ6EHqOetb8tnEiJqVtEjWjMizOVwDnuP61YurFYFnjK7LCX5kk2A8kfd46Z9asmxydxHJYTC6hljntpdo+Zuh7Hr0pk+nxI0DMVheQ5aSNi2RjP3a6KO1/0N1u5YmnCrD8yZAjPQj0/xqvcxSaRHEJJDcWZO2OOJxvRsfdbvjB7U1tdg4mfb391BchmtbRMLhZJ4zycjsOh6VJrUMMksRuNQW7lWQ5jtlwoHsB7+tbAtbQxNGjNfyHEheUEbHz0weg49M4pupXEFvH9t8iG3uxNhoUySxzghjwcD27VXS5NjV0RLuDQLM6ZCo3vJvjubhEeVs/L1zkY+lZur2mpRXgTW5rGXUpk2RRZDLDHzk5Uj8+pqzJq8EVvHP/ZNo0aMY7dFRlIHGfmJ7+oHtTXuY5nd4dItIbiSLDspxH1GBkkk9cY9RUodjyyBJFmEUOIJwdwlDDp6emKrzqj6lHJKoD878k4b/aqUlYblCBtUNtOT/nitbMNpM01tGk8Yx50Uq8Z9R3po5rGYLYbcgb426Zz/ADpDGtsr7kBkxhe4+ldHprNITHCkT28wAZPfscn+lY8iGW6b92QiscHGB+dJ6LQtW6mfGoVRk4bP4io5od77VJ6fMQOK2EhiJckgbMg4Gc/jSxQxqhIbLPyQeAPapuwsYbwLv5GR2AHGakigVU4Y4547ipvLaS4cL9wHAzzzTtu1cAgEnpjrmi7HykMMe6MuRjjA5zyKyruHcjkDocseP1NdJNCFgYcAgZ4GP/11mXURCEMQOMgbev1p3DlMiHft/esWUjGAO1XFt1A3RoCCORip1hJwX5OOnTAq6keyP5sYPIwf6UXaDlbMaSLYRnGGP3e9MRA2QykEdAfT2rWSFdzKF4PIao2gPnkNyRjOBk1TkxctjHePJ5UAEdPSohblpSoyAB1HSt14wFZkwQQOoquIyTvwdgbpSTYmY4Qq+VYjqARTkuLmEfJKwAPA3VpyQh5iNu7AyDn1qsIFaZxtJVeADxVLUWxLZa9f27ELOAT/ABuM4q5b+MtVi3YeMntkdD61iXcW1wMEc4ye9ROCCMkbqmxXNI7vTviRqUMZWSKJ5B9084z7+1QSfE3xFtZBNAqkk/JH3rl7SzkfdtKDAzlv5D3qCWAi4MZxkCrvoLnbJb7U77UZWe8uZp5HJzvbI/KnW0LyKM8A8YHNLbQnzAVCgn5cEcVp2MO6fanGR0B6ev8AKi+gmrlJrf5SoweM571A9uckq3HXJFa88eHxgqM4GB1FVJFfeVI+UdDSu2HKVEgGDkgnvkGup8Ho9q9xLCSrkBQynBxisJVKkOEyOmK6zwXH9plukKYYIpBHfqM0JiauTLYDzMn9Oc1O9qu3JA3fTFdClgx5fBPp3qCezMTEZGOxz0qG3c3hBMw9S0tokgLKCJAGDE/0rKW0jeb7gA79u9dFcwFkAbBx057elQ21mN2QfzNZt6m6pofBpyNBwMAehzVS603a+5D8w5BAxXWWtuFhyOvtVe4t85yM9uOKLszlST3Oat7u7tIxEzsYQ28qD1I6Gt20v49RfdvYXEgCMc4xk9vwqrc2oAOB9ay5oHhk8xAQw5yKaqdyHBxO4LxsweADcQBtbqdo5OD6DtUyRBY3HyiBAA6ufmJY5P49642x1KQSHzXY5OT6ge1dRp95H5YkVVd3YFtwLfN9fpVXuaRdy3cQKy+U7KCCoc9MJn+fXpSxQCRg2E3N8wQnjI5H6dfpQlwrS4ZuisFGOTk8ZNPt5VZAjhhs37fl4bPUE0XNuW4NCsjCVCT5jswQ8gt03D2HNIYY45C0e0xNKXdsAYXGMg+mTmrUkrtB+7Vd2Qdq8EBeCOaVbhFuOjfZyvIxhTx+PrmmNxGSWMc0a228FZHZWO7ggDh/zFLBbx3sEaXBRJ4Axk355AwMj2NEMjMqLuBKvkENyOxz7dKbLdqJCwk2zFmV8pg46lemMHtQmJrQSOOOzlQ3an7HI20xtyY5CMcg5O2proCzkNtZs0sDZCAEbkz1x+R496jurqN9ksXlNHIMYY5YjHfuD/Ws0ajI7bsRsFACvkgsM9xxz701LUl6F27W2tCDDuGmXEWZInAHlE8H6An8jWebkYNlLcKk9uOHfGHHG0OD1H05quJV8yR9qMqgIrBjtUZ5571DdnNrGGkAHBjdTyvbb7ijmJJLnUBIYrW5CrOH8xJ1IZWGOBnGccDg+lQSXsSQs8rRq0wKCKXO0L3OfWqSStNK5mllWRflASPOCOeoIqvIh82WaNpmA/vqCWx1IzkUr9RMnS4aePaGiuGRuGRsOUA4+Y44wO9TFzcMWYyPIykiPeGy3YkduKpARowSMM0bHd0VRmpLhbeMFFjkZ85CtOWz/s4AHHNBJaWPUMxMMq/EQWJt7gg/dznvnpzxTrn7PC0cX2e9jvIuHE5zuJzkcDgYxWpoWp2o0mGVI5POsFmK28Sb13uMLIWzxtGRzWR4h1NZmt7WOR5zbQCNppgVaRslice2RjNICinh+E6ZCZSoaXLeWMkkZ6D0NZf2Ca2njLL8zAjDkHMfrn/GunuNcjisorQ289pd2+Pl2cOfp9Kw4dLFwguHaZznLFhsTB7AHmtG9FYyS7kMzW7xoLadRIHAyWxtwcf/AF+KtHdaRrHNCtzFu+UiXj3wBzz61I1jbFkFrdQiRxu8t+QvtnGKq38s3mC2tW3uuCWIAMYHbJ/lSvYOUo3KI13ILeICJwGMYP3fQe9JeM0hERCb27IuAordWymFsI44SAwy07jgn2PU1VtLLy5Aqx/M5zuPJC/56VDLUCgkHkx4VzGEBZQOpx71Xjtt7+ZJuLHkdPwrW+zLc3ARZMohxyCCx/pUxtwk8obcpjAGCAMn3pXL5bGfNb+ZIiLgg4Zjnmq1/asIkDbWRu4Nalsm/dO24Enav0qK8j3FY1Hz5yST0XvUsdjEW3LEKcAE/Lk5FPW3kcbyMAcfTmtG4tw2xbccHJdTyFx/SpTA2xRINpxgEDAPtVMXKZH2OWMuWIIP4fSmRxkO/wA2dvIJ9PStpYskJkFwAOTnIx/OopLUidEQEkHk9RRsLlMmaKMQyKc525HtUCQqI9h+91Ge9bU9qJJfugKy5BU4we4P41BFbhgshX/VjbIBzzTZLiYyxHdI208Dp2qOGMNPKPujOSMe3Wt6S28tmkjTau0MnfIHqKq+Sg1BV6LMM8c9s8fnSTsQ4GNeWxJSZ1whJwT6etZ93CPOiXBAz6V10qvKZreQ4CrlQB0zx6VhX1q5hWRwCUYFgDwRnGa0SJZChkgQBZMBmG4BuD9amFi73G9l+8m5TndwPpU99bEWhJOMYyMY5xmtnTYy1uZAWYNEflZePzqkrkmNYWjPbZbqTkDHXrVq2iJkbdJiQcK3XkVd0mETWsYOcZyigZyauQ2TZYNl5M7iBwBkc1Ni0ZlxDkHnBB55zmopbddm5RnHbHOTWsLZDI+7KuHPyhc5x0zU0NrvlE1wuFHPTP06dM0JXFI52VWEbE7euflGKueEb1rXV4HAO0kxuA3VW+vocVe1Kzjdd0XzKARgDnArn7Rxb6kobKqzZBI6Gnbl1Jv0PaY4MDkkED0qvPAGBO0/lWnosgvdPhuOMSqD68jrWlJart+Vcg+3WiUTops4ia3BOAMH6Uy1tcSHOMV1M1p1AUflUMdpzyAPU4rDlO2OxHbwYjAUj1qC4gyeDmt6K2AXIAz9Kgkt8DBC8VNibHNyw8kFefWqF1ajZz+ddJNbAnjIOOhqhcQ4DDAz7VFmhOKOSntijbl69QaltLp7QFx80Z++o/nWlPDuBIAIA5qkYNqsSAF5GPX6VpB9DCUWtTZius7Sj4QjOR1HvirSXZ2kCUGRQOTnJGOv+NcdYSssuwmTC/cwc7h6VpRScqWyuPmDNGf5jqKdjSM9DqBesIgoEZGNp2vjt1B9agEyOwKCXZgbiOoI+nWsmOXaX/cyFcEEIW49+R0pElBDu6yhsA528Y9en8qB86NiZz5ruqkArkMVyGH5VUnvRIxZpXLYBO47T9R61Ta4PQx3X3cZjP8A9aomu3Y+YhuVKkAZTg0A5IsvdLMxIlRX2juCPb6Gmxu82xTKcLnlcHoOtVp5RKjnzW8zGfmiUfn2qtNJAwYi4TPYbCoHfoKERKRcmlWISFGKtg8N19QaoykyTxykHDnI4IyAOvpVeSeJplAuCyYBcxDj8ATVWbVIBKcSM4VcAygD+XSr8jNyNNRs+dYwgUFsGTBJx3JpVuALQRGNUj5yxcHJ65AJrmptXiVSiBAC24sqkn9aq3Osb4SNzl2yMbVAxRykOaR0kt2xjISUjyyJBucYFUG1WPazzP5uOilhjPtXLSzSyDG0Ang+1QmE7ecnsCaqxDnc9U0HW7e80hbe2v7W3dILlJ4JZlTzXYfI3OAR29q5LxjrTTNZWcVylzPb2qxzzxtuRnBJwvrgEDPtWhpdrPF4W046ZoljqczSSCeR7QTPEc/KpHXpzn8Kv67Y282n3azaTZWUlvYxzO9vEEMFwXx5ZI67l5weRQHMy9HZXF4wEcY+3I+DKZM7/wDeNWLq1tMSm6tmhn3iNW3b1J6HDf0q7dP5EU1qk0cUkx81WVSBjHIx6jGBU0M2n7ITM6tErrlG7HH3ivcmmrfM2sZd9p89vbzSJALW1ixukVlLP/SotM07yrISQ20ss1wxJDYIK/z/ABrYuR589vHLiCy3lkgB5kx3YH37VPqN1FBNJIkr5C8CPC7m9KGuo7WKSRiEC1ggL3ZbCRMxJUY5JI7Zq5caQsNnHDbTmS6mYAluoOOp9AKTSiLG6DySyPeXALSEDB3H+HBFXZpYlmmup1ZnU7Yx/GxA4/U/pSuXa6Me80+GGyhgtR5k7HHTa2epY+ozUM2mpCyWcZdmmG6dpFwUA64H6Vu2EMiXJa48ya4aMD5Wxg/3R9O9NZpIbzNsjvf3LBFDdAq9SfbJosrXHylDWrJLOKBbXEolUhIwMke9VG0+3gga4lIchcyMTzu9K6mGx+yv51zOAdoAZh0yTuxn3rNnt/tV6BHFttRIolcD5Wc9BUvTULHMafZSwtOwiInZAfKPI2ntj271cm0ohhHbIWRY/mzz15xnsa3LuOZ3LRxlL528tFxwy45zVi0jMFkI7X5ZYpELFhk5I5Y+ooSWwmrbHHRWqfY9iI3myr5m5W+7gnn61dW1U6dalEMokcZBGHDjGce2PWugjtLWzubjywfs7Rb14ywPrz1HJzikt4TA/wBuLBISRHEFP3WAxn6HJ/Kq5QscfDYO0pibYzzM2CTjBHpVe0tAJZ8LkxyfMAOvqa6+/wBOJs5TGifaBMZMg+h7Z7YH61V8iJWe5tsZBLSrn5mUgnB9McUrdybX1Ocgs2nhkiXmWDIIK9EPOfzrLa1kFtbyxAyMgYsuOcA4PFdjd+Vp2pJqDReZZSfupNvIKnByPoarx2f9l3C38kKtbJcOpkLAhom4Jx7Gq5b6GbRzUMUg1O0kQbVl+QM/Td6Gn6xpTm3vCLd4WjyrA5O3v19811GuW0cVm+6AGOOf7SjLgkAjkfQjP41bEcdnrNzYIpksNTthPZlm4BwM89+vT2q4xWzIkmeZkebpcWDuZlKncc896u+GLg/YJMOy+SCpO3OT2GPetNtPexdtLlUm3abMVwRs79eeg+vWqXhu1kjfULRSm0SSI7jHLAZGD7800ZW6EHhxS6Bm3oyOHJGQApznpWqyyuFlCMkjNgs3H04qhokZuZUtYyoZwwcsdoYjnP4V09vDFdNtiIYSxAByDgEHsPyrM3RioBHdyNImct8rE8juWq7FALuGYRgqAdxcyYyo7AflWnHp4upTOSTHbQ87Rt6dOB9TWtY6fFcKGhSNDgK6hcn1/GrjHUUkc1caS5gUxqzpICVz1Hr/ACrjNesTBJ5pTJU8juK+grfR47eye3iiSQt8wUgZGOePSuI8ZaD58LlIEVz12E8981c4XiZbMX4UXS3Jks7mYRQ581WPOMjBGPrXpWo20ETKIRjCjBOPm464rwvwRI1hqQDfK8Z+VWON3qK91sUtdTiiYFkJQHIPBOO4NZx1ibQlYxLpQqkhc1VGwkYDD2IrfaxVy0e3a6nnJ4rNuvsdp5n2qaOIp3ZsUcmh0qaSFRl8vDYHPUGqdw6+n41R1DxBpUKsY7pJQB/A2RXJ6h4xt4z+6U9cgnpWTi0R7ZHWs6kn0xVG5Ctkrwa4mbxmCfuE/hVV/GQLfcbp6VDix+3j3OunjDdBg+orQtNEmm0+OUpC0TOWZmBDKMf4dK4VPFsLACQED6VuaL4rSCbY0wktyOV9KqmrPUzqVE1oY2o2q2XiB4SPNVDncZPLyOoFPjZdvzW7sgGMeaMf5zW7DoV5r9/NqdhNAIpSNqyAnjGMVfi8Bai0hDXFogJJ3bDgVv7CW9jnjWinY5dIZXBdbW639TtbI2+nT1qWCEsjI8V1jG75JMcfTFdTF4CvwxYXUBUdsNg1JL4B1aNS4uoIxjk/N096XsJF+2RySjbIUU3pYfdXOabNcIpkBlvo+fk+Yc8cg0/W9Ot9KbfP4gtTKBysBZ3z+FcTeapLMSIWkKHkM461MoW3F7VPY3H1l1jkjS5u1JG1lwCGAPesy71yaTAkm3bVwP3YzWUUllXl3JHYmnJEQMqo5HOe1TZdQ52wku5ZG3nGcen61CwlYlix561cS3+QgHJPtUzRKUAwQQMH1ouCTe5miE5zjp2PerIgXgAflVorggBDnIqXaFwCOO3/ANelcOUzhABvAyCeMelDRBk/2u/HStFUyHzwOwphh8sggA76LhynWeF9PsUsdPMltcTXd7HcSCSK5eJQY84j+XqTisjxPDbBtPubCB7W1urcTmNnZyWyQS2ep4wD6Vp2K2unaHY3F1eaoxklaZEs2UJC68c7v4iD+VZfiHUI9Tv1kikvJQ6YLXRXdkZ4G0ABaEx2OhjcRTGSUbiVOQ0hUj6HpVZJ447hyLeQtj7vBK57io5XTaVa5dscMHjzj261Vtjkjy5QxIzypzmpaNbm810AhnxKq5AVHbk4689jTpdRN4Uk2AIjb1j3dT0rM3ytt/ffuey7WAz69KWOQjLlQwUFSohyfbmmkxtm5FdxbGmkkHncMZT/AA+oUH6mrtlNHO7zTeeZmTCnIwq9uT61zNoXO6JbcqSePlBbnpjniryz3awwqrTlFyVBXgDvzT1HzI3DfQwytOGkWWMgLtXOCe3PWpbSRVlMk/mNK/DqoPyDsAf51zKXjPciaSNh/CpCs2Djp9e1XoZpmUu28J1G4ZIPoaVy7pnQtdJE6O/mER5jVGXlfTAzz1pVna28mA7B5Z4AP8R65HfFYvmSGRJXimlDfKqyZwMDk+lSQSSeW0jDyBtKsxyCR1wMfzpuXYqJpJO3mFxGTJIzCA8/KAO31rQieOe1bzBHGsaDc5kJcjGSvFYKzhoizsrSKeMNgg44H1qwJVCRKyNheHIOFDZ5570k7FOJppNHLbxvcQGNjELdGHJRD1fHpiqc0yQSwRQbZIoSDHuH3gDkgj+VQy3YKoVdFQk+Yq8llByO3SiTbPLHGsQkiJJODwMnnB/CquKxavLmSN4Qu3DQ71jxz16Z+lV0gSKRBhxDIWjmzj7ucj8BVG7uWjuP3UHmKgwpAyQMHcDg89RSeawUqryEBSyhPfuc9vak2iWSWXksl1p8mBbFWaPeAdrHII9e+QaW3uYpNJvNJ1HLeSP3EwA+aMdz7/Ssu6uWaJG27Zl+fgcj1/OpL1xcRxSxsrSxENEWPG0gZBHvTUiGi1oPlyW8Wi35HaSKYn5mQg/Lk+mRVO/02ZYV0xpnFxa7p7KWQncoABKr+PanXtzBewSuUCyuyFSgyUI4z9BUFvc+eYRdSOs9o27cpyCo7jd0rRSTIsOjvYta0+RgznVxkSwuAACB94H0x+tc/GtzFJqaLlElVZiSvzDOecc9u9X5rUpbpqFiymdWIeJhzIC2efU4xTma21Z4LlF2TfLFNADwY+hIHqCc4p30MuXW5G8Labr4mSCGEwQbhFuyHXbgjnvzmtDRPLSzDgCQsPK4/wCWTZ4b8c1RaVJYzvIcFmQY4bIBCsc0QyrGpQZUng9/xH5Vi3Y2ijr4ZhZLaom3eEaGZIwe/rVrRLpLSZZJ4HQFtpYDge+O1cvbaigMiTDiRcFujbh05/GqN74iWGJY183cBhhnhh2H0rWErasmfY9u0Z0QyAXMbRsxdtxA3f7OPT3qn4x1jwuNMlN3cwx3CrtCBuU46ADNeESarf3CbEkeOP0DdqqtZtIQ8u52Pc80SrxWxmqcpEVxrDSamzWMZZA2QX/Sul0zxHqNpHmCQ5Jzs7DPasqw05vMUFMLkdK3Rpa5cpnZxjPWsfa9jVYdvUpX3iXXJEZjclW64HaueZby9uvOvLiSZ24O5iePp0rqJ9K3KeSPwptlpSq/Jz+FWqsmOVF2KVxpQ/s4vENrDnArlrqJVBDH5ga9cg09TZSJxyhxx1rzfUbFvtEmEwAfSqk76nLy2djnigJ4zmmC3J961mtyDgDn2FMkjIIDrkCpEZwt9uSxAz0NRtEUBKnA9q2Rb5XK8gUx7YHuNtK5aiS6D4q1rQvlsbnMI5Ebjcv/ANau40/4uSiJVvtOVnB+Zo3xkewNecm3OSNwGe1RiHM6KT14rSFZrZkOkj0fWvi3MR5ejWJjYjmW4OcfQDiuI1TxXrurOY9S1O5MTfwBiqfkKrJZ/vBv+XOeD04qAQRylwNoAxjNVKpKWrEklsRrGiklHOQPTqas2KRuSJlXfxgCordBvaNueTh8dqtywojxldoOMHHU1nuUnoPWAiQ7VHP3vekFsxDFSAAeOaltyGldf4xgYz1xVlELtJ8vzA4IxSbW1jSKuQC3xKoPKn371IYWTeCAO/BFSBVZY92QAakSDJkJXcSMggcCodikim0LOcYPHPXpU32dmiBGVbrtqUruEYYnDcHFTGEK8ZD4U8ZPJFNJWHYofZShUk7SeD3qRrUOyqhfb3NaUlovkv8AKWbqCeBTIY3URSOyShSG8og4IHUHHaiyHY6DR3vo/DtrDpuoafYSK8huEmdA0hz8rHIPbisPXYL+a9Q6hdW91MqApJAVKhcnAO0Dnr+daqX9j5cjnQLETccEvyPzqpqRt7x1uLazS22qB5URJB68nPeqVmKzKV237j/lq3YAtg5PsaoOHiDri4jIGMFcBvxqodStblwksTbznnzDuJ7VMsgiuMpLBsUZ2NIWBJqWiblyOdIlVZhLwAVIfjP5VLJeltgXeqHggtnPoapTXls0kRkt4mXodjnGPzqXz7Hy2MaLvJ4KM/AI6YxU2bZamiZ5yCJYZBnPUAjGf/r+lTfapG5CKxHJJyTn8aiRjPbfvN5CDBVLXoe2WNTyRloOLe8eBo+GEKque5zjpmr1EmPE8ghxNKu3klDJ09+OntT4PLcqFcylhyEHOfTmqsdm8dq7CwuiHX7wGQP0q2kkmFZprngZaMRNhcflUmly/CxEW02tyZAch95Axjp7VK5MhQLa7pgD958Z/DPNZy4n3qrXUsancyeX09+TTSjFmlS3m2kjDSMqgj24qWODs7m2k7xQIJd7ZX/liqkD26Zz70I0bR5y8J6DzHbK9x2rHs45Gj3W8dtgk5ElwoIx16mtKI3LwGNCoOckI0YH4kmjyNOdIvsGaEAzl9uMqCOFHpk5pGndlQPA20AqCy4XGc8YrNe5umcxrjYuAQ0yHrz19aWRU+zeZNH5fOFbzQ5znqAOafoHOWHmRw7RGOM4IOf4fpmqjEK4EOTASu9g2Cc9utVpJ12ZYgDGNxBB+uO1RPMhOIVh2gkbs8kmi5LdzRcqM4Ei7jllZshlB9evWoDI4wpjb5stsboPbjmqqlBL5JUqAu12L4A55559KhuJgrMSJgTgLghifTP6U0Z8xJLMDIrRo4YnPytkDHX9R0xSGWSWQhsFnOHOcnb6EHkdKhldTcBXkRPKj3fvQU3Edh1ycmlVmDM88iSgocFWD4z365z1pxuK9ywk0hcyxEJj5hk7dp7e9RSRPLPIyywFnKhpEPX3PHXuaSO82o0bSRzIBgeYjEdPpTIJodjMokRiOi8BfXH6U3dgJG0iJsLEqvXaMcA8E5pxudmzJwV5Oe/1qG6R1O/ymjilXIDuOSOtZd7KojwWBC8ADk0mmLmsWr29mmfaoYd+uKLK0aZg2S3HXNX9N0x5bcOQAM/nx2resrVIFwoFZzdjWlDm1KtnpOB8/wCVacenoozjp61ftomcEge1XUtVI5OTWfU7YQS3MuKBcABTn6VoxQMyDjr61YitwvAFXUTA5471cUVJJGJNattPemW1mxc4wPm4PtW1Ig2nA6+lLar8xCrzWsVqZTWg+K1xack8D0rgdZGJpVjXg5ycY5r1gbV0uT5cORzxzXkniPKyuFO5SecfWtGtDzZ6SOdeFt+R8xzmmMjMTlR61pWoDKcgE4zzTZ4DC2PUZzUtaGSabM4jaQFHWoJQcDGaumPLfMB+FNeDJAAAHuag3S0KcsQALE4x0ovrbYsRAAJYcg1Oy7unPqDV6e2L6SkrAEBipA60luNrQr31uyxbgylgNw54qvbRonDrjeOw79q07eB9QuYmwGRUG5RyM1U1FBFPEijjeBzW1jFpGXeo0M6bSN2/Bx3qdpp5nSHYpKDdnbyPxqbUoc6hbrgg53fhS2kbPNM+07ScdPSlrewFRNwuHPcEZNalplZyME71zyO1Q2kQFtI8gGDnAx1rVijd3hkIwHU5x6e1JGi2KTR7s4AJHYCrDRE+V5fXOCDwKuWtqrLM8zMEDZwBT/sBKQD/AJ6MPwxUWLsU4ULiVdoOzHPpViSAtLlvuKM9K1rW0SOJpG5TfgsP6VJaxeejgLk7sZI5KjvTS6DsUHgVoV6lsjIxkYoihSJ4FZPkVskfd3L3Gf61pSQZUrHktDJknPUf4Va+zB7tUGSu3GQMjOKrlexVkSaZpdrqKNd22gs0e/Zua8IBx1Iz2rL8Q6ULS4wtkLKNV3GMT+Z1JG7P9K6HTljWNIpBMIYDJAzBMowcHgf7Qz0qDU7MxLaWqiV5LeMQs0qYc4JOSPTBxQriPDZ7bAJAOfUcVFA9xFvjSRlVjk8VszhNhKnJ9KrAR4YEYIpHNoVXnuVEbI5DJ3UAVah1mdHMk6mVyeQ5bp+BoeHIUZ5xUDw4IGMmhNitY04NfQ3e5rSIIQMxiR1BI75zWlJqUBslzbKrjKErdE5/4Dn9K5g2zIxO1c+wqQRqE+cFlPUA07XC7O1it/PT7molcA4S4Rx+P+FMsLePDu9xd24B2kNAzqfb5T7iud08aWzhLi8ntmPfy9wHp0NdboXhyyvyw03xTbnLfcfKf1rRUnLZh7UhLDziTPZSsqjaZVdd2RnvUUUzOUxZabM2Tx9oKnH/AH0MV21r8N9YdibbVrOX+LBcnGOnah/hJ4huI2dHsJGf7yscH69OKToyRSqpnE29u0rCU6RbtEMZH2jGRn13Va8uNrrdHo+1QpJQXZP65rs1+DPiAwRySR6bHt7eaQT7ninSfCvxCAoj03TWC8Eic8/Wp5GV7RM5Ca1ES5fS2i+UnJuh+f61EAkZXbG6/KT810pHPt/Suqf4Y+KIZspp2nMACMeduB46kVm3/gXxHp8btPb6XEvUlmXj25FNU2DqoxYy6KkMlx8h5/16kD68cVCfsiDask0jE44ZTu6dsdKyNSkmtpJVnnst/wDEIdpH6Csl9ZZcEtGTjGQoHfNJxtow9pc6cvbGJnjLMzfKAR+ZwD9KJLyziR0jlAPCkyfxHg5HBx2HWuKOuMmRG2DnOcc0kV5NeP5cXmMScgAk80KJLqHTXF3amIAPIWcnJVwQBjjjHrzVOW4tEWXY5DcYBXr696uWXhu9lgWW+vhAgAAU9RWTq2iSww7oNQjkQHADdabpvsT7RA94qRgKwO7gDNaUF1/o5KquSAuSKy9N8H6nqGGt7qzLfe2NNg1rjwR4jQKNtq2OcC4HNP2U+xXtkNvL6Q2+AyiNG37Sw5NYs8xmuAzEOPvcHt6VsXXgvxOibfsCnHB2yqc/rWbb2E1hcy2mpJ5d0owyk5xQ6cluiXNS0PTdDZLnToBvKttyp6gDFWI4VR+c7qwPCGogJ9nfaPJ+77itwXBkYk9Sc1zVFbU78NJbGvasuBzx6VbDjHFZdpyQSce1asKfKMk1nHc7khVDMOc1bii3c8n3psUYyMknPatG3TIwowK1QpFJoxzhTzU9nBtlHGCDmtBLViPlBP4VPHbMoyykHvxWqMpaojuQRaSuB2NeRa4V3SvtCksQOf1r1bxFM1tprhP4/lAry7UYvOu0iK5IHIq7XVjzatrmdpsJdCFQk+tXpdPkZFJO5fcYrptG05GhUDCsKnv7Bki+TtzjHWtnT0MY6O5wNza+X91foajkhXyi2cEdq2rpDvO7jPGMVmvbsZDg4UVxzjys6oO5jPHuO5jgHip/tISyEY5y+ck1YuIhjAX3qpLGGG0jDZ/A1KKaNPwxIiwTgbhI7YyTwBRNYG78V2Nkzqqld5cj5cetUbB/I8oMCqCQ7nH8qvaPvu9bMk0bOj5jXHUgV0Qs0kcslrcsXlrHNrd49ptlit15lPQAdhWXLE0Nkm0MJbh8KD15NdtrMVta6dF9nKoMhGQDBPtWSYYwY57mMuwZViQ8cdyaqUbMcYvcq6lpDx2sVqiYPl7nJHpU1vbB5bUoC0USgt6Amr1xKTcXDTqxMhJxnhRjgVf0iBLeAG5jZmIGEHf2qZJXNoorLpe26u9o37AD14GRnNK9q5m09JjgbjvIHQYrVsrbbEzyx7Azkuue3an2sRmujcZVoWPlqmONucc0cvY0KmpW6QJtjRhGy7iD049KdHZPb2iSuQsjptAHcHtWnHbNNf3KAB41XapJzz3x9KbaEnVIAV3xw5C5H3mp6blWIbXT5I45sjcBCOUHT61LDB5FpCroGDAbfc+tXjIpv3+by4n+SRRwDSuzLv25WKD5oyOqntQlYOW5Jptj9p0RI3uhHGszs3yEggnrx37VPqNtBNLbfZ5WlMKiOVmXDMMn1p9le/Y9GtxNqM9uZWbaI0Bzzkk1DqsoaP7VFfyznyxKQy43JnGQfY9qVxWPn94GBHAGO1RC3Bm+YHcegrWkTaWlUbs9DVTaSynv2rG5hyIhmgKriNevWmLa/MAvfkmr5XDbn6moioZ8gEenNO4rXKhgG88k49qZcRKFZVYEnv6VoFNu49PcVXmhVYw3HPtTFYyJoAcbuvpUXlktkZQg+la8kAVBIVyD0FV3ty25wPlHTNUjNonsdb1fT1xY6hcxgDoGJFdBpnxb8T6QuyS4W5A5Hmjn9K5h02w8/UD1rKuo8gtKD0q4ya6kWPYNK+P148wXU7AMMcvE3P611SfGnSJYC7SXCOOdrKSc18121tk7+cZwK0TABGNx3AdParVVrcTieya/8dLqQeXo9uAD/wAtZOMn6V5Z4j8Varrkxa/u5HUnhQcL+VZKQlkGeFzxTzBwRwSBUyqN6FKJREcjj5m/CmNFhcnnFaaxYOSRjpUc0QxtPP4VncdjI2DzAOlek/DzSYWtprwlRIgwA1cAkYWY5Ofwr1L4bWSzWMrO2CD09qunuKSvoR6hE0m4yfNnP0FY0tuSxCrkemOK9FubCMKR396y5tOUscDp7VM5s6IUPIzPD2lWTKZLwgN7cVr31jYLDvjnbOOMP0qaOyjW2KBOe5xUR0rKhmHFQ6jWxr9VOSubq+tpybS7nC/71Y10s9zdvPcszzucs3rXdzaSueDwaoy6QcE8c1lKq3uV9WscnbF4Jd6uQRyM9jXWaTqqzBTKcSDr6H3FZtxpe0sCDgd6pG0kiIOSR9KFO+5PI4bHpVnLE/zIQT9a14HLuB2rzDT76a3PBI9BXaaN4gT5RMuPcVXU6YVuh3Om2LXO0gYGcFiK6zTdOs7Vd1xIrPjgVyul6lFNDthlCg4IBOOa6AB0jG58jHHPWtEl0LbuW7meGOICJMY4NY7XcsriNFDfSmX0wCkeZ1PTjisS71cWMMghJa4kGEHHFUTJWRU8V3UhuFtCd5j+ZsHofSsbStNt3LSvvnmPPAwAfrUMMN/dzsk7ohkbc7Hqa7a0tfsVoscUqkn0TFaQ0Z5s05MoRKIYFYxIg6YHUGs27uiqtn6CtS9lAiJdizZ5FcrfT7HY7vl9DWkp6BGBS1HY8u8c5NZ8qk4BIBHSpWcSEkfp0qFmKnJrjm7nTCNinIobJ7kVmXSlRnr3OK12CsARxkdapTr2I5HQ1mkXMoW6NK0cOSUd8keldhpkREMi2KHzosMvqKxNLijVmklQnPyqfet9Y2t/3gYKQAGx6n/Ct4aHO1cj3y3OpLcyso8hclcfxelaNtb70e4uZN0sg2YxwB9KisrJZFbfnA+YknAPoTUA84xSSq+FI2Jt5ye5rS7Q1oLBbTSJNKpBR22rn0HfFbmnpFIgvpWZ9h8tA3H4is6JRHZeWXO4YUIfvY9q1opcWxU7EULyB2qbFxSLF7Mn2KO1AVrg5ZtvQKfWkudttpwjgJG7gY7VRtZI1ywbJf5R7DsKstMVkjO0HGTljwKTdzZItpKlvGoOG2r8gx94mqZka3QMuDtbcQBznvTRcpEpZzmTOUXrtNRvco0BAK+Y2eTxS5tLMfJfUmMsagjaxZzu4OcGqUt4FTbIC3mnr/dqsZZFiCiVSecjNVbmPOwGXGR0Bz+lTzD5bHQQ3o/s+Nr57JbLcfKWZWZie5G3kCsvWNUntpJkcxNDcxoIpIR8vlg/dX0GetVjdWRsora9huJhESUkjYIwB5IIPUZqpr8iyNZFVMVr5P7hAckLk9T6k5qJNsm1jm5IdiBj+AqqYnMyggYHPtW/cwH5fNHGM8VQmVt4AXg07WOexnyQl2IU8e9NW2KqfatW4t1VDwRJ6VTMJWFgWO72oCxB5eLUnIzVcnzHSL+HqferTgtGIwD6E002wwCe3tVEvUjCGR9hXlKLmPahVR87deaI2YXL5yBUYL/airE5OcZq1qZ2KM8TebGhAAIzUd1Y7x8vHFaEgIu13DoOKuLZedEJCQpHr0pog5EW2x9oIyO1aCr5UDHZgHjmm3ls0Op7COvoa0b21dbZUI64IxQxrUy40/d5xxUgjByeKWKF8leRj1qwkbAYxzWbZoloU5FZVA4zUf2eSVNyqWH0rQlhyB8ucVpaUqrE21QT06VcNWRJWOVFjMZOI29wRXpPwzidVnhPygGs+GAyliqKAvcKK2fB8hj1ZkYYDjjHStOWzM4vU6iSIyZJpqW29M4+Y9q1mtjzgHNSQwFc4XkCsZI9KnsZKwZQArgilkChAB39q05YDICxXn6VVeH6LWZ1Qjcz5IgeoGO1VzCrKRgVfkUlsY6VGIiCOOM1EjblRmS2YbOAOe1Z1xpSsCQBnPeulK+1NZNynIqbEypp6HD3GllVbjjNUkla2kA/hrvJ4FA5A/Gud1XTlcEqBnrxRexy1KJFaatcQMoVt0Q6A9q6a08UXoiVQhYegOa4GIyW04jIbBrttGnY2yEYL5wcDqK0WvUyhNr3S7c69qUy74LHamOSx/Wsyzs9R1O6Z2cq7HJK8BR6VdnuWC7fmU/zFJZarcWpZUwyn061rG3Vmj5mj0fwzoOk6VbfaNRmEsxGeuTmszXdUje6/cDZEuRgVzS300qZYt9AagErFm3A+uTVc6Wxg6be5enkLAktwT3rFvyrgYAAHQetWrmUOqrv4HXiqLMoBXk45JPeolPmNI07FTyGUHHKnmq1z8nIUHritBsgdcGqFwj4yenoazY2rFcHMfKqveqkkm8HCgjpUs2/y8ZIA6Co49wVUwcEgZ6UIzk31LNu6xKkbgAAZq/dFQls6hkU46n7xrN8txISdqqD65p2ozyG1AZsqp457+1aKSSItc2mZZJWaV9kSgDaD1arNvJDHHsEigEcKc8fhXJ2t+kcZRTlhxgmnf2jsG0HAJ6g8mmqiQcp0sjNE5OQHHR++DUrT7drKu8kY2nn8cVzlreSzsQhCqOpPFSPdvazFZZkZevyv1pOVy0jZW5TLGQsZM/LtHFSi4ef5gx2+jHhawV1aKMgLHCMDuS1MTUQ0j/uRKGyQFyB+FRzI1TNtZVR2w/msc5CE4FRTvGQQUkBzhSTjNYqXaAuUR1z239PaoGvurZ577mzmocy09DblmgA+868Yx1xTI54VliDOwjJyxXGcd8e9c7NqGTksMf3c1VW6W4uIoY1DyOQiKWxkk8UJt9CJTOxlm0NSSJ9SPPfy6qazeafO9pFa3Enk28GwGRfmJyT2+tZi2tg07W638r3CnaRb2jyIG7jPf61Jc+D/ETXCC3sXlt5FDxz42KQfUNyPpVKEnsjGVVLdnQC3IfdKTtIwB2qC4sgqiWQcngYrqdQiiKoiYOCN3HSmX9rE6qpXAI4ANaqIbnI3Vv95x1A6VWigzCBIgYk8V2M+mGWMJGAGxk+1QHT0a3beAHj60lHUVuxyBgC3TLtwSO9NvbcRBF3ZJPpW9d2LxvHclfkbqfal1HTjLaB4vmPBo5WS+xyd1blJ92OozVS9jYeXIAQOhrsooFmVNy5YcHNZcliXS5jZSCvIGa0UepnJHO30bKiSrnA5zVqeUDR2kz3HetjQrZLhWhuRtwO9VrrSHFreLG4aEEkY7VUYtGRzt6olubaQcsRirOos5kQEcAY61R0qVUmVbjnbwKv3kolYFQdvY1nUZcFqV44cc45JqwYto7nmpIFLACrcsB8rpyfeskze1ihsBIJGKu2yiMegogTaQCASfSpnjIfkGtoWRjJFyz2chHGD15pLO6FnfxzYBKnnHSs6UkcRjaaWztpJZQCxG7jpWsndaGUVaR7Jazi5hSVV+UjNWzhQSo9qw/COTZ+TK+WjAANdJAoB55rKSdz0aT0K+RyCAPpVWREY5xitloCy/d4IqrLYvggJn6VnY7INGUbdG6c1FJafLkZq81v5RxnFN2sBz2qWjVPsZDwEHNV5BtGOa13I6H1qlPGpGeCM1DVh6GdId2M881UuY1YfXtV90AzjINUpEMr4Xrnn6VKTZlVmoo5rVIVQlsAY71d0iQtb5XP4Gqfi68iiiFrHy4GWPpUOgXkKwBGfBxzWyjbY8tTXMdDK4K8/wA6gilO4r0PtTZriFkyjgkc8moobiBjlHWjlbOtVFY3owVhGNuaQ5xyRk+lJBMgjGSpPXg1FPcxA8MFJ75o5SOdC4Ayc5IpjQiTJY8etVWu4w+S4wO3tTZNTgRcl1wOhJxRyh7Qt+SCMVWnRc4ODjrVGfVTI22GJ3Y9cKTUaW2t3gf7Jpl04x2Q0WYpVEivPIh3AH5h2rIurl0KgH7vOK2B4Q8WXL5j0qX5+fmIBFX7f4SeLblt8sUMOeMO2TT5JPoYTqxOW+3uEyz7fbtVGe/Z3CgkqOgHQ167pPwUuEKtqc5mIOSq/KMV3GnfDaz09ENtp9pHIDnds3H9a0VB21Zl7c+ZobXUWdpI7S4ZCeSqE0MLxWLNbzDHy8oeK+uk8PXWwDz0UDqqIFqVPCMMgBlRH7nIq/Yw7kOtI+QoRdMcrBM3sENWvseoyuu3T7lyeg8tua+vI/CNlEAUiTnqe1XY9At4yvlRovHYZpexj3D2zPkG30LXbniLSroj12Yx+datp4G8W3SAiz2KBzvkxj8q+sY9KjhVygLEDnjFIlgJQuwqvGCNuKXsodQdeR8xWnwq8SzMFnlt4VPJIJbGa2bX4MXbtm51RgMcqqV9DxWyL8qkB168VZWzXaC0ZyfQVXJCL2JdWTPBrL4KaYgBurq5mJ6/Niuk0r4VaHaSxyQ2y+ZGwZWfqDXqv2dFzmPle5OKmjtzvUoARVXS2RPO2zj7fwpYxyfJZxRkksShIBNXG0WF5F/dYVFwBngCuobcA2VwPWszULtd7bAVQDB4oUrg3Y8Lnlj2yCMAlqWJTIqo2N69O1eQWHiq+tx8+Wx0rqNI8awzMDP8j9KyUkdiqHoc0ikK6HYyjBx3qtKiKUKt8spw/PesSHWoZJ1kjkVlbquavS3sMoJXrnIHvQlctMt3DQrss7oHHIDVFbWyr58Y5AJ259KjYi6EfnAHHQ45qKQPbTMVc7WHGaq4mihL/oeo4AzGRzgZwaWe3QTNIclWXrVuEqWeSVAQ3eqbzG3LRSndEW+XFO5DVzMvIx9mE0BwycMOmRVbVFRdL863c5fhhmtTUolQbk5gfGcCszVIfKswkeGT37UNsjl7nEalb7J45E4BABxVtDvCk8jGK0LmDzlCEY4z0qrFAyxEEjjgVzzLhoy1bnGAcbsVbBLYHTPaqtqgwdx4AzzVxNpXgjPqKk30YJCQwYr0qabdIemfqKfHJlSCBSggsQo4HvVqRDjoQwQK8vzDjitVrWIRfL98c+oFQwRAMGOM1tWFqlxiN0610RaaMZRIvDt+1vdrv+43BNd3JIqANGeG54Nc1/wj09u4ltxuXuDV+3nkjkVZI/l70noaUtzchu2ZlXd0FdLoNwh3eYqsOBzXBPdAXOU5HStjT79UUgkjPtWZ2W0Otu9Nt7qXbCm3PtXOapp5tJCrjBx1ArU07WSkqYbI461Jr9zFcwF8cgUWuCly6HBXucnA4qixO3vU+oTgTsM8A1Sa6iSP94cd81k4GrrJLQmSPzcA5yeKzPEF3Fplqwjw07e9Rza2iZW2G565/UVe4lZ5TuJ5PtRdRWhxz5pu7OdkSa+uS0hJYnJr6M+H3wv8OX2iQ3F7ab5nQE8nqa8L0+3/ANMjjUYywGce9fXngSMQ6BbpxlUHT6VvT0i2cdVWdjn7j4S+FZI9g08YHPykg1Wi+DnhU8m1mUjr+8NelF1HU0B1J4I/OjmZnd9zgf8AhVHhxQAkMmB/CXNPX4U+GFbcLVif9piRXe0xpEU4LAH0qbjucUPhh4YUD/iXxt/vDNXIvAWgwjCafDj3QV1YI7GkLgHHempNCb8zDtvDGmwEtFaQo3sgNXV0q1VhiILxg7QAD9auo+5ckjr2NKZABk9Kbk2Tp3Kg0+BSSFNMNrGzgyK+BzmrTTJnO7gdcUPKm0E5I9qLsTsRLawsVbafp603Yvz5UjB4IHSllulUIRyc9h0qNLoCVxvwPVutF2IcqAg7MMR1yOaGjikQgDcy4JAOMU03EQ+dsHHG4cGkaeOZPkyemcdfzp3YEqRIVLBQQTyG6j8aFRWYjYcBcDmoopkC4Ktu6YPBppbb8251BPrnFICyoxhQhz0OT0qOYCMuMAlh2HNRi4zJje20DGD3pssu3+Nd57Y60ASGMADb0PUHHNWxjZkbv61ntJIcFwCPTrT47jCgKrZPXsBQ9R2sTBRJI4fIQ9NwprbI8bjhQOOetZ19qnlpwwBHbPFc3rfiKG2QSXci7B1wegqlFtBY3dUuoURjczhY+o3ZB/DFeLfFP4mCz3WGkHfKF2lip/Oqni/x/wDbtRm0uYhLKVeLqFt3l56MuP1FcL4tsM/2XF5q3BjtQDKhyHO9uc1Dqcj0OiNG6uzmzpwAI/pSJpoDjr611M1njdkc5qJbcck5yPasHKx0qj1MA20kT7on596ntr+8tpMszEYxWxJDxjP5VFJahsDnpUqoN0X0Lmla6ZMLK23Heti5vxMqJJyD3Brj3tdhOM/jUlheLBNslcjHAFbxmpaGMrx3OqjmeIGN95TPBz2qRWinn2/MUx07VnrcrOmYmJbgVdDvCgWSP5NuSK02GVboGJymd0XPfpWdeBnVRuO3PTNaErxOpIchz/C1ZUrEuUfIIPAqWIoXDCSXhdoxyKqMjowXIwOlWXDbW6gg01zkAgc/SsmrjSdxE+UdA3HPFW7bCkE9PSqSM2/G3jvV+Ffk5+92qTWBbh2upHepUQhj0B9qqKjb+/FX40YkcDp3qFe+pstSWMY4NbGmT+XgsRketZYRiAQKlDlPpW0ZWQnTueo+G9btHg8u7AHFGqWFo8nmWsqjd6HivObe4P6VfhupmGFYjFUpjVM273StiGS3ly/XrSaVrkNpKE1K1Yqpxnb1qmlxOgBLZB6803zjIf3gGM+lNtD5Hszf1jWtKKCWxQqw7AYrmdU8TMYwEU4+lWw8Cqu9F61WvGjlXhFx24qW/MPZo5a41W4mYFEJJ9abHZzXozPKcH+EGtqSGBcZAyPWqe7bJhQcZrJ92NRSIFso4EIXqOKz7zIJCitWVnbPIxVKVFUEtgnsKSVyZ6DfDNm91qkKDnkcZr6R0uR7TT4oVXhQBn0OK8z+Geg4f7dcpweVr06Z12LjjA7V3xjyxseXUlzSJH1CZXIDHHXmmjVpQ5w7ZPU5qhK7St8vJHY1FkI+AoJPXNOyIZu/2tN907sEdzion1aZWbBAHQk1EqxiFQp+YjoKqzKS5EmAuOeegqeVIRotqsxQAtxjsaYNVm4w/fqTWcEQfMD9MdKgkV0Yg556EU7Aa/8AajMCxc7jwPSj+05Soc5wO4NZcFs3JZt307UrI7EqMLj1p2QrIvy6ocbiCQe2ab/au4bgCD04PNZQTO75CTTlRdpIHU5Jz0o5UOxpLqnzYdiOwzzTl1Jmb5nOAfTpWfHGrYdBllOTmlZlfgEb/aiyCxqNeM5BBVlxjB6U5NQKkgMqj2rGZztKKcY4x60krnaqv81FkFjbiu3yW3gkjpTTqAQMckkH64rHSRY85GG7U4TqRtIwe/FHKgsjbGqkIP3mSB0xSxah5jb2b5uv/wBasPzYiwyxXbz9TULXGxgUJ+vrQ0FjpPtJw22TP0ps16kEJbdzjpWCLp1GPX2rJ1a8bJByFUZIojG7BuxL4h8QR2MMkssgHBPPavB/FXiS5126kjheQWu47QOrVo+OtbfUrg2kJOxThzmsTR1S2v7aSRSUSRWb2Ga58RVUXyROrD0eb3mTQaPHb4juLqCG5/55bWbacdGIGB/Slls5IJzHKgDAZJByCOxB7iujFs63dk5neNoAMBImYycklkIGG3Z703U4N80MYXa0aEMufu5YkLx6AgVz3PQhTuV5wNzcVYtLaORGZgSR0oooe5XQqzxIGbjoaqso5+lFFZvcbIfLVgcisHWQEClRyaKKunucdfYNIupWI+bHPUV1EVzIygOQw4HIoorpZnDYivcEocAfSsudm+35JzgDFFFAdRv3uvc065AAQADoaKKzGQqgxWnp8SEZI5oopMuG5dMahRgVLAoJIPaiikbxLigbtoAxUbqPSiihGoqKFYAd6uAlV+UkUUUxoaZXyo3E5NWAxwaKKoJAxJxmoHYk9aKKkkjHzZzzVeQYOR60UUhEcxwv4Vd8IWcN9q8a3ILKO2aKKuj8RhiNj2qGGO3t4lhUKoXgCnxHJGaKK7Dy1uQSMUYleDTydxG4A5PeiigplvAVRiqvDSEsMkUUVK6iLEMYyOvPOKdKi7duOPSiigRVMjAKBx9KcjF4WJ6iiimwRWlOwttA61EXIfGBjFFFMY4SExsOO9V2dllwpx70UUAMllcZOcnHeoYZn55oopAEzsTnpz2oR2wDuOSKKKAFlycjJ45q0owijPAoooAlhUFyPTpXJeLJWhtJSh5O6iiriNHjK/PK7tyxY5NXbZR1oory6vxM9XD/AAI3LCWWOEpHNKiEfdVyB+VX7VFOOMUUVMdzvjsf/9k=);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Bulbous swelling of the distal phalanges of the fingers with increased nail curvature is present.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_40_26242=[""].join("\n");
var outline_f25_40_26242=null;
var title_f25_40_26243="Angiogram showing postpartum hemorrhage";
var content_f25_40_26243=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F67041%7EOBGYN%2F78839&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F67041%7EOBGYN%2F78839&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Right hypogastric angiogram",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 248px; height: 226px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Right hypogastric angiogram on a 34-year-old woman with postpartum hemorrhage shows an area of extravasation (arrow).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Right uterine angiogram",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 420px; height: 275px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Right uterine angiogram reveals occlusion of the right uterine artery (arrow) after superselective uterine artery embolization. The procedure successfully stopped the bleeding.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_40_26243=[""].join("\n");
var outline_f25_40_26243=null;
var title_f25_40_26244="Pneumothorax PI";
var content_f25_40_26244=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PI%2F64892&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PI%2F64892&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 538px\">",
"   <div class=\"ttl\">",
"    Pneumothorax (collapsed lung)",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 518px; height: 616px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The lungs sit in the chest, inside the ribcage. They are covered with a thin membrane called the &ldquo;pleura.&rdquo; The windpipe (or trachea) branches into smaller airways. In this drawing, 1 lung is normal, and 1 has collapsed because air has leaked out of it. The air that has leaked out of the lung (shown in blue) has filled the space outside of the lung.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_40_26244=[""].join("\n");
var outline_f25_40_26244=null;
var title_f25_40_26245="Pellagra dermatitis";
var content_f25_40_26245=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F69889&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F69889&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Pellagra dermatitis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 369px; height: 557px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Dermatitis due to niacin deficiency (pellagra). The term \"pellagra\" derives from the Italian words for \"rough skin\". The condition is characterized by an erythematous, blistering rash that may be pruritic or painful. The rash occurs in areas of sun exposure, and is therefore often seen around the neck (\"Casal's necklace\"), arms, hands, or malar area.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_40_26245=[""].join("\n");
var outline_f25_40_26245=null;
var title_f25_40_26246="Perianal abscess: Clinical manifestations, diagnosis, treatment";
var content_f25_40_26246=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Perianal abscess: Clinical manifestations, diagnosis, treatment",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?25/40/26246/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?25/40/26246/contributors\">",
"     Elizabeth Breen, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?25/40/26246/contributors\">",
"     Ronald Bleday, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?25/40/26246/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?25/40/26246/contributors\">",
"     Martin Weiser, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?25/40/26246/contributors\">",
"     Lawrence S Friedman, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?25/40/26246/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?25/40/26246/contributors\">",
"     Rosemary B Duda, MD, MPH, FACS",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?25/40/26246/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 28, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;A perianal abscess, a simple anorectal abscess, is the acute phase manifestation of a collection of purulent material that arises from glandular crypts in the anus or rectum. In comparison, a perianal fistula represents the chronic phase of suppuration in this perirectal process [",
"    <a class=\"abstract\" href=\"UTD.htm?25/40/26246/abstract/1\">",
"     1",
"    </a>",
"    ]. Perianal abscesses traverse distally in the intersphincteric groove into the perianal skin, where they present as a tender, fluctuant mass (",
"    <a class=\"graphic graphic_picture graphicRef67524 \" href=\"UTD.htm?2/48/2820\">",
"     picture 1",
"    </a>",
"    ). A perianal abscess, if undrained, can expand into adjacent tissues (eg, ischiorectal space, supralevator space) as well as progress to a generalized systemic infection.",
"   </p>",
"   <p>",
"    The anatomy of the anal canal and ischiorectal fossa, clinical manifestations, and treatment of an anorectal fistula are reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/51/5946?source=see_link\">",
"     \"Operative management of anorectal fistulas\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/25/12694?source=see_link\">",
"     \"Anorectal fistula: Clinical manifestations, diagnosis, and management principles\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H471696604\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Benign perianal diseases, including fissures, abscesses, fistulas, and hemorrhoids, are common. The prevalence of specific disorders is difficult to estimate since almost any anorectal discomfort is often attributed to symptomatic hemorrhoids.",
"   </p>",
"   <p>",
"    The prevalence of anal abscesses in the general population is probably much higher than seen in clinical practice since the majority of patients with symptoms referable to the anorectum do not seek medical attention. It is estimated that there are approximately 100,000 cases per year in the United States [",
"    <a class=\"abstract\" href=\"UTD.htm?25/40/26246/abstract/1\">",
"     1",
"    </a>",
"    ]. The mean age for presentation of anal abscess and fistula disease is 40 years (range 20 to 60) [",
"    <a class=\"abstract\" href=\"UTD.htm?25/40/26246/abstract/2-5\">",
"     2-5",
"    </a>",
"    ]. Adult males are twice as likely to develop an abscess",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    fistula compared with women [",
"    <a class=\"abstract\" href=\"UTD.htm?25/40/26246/abstract/1,5\">",
"     1,5",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H169001136\">",
"    <span class=\"h1\">",
"     PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;An anal abscess usually originates from an infected anal crypt gland [",
"    <a class=\"abstract\" href=\"UTD.htm?25/40/26246/abstract/6\">",
"     6",
"    </a>",
"    ]. There are typically 8 to 10 anal crypt glands, arranged circumferentially within the anal canal at the level of the dentate line. The glands penetrate the internal sphincter and end in the intersphincteric plane. An anal abscess develops when an anal crypt gland becomes obstructed with inspissated debris, which permits bacterial growth and abscess formation. The suppuration follows the path of least resistance and the infected fluid collects in the space where the gland terminates. An anal fistula is a connection between two epithelial structures and connects the anal abscess from the infected anal crypt glands to the skin of the buttocks. There is no model to predict when an abscess will develop a fistula [",
"    <a class=\"abstract\" href=\"UTD.htm?25/40/26246/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The anatomy of the anal region is described elsewhere (",
"    <a class=\"graphic graphic_figure graphicRef72874 \" href=\"UTD.htm?12/22/12647\">",
"     figure 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_figure graphicRef54523 \" href=\"UTD.htm?20/54/21348\">",
"     figure 2",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/51/5946?source=see_link&amp;anchor=H22288673#H22288673\">",
"     \"Operative management of anorectal fistulas\", section on 'Anatomy of the anal region'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H88522735\">",
"    <span class=\"h1\">",
"     CLINICAL FEATURES",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H88522743\">",
"    <span class=\"h2\">",
"     Clinical manifestations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with a perianal abscess often present with severe pain in the anal or rectal area. The pain is constant and not necessarily associated with a bowel movement. Constitutional symptoms such as fever and malaise are common. Purulent rectal drainage may be noted if the abscess has begun to drain spontaneously [",
"    <a class=\"abstract\" href=\"UTD.htm?25/40/26246/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    On physical examination, an area of fluctuance or a patch of erythematous, indurated skin overlying the perianal skin may be noted. However, in some patients and with some types of abscesses (eg, supralevator) there are no findings on physical inspection, and the abscess can only be felt via digital rectal examination.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21936119\">",
"    <span class=\"h2\">",
"     Clinical course",
"    </span>",
"    &nbsp;&mdash;&nbsp;Approximately half of anal abscesses will result in the development of a chronic fistula from the inciting anal gland to the skin overlying the drainage site. The risk of developing a fistula is not influenced by whether the fistula drained spontaneously or whether surgical drainage was performed. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/25/12694?source=see_link\">",
"     \"Anorectal fistula: Clinical manifestations, diagnosis, and management principles\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H88522767\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of a perianal abscess is based upon the findings from the history and physical examination and includes anorectal pain, fever, and a palpable perirectal mass.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6285501\">",
"    <span class=\"h2\">",
"     Imaging studies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Imaging studies, such as computed tomography (CT) or magnetic resonance imaging (MRI), are helpful in the setting of a clinical suspicion of nonpalpable anorectal abscess. The role of imaging tests in the evaluation of anal abscesses is presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/25/39319?source=see_link\">",
"     \"The role of imaging tests in the evaluation of anal abscesses and fistulas\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H88522775\">",
"    <span class=\"h1\">",
"     DIFFERENTIAL DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;A simple perianal abscess should be distinguished from other conditions that result in an abscess formation and drainage in the presacral, perianal, and perineal regions [",
"    <a class=\"abstract\" href=\"UTD.htm?25/40/26246/abstract/8\">",
"     8",
"    </a>",
"    ]. Some conditions present in the perirectal region (eg, fistula, complex anorectal abscesses), while others can be diagnosed based upon their location (eg, Bartholin cyst, pilonidal cyst).",
"   </p>",
"   <p>",
"    The differential diagnosis of a perianal abscess includes:",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6284786\">",
"    <span class=\"h2\">",
"     Anorectal fistula",
"    </span>",
"    &nbsp;&mdash;&nbsp;An anorectal fistula is the epithelialized track between the abscess and the perirectal skin, and, less common, adjacent organs. The external opening of the fistula can be indurated and drain purulent fluid, but fever is uncommon unless there is an associated undrained abscess. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/25/12694?source=see_link\">",
"     \"Anorectal fistula: Clinical manifestations, diagnosis, and management principles\"",
"    </a>",
"    .) &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6284796\">",
"    <span class=\"h2\">",
"     Presacral epidermoid cyst",
"    </span>",
"    &nbsp;&mdash;&nbsp;An infected epidermoid cyst is a discreet nodule that can progressively enlarge, become inflamed, and rupture. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/34/553?source=see_link&amp;anchor=H1101420445#H1101420445\">",
"     \"Overview of benign lesions of the skin\", section on 'Epidermoid cyst'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6284806\">",
"    <span class=\"h2\">",
"     Hidradenitis suppurativa",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hidradenitis suppurativa can occur in the perirectal area and become infected with purulent drainage. (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/7/6265?source=see_link\">",
"     \"Pathogenesis, clinical features, and diagnosis of hidradenitis suppurativa\"",
"    </a>",
"    )",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6284836\">",
"    <span class=\"h2\">",
"     Internal hemorrhoid",
"    </span>",
"    &nbsp;&mdash;&nbsp;An internal hemorrhoid is a normal vascular structure in the anal canal that can become enlarged, engorged, and strangulated, leading to gangrene. A fluctuant mass is palpated on rectal examination (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/14/5348?source=see_link\">",
"     \"Overview of hemorrhoids\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6285235\">",
"    <span class=\"h2\">",
"     Pilonidal disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with pilonidal disease can present with an acute abscess. Intergluteal pilonidal abscesses generally occur in the midline, although they may occur off-center. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/42/4774?source=see_link\">",
"     \"Management of intergluteal pilonidal disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6285245\">",
"    <span class=\"h2\">",
"     Bartholin duct abscess",
"    </span>",
"    &nbsp;&mdash;&nbsp;An obstructed Bartholin duct can become obstructed and form an abscess. (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/54/22375?source=see_link&amp;anchor=H5#H5\">",
"     \"Disorders of Bartholin gland\", section on 'Bartholin duct abscess'",
"    </a>",
"    )",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6284846\">",
"    <span class=\"h2\">",
"     Classification of complex anorectal abscesses",
"    </span>",
"    &nbsp;&mdash;&nbsp;A perianal abscess is classified as a simple anorectal abscess. Complex anal abscesses involve different planes in the anorectum, and can have distinct clinical presentations. The complex anal abscesses are classified based upon their anatomic location (",
"    <a class=\"graphic graphic_figure graphicRef63704 \" href=\"UTD.htm?32/32/33284\">",
"     figure 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?25/40/26246/abstract/6\">",
"     6",
"    </a>",
"    ]. Complex abscesses are typically associated with complex fistulas and management is also more complicated than that of a simple perianal abscess. (See",
"    <a class=\"local\" href=\"#H88522783\">",
"     'Treatment by site of abscess'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The classification of complex anorectal fistulas includes:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Ischiorectal abscess (ischioanal abscess)",
"      </strong>",
"      &minus; Ischiorectal abscesses, also referred to as ischioanal abscesses, penetrate through the external anal sphincter into the ischiorectal space and present as a diffuse, tender, indurated, fluctuant area within the buttocks (",
"      <a class=\"graphic graphic_figure graphicRef63229 \" href=\"UTD.htm?10/37/10837\">",
"       figure 4",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      <strong>",
"       Intersphincteric abscess",
"      </strong>",
"      &minus; Intersphincteric abscesses account for only 2 to 5 percent of all anorectal abscesses. They are located in the intersphincteric groove between the internal and external sphincters. As a result, they often do not cause perianal skin changes, but can be palpated as a fluctuant mass protruding into the lumen during digital rectal examination.",
"     </li>",
"     <li>",
"      <strong>",
"       Supralevator abscess",
"      </strong>",
"      &minus; Supralevator abscesses can originate from two different sources: the typical cryptoglandular infection that travels superiorly within the intersphincteric plane to the supralevator space and an inflammatory pelvic process such as perforated diverticular disease or Crohn's disease, or a perforated neoplastic process. As a result, it is important to obtain a history of potential sources of pelvic infection.",
"      <br/>",
"      <br/>",
"      Patients with a supralevator abscess present with severe perianal pain, fever, and sometimes urinary retention. Physical examination usually reveals no obvious external findings. On digital examination, an area of induration or fluctuation can often be felt above the level of the anorectal ring. Because of the paucity of physical examination findings, an abdominopelvic CT scan may be required to establish the diagnosis. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?38/25/39319?source=see_link\">",
"       \"The role of imaging tests in the evaluation of anal abscesses and fistulas\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Horseshoe abscess",
"      </strong>",
"      &mdash; A horseshoe abscess is a complex abscess. Horseshoe abscesses form in the potential space posterior to the anal canal that is bounded by the pelvic floor superiorly, the anococcygeal ligament inferiorly, and the coccyx and anal canal. Because of these relatively rigid boundaries, abscesses in this space are forced into the ischiorectal space, where they can be unilateral or bilateral.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H88522975\">",
"    <span class=\"h1\">",
"     GENERAL PRINCIPLES OF MANAGEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Recommendations for the management of anal abscesses and fistulas have been established by the American Society of Colon and Rectal Surgeons [",
"    <a class=\"abstract\" href=\"UTD.htm?25/40/26246/abstract/9\">",
"     9",
"    </a>",
"    ]. These guidelines are available online at:",
"    <a class=\"external\" href=\"file://www.fascrs.org/\">",
"     www.fascrs.org",
"    </a>",
"    .",
"   </p>",
"   <p>",
"    The following principles were proposed:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Anal abscesses should be drained in a timely manner. Lack of fluctuance should not be a reason to delay treatment.",
"     </li>",
"     <li>",
"      Antibiotics may have a role in special circumstances including valvular heart disease, immunosuppression, extensive cellulitis, or diabetes.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A concomitant fistulotomy performed in the same setting as drainage of an anal abscess is",
"    <strong>",
"     not",
"    </strong>",
"    recommended because of the high frequency of anorectal dysfunction associated with this procedure. In one trial, for example, 70 patients with an anorectal abscess were randomized to incision, drainage, and fistulotomy with primary partial internal sphincterotomy, or to incision and drainage alone, and patients who underwent fistulotomy were twice as likely to have anal dysfunction (40 versus 21 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?25/40/26246/abstract/10\">",
"     10",
"    </a>",
"    ]. However, after a median follow-up of 42.5 months, the combined recurrence or persistence rate was significantly higher in patients who did not undergo fistulotomy (40 versus 3 percent). Since primary fistulotomy may be associated with a high rate of anorectal dysfunction, it should be reserved for patients who have refractory symptoms, such as patients with a horseshoe abscess (See",
"    <a class=\"local\" href=\"#H88523161\">",
"     'Horseshoe abscess'",
"    </a>",
"    below.).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H88523010\">",
"    <span class=\"h2\">",
"     Role of abscess culture",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cultures are generally",
"    <strong>",
"     not",
"    </strong>",
"    required in the treatment of an anal abscess, as antibiotic therapy is typically not needed following an incision and drainage in most patients. However, cultures may be useful in the following settings:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      To distinguish between a cryptoglandular abscess (typically due to colonic flora) and an abscess of the perianal skin (typically due to staphylococcal species)",
"     </li>",
"     <li>",
"      Patients who would typically be treated with antibiotics, including those with valvular heart disease, immunosuppression, extensive cellulitis, and diabetes",
"     </li>",
"     <li>",
"      Patients who have been on multiple courses of antibiotics",
"     </li>",
"     <li>",
"      Patients with pain out of proportion to findings, who may have an unusual pathogen (eg, immunocompromised patients)",
"     </li>",
"     <li>",
"      Patients with leukemia or lymphoma who may have unusual or resistant bacteria",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H88522783\">",
"    <span class=\"h1\">",
"     TREATMENT BY SITE OF ABSCESS",
"    </span>",
"    &nbsp;&mdash;&nbsp;A perianal abscess can be managed in the office, emergency department, or minor operating room using local anesthesia (",
"    <a class=\"graphic graphic_figure graphicRef63704 \" href=\"UTD.htm?32/32/33284\">",
"     figure 3",
"    </a>",
"    and",
"    <a class=\"graphic graphic_figure graphicRef78125 \" href=\"UTD.htm?5/32/5634\">",
"     figure 5",
"    </a>",
"    ). Complex abscesses should be drained in the operating room, preferably using a regional or general anesthetic, or for smaller lesions, local anesthesia with intravenous sedation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H88523133\">",
"    <span class=\"h2\">",
"     Perianal",
"    </span>",
"    &nbsp;&mdash;&nbsp;Perianal abscesses can be readily drained in the outpatient setting. The overlying skin is anesthetized with local anesthesia (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/34/35360?source=see_link\">",
"     lidocaine",
"    </a>",
"    with bicarbonate) and the cavity is drained with a cruciate incision as close to the anal verge as possible. The proximity of the drainage site to the anal verge is important in minimizing the potential fistula tract. After drainage, the area is cleaned by frequent sitz baths or hand-held showers.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6285293\">",
"    <span class=\"h2\">",
"     Complex",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H88523140\">",
"    <span class=\"h3\">",
"     Ischiorectal",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ideally, an ischiorectal abscess is best drained in the operating room where adequate anesthesia, lighting, and exposure are helpful. However, a limited and well-defined ischiorectal abscess without fistulas can sometimes be drained in the office using local anesthetic.",
"   </p>",
"   <p>",
"    The overlying skin is anesthetized with local anesthesia and the cavity is drained with a cruciate incision as close to the anal verge as possible. The incision for the drainage site should be performed as close to the sphincter complex as possible to minimize the potential for the development of a fistula tract. After drainage, the area can be kept clean by frequent sitz baths or hand-held showers.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H88523147\">",
"    <span class=\"h3\">",
"     Intersphincteric",
"    </span>",
"    &nbsp;&mdash;&nbsp;Intersphincteric abscesses must be drained in the operating room where a retractor can be placed within the anal canal allowing visualization and access to the abscess cavity through the internal sphincter muscle.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H88523154\">",
"    <span class=\"h3\">",
"     Supralevator",
"    </span>",
"    &nbsp;&mdash;&nbsp;Supralevator abscesses can be drained in one of two ways depending upon the site of origin of the abscess. Although the origin is not always readily apparent, abscesses stemming from an extension of an ischiorectal abscess should be drained via the skin overlying the buttock. Abscesses originating from a pelvic process should be drained into the rectum to avoid creating an extrasphincteric fistula.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H88523161\">",
"    <span class=\"h3\">",
"     Horseshoe abscess",
"    </span>",
"    &nbsp;&mdash;&nbsp;Drainage of a horseshoe abscess is the one setting in which a primary fistulotomy can be performed in the same setting with drainage for anal abscess [",
"    <a class=\"abstract\" href=\"UTD.htm?25/40/26246/abstract/11\">",
"     11",
"    </a>",
"    ]. Fistulotomy should be performed through the posterior midline into the deep post-anal space. A counter incision should be made over the ischiorectal abscess. However, in most patients, the first step is drainage of the horseshoe abscess with one to three incisions. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/51/5946?source=see_link&amp;anchor=H22288799#H22288799\">",
"     \"Operative management of anorectal fistulas\", section on 'Fistulotomy'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/51/5946?source=see_link&amp;anchor=H22288841#H22288841\">",
"     \"Operative management of anorectal fistulas\", section on 'Fistulotomy and setons'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?20/23/20849?source=see_link\">",
"       \"Patient information: Anal abscess and fistula (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5517444\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Benign anorectal diseases, including fissures, abscesses, fistulas, and hemorrhoids, are common. However, the prevalence in the general population is probably much higher than seen in clinical practice since the majority of patients with symptoms referable to the anorectum do not seek medical attention.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The majority of anorectal abscesses originate from infected anal glands. (See",
"      <a class=\"local\" href=\"#H169001136\">",
"       'Pathogenesis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients with an abscess often present with severe pain in the anal or rectal area that may be constant but not necessarily associated with a bowel movement. Additional symptoms may include fever and malaise. (See",
"      <a class=\"local\" href=\"#H88522743\">",
"       'Clinical manifestations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The physical examination on most patients with a simple perianal abscess reveals an area of fluctuance or a patch of erythematous, indurated skin overlying the perianal or ischiorectal space. In some patients, there are no findings on physical inspection, and the abscess can only be felt via digital rectal examination. (See",
"      <a class=\"local\" href=\"#H88522743\">",
"       'Clinical manifestations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients with a suspected anorectal abscess that is not palpable, we perform an MRI of the pelvis. (See",
"      <a class=\"local\" href=\"#H6285501\">",
"       'Imaging studies'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      An anorectal abscess, fluctuant or not, should be incised and drained. (See",
"      <a class=\"local\" href=\"#H88522975\">",
"       'General principles of management'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For select patients, including those with valvular heart disease, immunosuppression, extensive cellulitis, or diabetes, we use antibiotics in conjunction with incision and drainage of the anorectal abscess. We do not administer antibiotics for other patients. (See",
"      <a class=\"local\" href=\"#H88522975\">",
"       'General principles of management'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For select patients, including those with leukemia, pain out of proportion to clinical findings, and those for whom we administer antibiotics, we obtain a culture and sensitivity on the purulent fluid. (See",
"      <a class=\"local\" href=\"#H88523010\">",
"       'Role of abscess culture'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients with a perianal abscess are drained in the office setting, emergency room, or minor operating room, using local anesthetic. (See",
"      <a class=\"local\" href=\"#H88523133\">",
"       'Perianal'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      More complicated anorectal abscesses, such as intersphincteric, supralevator, and horseshoe abscesses, are treated in the operating room setting. (See",
"      <a class=\"local\" href=\"#H6285293\">",
"       'Complex'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     Abcarian H. Anorectal infection: Abscess-fistula. Clinics in colon and rectal surgery 2011. 24:14.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/40/26246/abstract/2\">",
"      Piazza DJ, Radhakrishnan J. Perianal abscess and fistula-in-ano in children. Dis Colon Rectum 1990; 33:1014.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/40/26246/abstract/3\">",
"      Niyogi A, Agarwal T, Broadhurst J, Abel RM. Management of perianal abscess and fistula-in-ano in children. Eur J Pediatr Surg 2010; 20:35.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/40/26246/abstract/4\">",
"      Nelson RL, Abcarian H, Davis FG, Persky V. Prevalence of benign anorectal disease in a randomly selected population. Dis Colon Rectum 1995; 38:341.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/40/26246/abstract/5\">",
"      Sainio P. Fistula-in-ano in a defined population. Incidence and epidemiological aspects. Ann Chir Gynaecol 1984; 73:219.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/40/26246/abstract/6\">",
"      Rizzo JA, Naig AL, Johnson EK. Anorectal abscess and fistula-in-ano: evidence-based management. Surg Clin North Am 2010; 90:45.",
"     </a>",
"    </li>",
"    <li>",
"     Anal abscess/fistula. American Society of Colon &amp; Rectal Surgeons. 2008. www.fascrs.org/patients/conditions/anal_abscess_fistula/ (Accessed on April 25, 2011).",
"    </li>",
"    <li>",
"     Barnett, JL, Raper, SE. Anorectal diseases. In: Yamada Textbook of Gastroenterology, 2nd edition, Yamada, T, Alpers, D, Owyang, et al (Eds), JB Lippincott, Philadelphia 1995. p.2027.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/40/26246/abstract/9\">",
"      Practice parameters for treatment of fistula-in-ano. The Standards Practice Task Force. The American Society of Colon and Rectal Surgeons. Dis Colon Rectum 1996; 39:1361.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/40/26246/abstract/10\">",
"      Schouten WR, van Vroonhoven TJ. Treatment of anorectal abscess with or without primary fistulectomy. Results of a prospective randomized trial. Dis Colon Rectum 1991; 34:60.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/40/26246/abstract/11\">",
"      Pezim ME. Successful treatment of horseshoe fistula requires deroofing of deep postanal space. Am J Surg 1994; 167:513.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1378 Version 9.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-221.10.40.236-33BC93883C-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_40_26246=[""].join("\n");
var outline_f25_40_26246=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H5517444\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H471696604\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H169001136\">",
"      PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H88522735\">",
"      CLINICAL FEATURES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H88522743\">",
"      Clinical manifestations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21936119\">",
"      Clinical course",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H88522767\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6285501\">",
"      Imaging studies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H88522775\">",
"      DIFFERENTIAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6284786\">",
"      Anorectal fistula",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6284796\">",
"      Presacral epidermoid cyst",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6284806\">",
"      Hidradenitis suppurativa",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6284836\">",
"      Internal hemorrhoid",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6285235\">",
"      Pilonidal disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6285245\">",
"      Bartholin duct abscess",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6284846\">",
"      Classification of complex anorectal abscesses",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H88522975\">",
"      GENERAL PRINCIPLES OF MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H88523010\">",
"      Role of abscess culture",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H88522783\">",
"      TREATMENT BY SITE OF ABSCESS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H88523133\">",
"      Perianal",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6285293\">",
"      Complex",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H88523140\">",
"      - Ischiorectal",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H88523147\">",
"      - Intersphincteric",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H88523154\">",
"      - Supralevator",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H88523161\">",
"      - Horseshoe abscess",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5517444\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"SURG/1378\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"SURG/1378|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?12/22/12647\" title=\"figure 1\">",
"      Anatomy of the anal canal and rectum",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?20/54/21348\" title=\"figure 2\">",
"      Anal rectal anatomy lateral view",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?32/32/33284\" title=\"figure 3\">",
"      Location of anorectal abscesses",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?10/37/10837\" title=\"figure 4\">",
"      Anatomy of the ischiorectal fossa",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?5/32/5634\" title=\"figure 5\">",
"      Submucosal rectal abscess",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"SURG/1378|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?2/48/2820\" title=\"picture 1\">",
"      Perianal abscess",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/25/12694?source=related_link\">",
"      Anorectal fistula: Clinical manifestations, diagnosis, and management principles",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/54/22375?source=related_link\">",
"      Disorders of Bartholin gland",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/42/4774?source=related_link\">",
"      Management of intergluteal pilonidal disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/51/5946?source=related_link\">",
"      Operative management of anorectal fistulas",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/34/553?source=related_link\">",
"      Overview of benign lesions of the skin",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/14/5348?source=related_link\">",
"      Overview of hemorrhoids",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/7/6265?source=related_link\">",
"      Pathogenesis, clinical features, and diagnosis of hidradenitis suppurativa",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?20/23/20849?source=related_link\">",
"      Patient information: Anal abscess and fistula (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/25/39319?source=related_link\">",
"      The role of imaging tests in the evaluation of anal abscesses and fistulas",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f25_40_26247="Esophageal multichannel intraluminal impedance testing";
var content_f25_40_26247=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Esophageal multichannel intraluminal impedance testing",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?25/40/26247/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?25/40/26247/contributors\">",
"     Radu Tutuian, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?25/40/26247/contributors\">",
"     Donald O Castell, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?25/40/26247/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?25/40/26247/contributors\">",
"     Nicholas J Talley, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?25/40/26247/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?25/40/26247/contributors\">",
"     Shilpa Grover, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?25/40/26247/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 29, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Multichannel intraluminal impedance (MII) is a new technique designed to detect intraluminal bolus movement without the use of radiation. It is generally performed in combination with manometry or pH testing. When combined with manometry, it provides information on the functional (ie, bolus transit) component of manometrically detected contractions. When combined with pH testing, it allows for detection of gastroesophageal reflux independent of pH (ie, both acid and non-acid reflux).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     PRINCIPLES OF MII",
"    </span>",
"    &nbsp;&mdash;&nbsp;Impedance testing depends upon measurement of changes in resistance (in Ohms) to alternating electrical current when a bolus passes by a pair of metallic rings mounted on a catheter. In an empty tubular organ (ie, esophagus or small intestine) the electrical current between the two rings is conducted by the few ions present in and on the esophageal mucosa. Liquid containing boluses with an increased number of ions have a higher conductivity and when entering the impedance measuring segment will lower the impedance to a nadir value.",
"   </p>",
"   <p>",
"    The impedance stays at its nadir as long as the bolus is present in the segment, returning to baseline once the bolus is cleared by a contraction. The contraction produces a slight increase in impedance above the baseline due to a decrease in luminal cross-section. Gas passing transiently by the impedance measuring segments will produce a rapid rise in the impedance since it has poor electrical conductance.",
"   </p>",
"   <p>",
"    Measuring impedance at multiple sites (multichannel) allows for determination of direction of bolus movement based upon temporal differences in bolus entry and exit (ie, bolus entries progressing from proximal to distal indicate antegrade bolus movement while bolus entries progressing from distal to proximal indicate retrograde bolus movement) (",
"    <a class=\"graphic graphic_waveform graphicRef56477 \" href=\"UTD.htm?26/32/27151\">",
"     waveform 1",
"    </a>",
"    ). Combined with manometry (multichannel intraluminal impedance and manometry; MII-EM) it provides information about both pressures and bolus transit within the esophagus. Combined with pH (multichannel intraluminal impedance and pH; MII-pH) it permits detection of both acid and non-acid gastroesophageal reflux.",
"   </p>",
"   <p>",
"    The United States Food and Drug Administration approved MII to detect intraluminal bolus movement in July 2002. Combined MII-EM is approved for esophageal function testing and combined MII-pH for gastroesophageal reflux monitoring (Sandhill Scientific Inc, Highlands Ranch, CO, USA).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     COMBINED MULTICHANNEL INTRALUMINAL IMPEDANCE AND MANOMETRY (MII-EM)",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Indications",
"    </span>",
"    &nbsp;&mdash;&nbsp;The indications for MII-EM are similar to those for esophageal manometry: evaluation of patients with dysphagia, non-cardiac chest pain,",
"    <span class=\"nowrap\">",
"     heartburn/regurgitation,",
"    </span>",
"    preoperative evaluation before anti-reflux surgery or endoscopic anti-reflux procedures and location of the LES prior to pH catheter placement. One study suggested better sensitivity compared with standard manometry for detection of motility disturbances in patients with non-obstructive dysphagia [",
"    <a class=\"abstract\" href=\"UTD.htm?25/40/26247/abstract/1\">",
"     1",
"    </a>",
"    ]. &nbsp;",
"   </p>",
"   <p>",
"    In one study, dysphagia was more common in 158 patients with normal manometry and abnormal bolus transit on MII-EM testing compared with 146 patients with normal manometry and normal bolus transit (23 versus 10 percent). The authors suggested that combined MII-EM is more sensitive in detecting an esophageal abnormality than is standard manometry in dysphagia patients [",
"    <a class=\"abstract\" href=\"UTD.htm?25/40/26247/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Ongoing studies are helping to determine whether there will be a role in diagnosis of extra-esophageal disorders related to GERD, such as chronic cough [",
"    <a class=\"abstract\" href=\"UTD.htm?25/40/26247/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Procedure",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients are asked to fast for four to six hours, after which the combined MII-EM catheter is inserted transnasally through the esophagus into the stomach. The procedure is performed in an outpatient setting. The lower esophageal sphincter (LES) is located by stationary pull-through technique and the most distal sensor is placed in the high-pressure zone of the LES.",
"   </p>",
"   <p>",
"    The design of the catheter determines the location of the pressure and impedance-measuring segment. The currently available 9-channel esophageal function testing catheter (Sandhill Scientific Inc, Highlands Ranch, CO) has five pressure sensors 5 cm apart and four impedance measuring segments straddling the four proximal pressure sensors, allowing pressure measurements in the LES, and at 5, 10, 15, and 20 cm above the LES. Impedance measuring segments are centered at 5, 10, 15, and 20 cm above the LES.",
"   </p>",
"   <p>",
"    After successful catheter placement, 10 liquid (ie, 0.9 percent normal saline) and 10 viscous (ie, standardized viscous solution; Sandhill Scientific Inc, Highlands Ranch, CO) swallows are given, each 30 seconds apart. Saline is preferred over plain water since it has a standardized ionic concentration allowing reliable identification of bolus presence by impedance. The impedance of water can vary depending upon its source, leading to potential impedance artifacts.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Data analysis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Data analysis is performed using dedicated software (BioView Analysis, Sandhill, Scientific Inc, Highlands Ranch, CO).",
"   </p>",
"   <p>",
"    Swallows are classified by manometry as:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Normal, if contraction amplitudes at 5 and 10 cm above the LES are each greater than or equal to 30 mmHg and distal onset velocity is less than 8",
"      <span class=\"nowrap\">",
"       cm/second",
"      </span>",
"     </li>",
"     <li>",
"      Ineffective, if either of the contraction amplitudes at 5 and 10 cm above the LES is less than 30 mmHg (this includes contractions that have been defined as \"poorly transmitted\" or \"not transmitted\" in some reports)",
"     </li>",
"     <li>",
"      Simultaneous, if contraction amplitudes at 5 and 10 cm above the LES are each greater or equal to 30 mmHg and distal onset velocity is greater than 8",
"      <span class=\"nowrap\">",
"       cm/second",
"      </span>",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Swallows are classified by MII as showing:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Complete bolus transit, if bolus entry occurs at the most proximal site (20 cm above LES) and bolus exit points are recorded in all three distal impedance-measuring sites (ie, 15, 10, and 5 cm above the LES)",
"     </li>",
"     <li>",
"      Incomplete bolus transit if bolus exit is not identified at any one of the three distal impedance measuring sites",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The interpretation of the manometric information is based upon published criteria [",
"    <a class=\"abstract\" href=\"UTD.htm?25/40/26247/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Normal esophageal manometry is defined as not more than 40 percent ineffective and not more than 10 percent simultaneous swallows, an average distal esophageal amplitude (DEA) &lt;220 mmHg and normal LES resting and residual pressures",
"     </li>",
"     <li>",
"      Achalasia is defined by absent esophageal body peristalsis and, if present, poorly relaxing LES",
"     </li>",
"     <li>",
"      Scleroderma is defined based upon an appropriate clinical diagnosis and confirmed by low amplitude or absent contractions in the distal esophagus with or without a low LES pressure",
"     </li>",
"     <li>",
"      Distal esophageal spasm is defined as 20 percent or more simultaneous contractions",
"     </li>",
"     <li>",
"      Ineffective esophageal motility is defined as 50 percent or more swallows with contraction amplitude less than 30 mmHg in either of the two distal sites located at 5 and 10 cm above the LES",
"     </li>",
"     <li>",
"      Nutcracker esophagus is defined as normal peristalsis of the esophageal body with DEA exceeding 220 mmHg",
"     </li>",
"     <li>",
"      Poorly relaxing LES is defined as average LES residual pressure exceeding 8 mmHg associated with normal esophageal body contractions",
"     </li>",
"     <li>",
"      Hypertensive LES is defined as LES resting pressure exceeding 45 mmHg with normal esophageal body contractions",
"     </li>",
"     <li>",
"      Hypotensive LES is defined as LES resting pressure below 10 mmHg with normal esophageal body contractions",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Esophageal transit abnormalities are considered to be present if 30 percent or more of liquid swallows have incomplete bolus transit or if 40 percent or more of viscous swallows have incomplete bolus transit. These values are based upon data from 43 healthy volunteers [",
"    <a class=\"abstract\" href=\"UTD.htm?25/40/26247/abstract/1\">",
"     1",
"    </a>",
"    ]. Studies in patients with esophageal motility abnormalities indicate that no patients with achalasia or scleroderma have normal bolus transit, while almost all (ie, 95 percent or more) patients with normal manometry, nutcracker esophagus, or isolated lower esophageal sphincter (LES) abnormalities (ie, hypertensive LES, hypotensive LES or poorly relaxing LES) have normal bolus transit. Approximately 50 percent of patients with ineffective esophageal motility (IEM) or distal esophageal spasm (DES) have normal liquid bolus transit [",
"    <a class=\"abstract\" href=\"UTD.htm?25/40/26247/abstract/5\">",
"     5",
"    </a>",
"    ]. A study using relatively sensitive criteria to define abnormal bolus transit (ie, abnormal bolus transit for liquid",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    viscous swallows) in patients with non-obstructive dysphagia found abnormal bolus transit in 35 percent of patients with otherwise normal manometry, 66 percent of those with DES, 85 percent of those with IEM and 100 percent of patients with achalasia [",
"    <a class=\"abstract\" href=\"UTD.htm?25/40/26247/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Combined MII-EM helps clarify the functional defect in patients with manometrically defined ineffective esophageal motility (IEM) and distal esophageal spasm (DES). We found that the current criteria used to distinguish manometrically normal from IEM were only 85 percent sensitive and 65 percent specific in a group of 70 patients who we evaluated with MII-EM [",
"    <a class=\"abstract\" href=\"UTD.htm?25/40/26247/abstract/7\">",
"     7",
"    </a>",
"    ]. Based upon liquid and viscous swallows, approximately one-third of patients had a mild functional defect (ie, normal bolus transit for both liquid and viscous), while another third had a moderate defect (ie, abnormal bolus transit for either liquid or viscous), and the remaining third had a severe defect (ie, abnormal bolus transit for both liquid and viscous).",
"   </p>",
"   <p>",
"    Studies from our laboratory using combined multichannel intraluminal impedance and manometry (MII-EM) to evaluate esophageal peristalsis and bolus transit in 71 patients with DES indicate that approximately half of patients who have manometric criteria of DES have normal bolus transit for both liquid and viscous swallows (ie, no functional defect). About 25 percent of DES patients have abnormal bolus transit for both liquid and viscous swallows (ie, a severe functional defect), while the remainder have abnormal bolus transit for either liquid or viscous swallows (ie, a moderate functional defect) [",
"    <a class=\"abstract\" href=\"UTD.htm?25/40/26247/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Another group described the results of combined impedance-manometry testing in 80 patients who underwent laparoscopic Nissen fundoplication [",
"    <a class=\"abstract\" href=\"UTD.htm?25/40/26247/abstract/9\">",
"     9",
"    </a>",
"    ]. While manometric findings were similar in patients with and without dysphagia (impaired peristalsis 17 versus 14 percent), MII found more bolus transit abnormalities in patients with dysphagia than in those without dysphagia (62 versus 32 percent). These findings suggest that combined MII-EM can identify esophageal function abnormalities in patients with post-operative dysphagia missed by conventional manometry.",
"   </p>",
"   <p>",
"    Functional information provided by such analysis allows for categorization of transit abnormalities into those with a pressure-only defect and those with a pressure and bolus transit defect (",
"    <a class=\"graphic graphic_table graphicRef81342 \" href=\"UTD.htm?4/42/4779\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Combined impedance-manometry testing can be used to quantify esophageal function (peristalsis and bolus transit) during unrestricted swallowing as it occurs physiologically during meal consumption. One study, for example, quantified the passage of a food bolus through various levels in the esophagus in 10 healthy volunteers [",
"    <a class=\"abstract\" href=\"UTD.htm?25/40/26247/abstract/10\">",
"     10",
"    </a>",
"    ]. The volunteers consumed two pieces of toast and 2 ounces of liquids. The authors observed that liquids and solids were present in the esophagus for less than 33 percent of the duration of meal ingestion.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     COMBINED MULTICHANNEL INTRALUMINAL IMPEDANCE AND PH (MII-PH)",
"    </span>",
"    &nbsp;&mdash;&nbsp;Another FDA-approved application of multichannel intraluminal impedance is gastroesophageal reflux monitoring using combined MII-pH (Sandhill Scientific Inc., Highlands Ranch, CO, USA). Reflux is detected by impedance and classified as acid or non-acid depending upon the concomitant changes in the intraesophageal pH. A consensus statement prepared by an international panel of esophageal experts considered impedance monitoring currently the best method that can achieve high sensitivity for detecting all types of reflux episodes [",
"    <a class=\"abstract\" href=\"UTD.htm?25/40/26247/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Indications",
"    </span>",
"    &nbsp;&mdash;&nbsp;Assuming that the results would alter clinical management, the indications for combined MII-pH studies are to quantify and characterize gastroesophageal reflux (GER), especially in patients with persistent symptoms on acid-suppressive therapy who have normal endoscopic findings [",
"    <a class=\"abstract\" href=\"UTD.htm?25/40/26247/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    For the detection and quantification of GER in patients off acid suppressive therapy, conventional pH testing (using catheter or catheter-free systems) should be sufficient, since non-acid reflux is uncommon in patients off acid-suppressive therapy. However, this conclusion may not apply to the post postprandial period or to patients who do not produce acid due to prior gastrectomy or atrophic gastritis.",
"   </p>",
"   <p>",
"    Given the popularity of empiric trials of PPIs, we suggest that patients be on high dose acid suppressive therapy (ie, at least a PPI twice daily before meals) for at least one week before combined MII-pH testing.",
"   </p>",
"   <p>",
"    Other indications for combined MII-pH studies are evolving. The following benefits have been noted with combined MII-pH studies in different reports:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Facilitated diagnosis of reflux in patients with refractory GER disease on a PPI [",
"      <a class=\"abstract\" href=\"UTD.htm?25/40/26247/abstract/13\">",
"       13",
"      </a>",
"      ]. Efficacy in this setting was demonstrated in a study of 39 patients with refractory reflux: 14 had abnormal impedance testing while on PPI therapy, 13 of whom had persistent acid reflux off therapy. Thus, an abnormal impedance test while on therapy was a strong predictor of acid reflux off therapy. In contrast, normal impedance testing on therapy did not exclude acid reflux off therapy.",
"     </li>",
"     <li>",
"      Facilitated diagnosis of reflux compared with pH data alone in patients in whom a PPI was temporarily discontinued [",
"      <a class=\"abstract\" href=\"UTD.htm?25/40/26247/abstract/14\">",
"       14",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Improved detection of laryngopharyngeal reflux and microaspiration [",
"      <a class=\"abstract\" href=\"UTD.htm?25/40/26247/abstract/15,16\">",
"       15,16",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Procedure",
"    </span>",
"    &nbsp;&mdash;&nbsp;Combined MII-pH testing is similar to pH testing. Patients are asked to fast for four to six hours prior to the probe insertion. Patients taking acid-suppressive therapy should be instructed to take the medications as prescribed, even on the day of testing. The combined MII-pH probe is placed transnasally into the esophagus. Currently available probes are 2.1 mm in diameter (similar to conventional pH probes) and allow for pH sensors to be placed 5 cm above the LES and 10 cm below the LES with impedance measuring segments at 3, 5, 7 and 9 cm above the LES in the distal esophagus and at 15 and 17 cm above the LES in the proximal esophagus (",
"    <a class=\"graphic graphic_figure graphicRef68998 \" href=\"UTD.htm?24/50/25390\">",
"     figure 1",
"    </a>",
"    ). Patients are instructed to have a \"usual\" day and are provided a diary to record the time and content of meals, time of upright and recumbent periods, time of administration of acid-suppressive medication, and time of symptoms. We encourage patients to induce as many symptoms as they can by either ingesting foods",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    doing activities known to produce symptoms. The following day the patient returns the logger and diary and data are downloaded (Zephyr, Sandhill, Scientific Inc, Highlands Ranch, CO).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Data analysis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Data analysis is performed using dedicated software (BioView GER Analysis, Sandhill, Scientific Inc, Highlands Ranch, CO).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     GER composition and proximal extent",
"    </span>",
"    &nbsp;&mdash;&nbsp;Reflux episodes can be classified by MII as containing gas, liquid, or both, based upon different impedance patterns. Air conducts electricity poorly and therefore has very high impedance, whereas liquid gastric contents have low impedance. Mixed reflux events are a combination of both a liquid and gas pattern. The proximal extent of a reflux event is defined by the most proximal impedance measuring segment reached by the liquid component of the reflux episode. Gas reflux events are not assigned a proximal extent since they typically penetrate the UES and are eliminated.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     GER content: Acid, non-acid, weakly acidic, weakly alkaline reflux",
"    </span>",
"    &nbsp;&mdash;&nbsp;An acid reflux event is defined as an event during which there is a drop of pH to below 4.0. Non-acid reflux is defined as an event during which the pH stays above 4.0 (",
"    <a class=\"graphic graphic_figure graphicRef55868 \" href=\"UTD.htm?4/10/4256\">",
"     figure 2",
"    </a>",
"    ). Acknowledging that solutions with pH between 4.0 and 7.0 are acidic from a chemist point of view, some investigators prefer using the term \"weakly acidic\" for reflux episodes with pH 4.0 to 7.0, and the term \"weakly alkaline\" for reflux episodes with pH &gt;7.0 [",
"    <a class=\"abstract\" href=\"UTD.htm?25/40/26247/abstract/11\">",
"     11",
"    </a>",
"    ]. Since weakly alkaline reflux episodes (pH &gt;7.0) are rare, from a practical point of view the terms \"weakly acidic\" and \"non-acid\" describe the same event, ie, reflux episodes with pH &gt;4.0.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Combined MII-pH parameters",
"    </span>",
"    &nbsp;&mdash;&nbsp;Combined MII-pH is a dual modality technique for detecting GER. Its parameters are more complex than those used during traditional 24 hour ambulatory pH monitoring (ie, the number of episodes and percent time pH &lt;4 identified). In addition to these two pH-parameters, combined MII-pH defines the number of MII-GER episodes as the total number of MII-detected episodes.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Refluxate presence time is defined as the total amount of liquid containing MII refluxate presence time (absolute or percent of the study period) detected by the impedance-measuring segment located at 5 cm above the LES",
"     </li>",
"     <li>",
"      Refluxate clearance time is defined as the average duration of liquid containing MII-refluxate presence at 5 cm above the LES",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    All of the above mentioned parameters are further separated into acid and non-acid based upon the pH changes recorded at the time when the reflux occurred. According to the position of the subject at the time the GER occurs, these parameters are further separated into upright and recumbent.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Overall study interpretation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Overall study interpretation was based initially upon normative data described in a study of 60 healthy volunteers [",
"    <a class=\"abstract\" href=\"UTD.htm?25/40/26247/abstract/17\">",
"     17",
"    </a>",
"    ]. Subsequent studies have found that postprandial gastroesophageal reflux data with impedance monitoring are as reproducible as when assessed with pH monitoring [",
"    <a class=\"abstract\" href=\"UTD.htm?25/40/26247/abstract/18\">",
"     18",
"    </a>",
"    ]. In the postprandial period, acid suppressive therapy primarily changes the ratio of acid versus non-acid reflux episodes with less effect on the total number of episodes [",
"    <a class=\"abstract\" href=\"UTD.htm?25/40/26247/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Studies evaluating the number of acid and non-acid reflux episodes in healthy volunteers monitored on PPIs twice daily indicate that acid suppressive therapy decreases the total number of reflux episodes, presumably by reducing the total amount of gastric secretion [",
"    <a class=\"abstract\" href=\"UTD.htm?25/40/26247/abstract/20,21\">",
"     20,21",
"    </a>",
"    ]. As a result, different normal values should be used when interpreting the total number of reflux episodes in patients \"off\" and \"on\" acid suppressive therapy (",
"    <a class=\"graphic graphic_table graphicRef56522 \" href=\"UTD.htm?4/5/4188\">",
"     table 2",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Influence on management",
"    </span>",
"    &nbsp;&mdash;&nbsp;Accumulating studies have evaluated the role of impedance testing in evaluation of patients with esophageal symptoms, particularly in those who continue to have symptoms despite acid suppression. As a general rule, these have demonstrated that impedance testing clarifies the relationships among symptoms, acid and non-acid reflux [",
"    <a class=\"abstract\" href=\"UTD.htm?25/40/26247/abstract/3,22-29\">",
"     3,22-29",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Patients with persistent symptoms despite PPIs in particular represent a diagnostic dilemma during conventional pH testing. Combined MII-pH helps clarify the association of symptoms with reflux events, and has demonstrated that about one-half of patients with persistent symptoms on therapy do not have a temporal correlation between their symptoms and any type of reflux. In addition, about 40 percent of patients with persistent symptoms on PPI therapy have a temporal association between their symptoms and reflux, primarily of the non-acid type.",
"   </p>",
"   <p>",
"    However, whether the improved understanding of symptoms to reflux and non-reflux events translates into better health outcomes has not yet been well-established.",
"   </p>",
"   <p>",
"    The following are illustrative of the range of findings:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A multicenter collaborative study including 168 patients found that only 11 percent of patients with persistent symptoms on acid-suppressive therapy had symptoms related to continued acid reflux [",
"      <a class=\"abstract\" href=\"UTD.htm?25/40/26247/abstract/22\">",
"       22",
"      </a>",
"      ]. The other 89 percent had symptoms associated either with non-acid reflux or not associated with any type of GER.",
"     </li>",
"     <li>",
"      Up to one-half of patients with persistent typical gastroesophageal reflux disease (GERD) symptoms on PPI therapy had symptoms associated with non-acid reflux in another report [",
"      <a class=\"abstract\" href=\"UTD.htm?25/40/26247/abstract/22\">",
"       22",
"      </a>",
"      ], while in another study, acid reflux was associated with symptoms in only 5 percent of patients [",
"      <a class=\"abstract\" href=\"UTD.htm?25/40/26247/abstract/23\">",
"       23",
"      </a>",
"      ]. A third report involving 150 patients classified as having nonerosive reflux disease found that a substantial proportion of patients had symptoms attributable to non-acid reflux [",
"      <a class=\"abstract\" href=\"UTD.htm?25/40/26247/abstract/29\">",
"       29",
"      </a>",
"      ]. Reclassifying those with symptomatic non-acid reflux as having a hypersensitive esophagus reduced the number of patients classified as having functional heartburn from 43 to 26 percent.",
"     </li>",
"     <li>",
"      A study of 125 patients with persistent symptoms despite PPIs demonstrated that most reflux episodes were asymptomatic [",
"      <a class=\"abstract\" href=\"UTD.htm?25/40/26247/abstract/28\">",
"       28",
"      </a>",
"      ]. However, reflux episodes extending proximally and having a mixed (liquid-gas) composition were significantly associated with symptoms, irrespective of whether the pH was acidic or non-acidic.",
"     </li>",
"     <li>",
"      Another study evaluating 22 patients with chronic cough off PPI therapy found that 10 patients (45 percent) had a positive symptom association between cough and reflux [",
"      <a class=\"abstract\" href=\"UTD.htm?25/40/26247/abstract/3\">",
"       3",
"      </a>",
"      ]. Symptoms were associated with non-acid reflux, which was detectable only by impedance-pH monitoring.",
"     </li>",
"     <li>",
"      Our group evaluated 50 patients with persistent cough while on a PPI and found an association between cough and reflux in 13 patients (26 percent) [",
"      <a class=\"abstract\" href=\"UTD.htm?25/40/26247/abstract/24\">",
"       24",
"      </a>",
"      ]. The clinical relevance of these findings was underscored by the clinical improvement in six patients with a positive association between cough and reflux who underwent laparoscopic fundoplication.",
"     </li>",
"     <li>",
"      A study in 30 patients with typical GERD symptoms found a similar total number of impedance detected reflux episodes while patients were off (73 &plusmn; 33) or on (69 &plusmn; 35) acid suppressive therapy [",
"      <a class=\"abstract\" href=\"UTD.htm?25/40/26247/abstract/30\">",
"       30",
"      </a>",
"      ]. This underscores the concept that PPI therapy changes the pH of the refluxate but has no influence on the frequency of gastroesophageal reflux episodes. A positive symptom association (SAP) was found in 15 out of 28 (54 percent) patients reporting symptoms while monitored off therapy and in 11 out of 23 (48 percent) patients reporting symptoms while monitored on therapy.",
"     </li>",
"     <li>",
"      A study in a cohort of 19 patients who underwent anti-reflux surgery based upon the results of MII-pH monitoring found that 17 of 18 patients with documented positive symptom association between reflux (acid and non-acid) reported no symptoms at a median follow-up time of 14 months after surgery [",
"      <a class=\"abstract\" href=\"UTD.htm?25/40/26247/abstract/25\">",
"       25",
"      </a>",
"      ]. These results indicate that MII-pH monitoring on therapy helps identify patients with persistent typical and atypical reflux symptoms who may benefit from anti-reflux surgery.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Measuring impedance at multiple sites (multichannel) allows for determination of direction of bolus movement based upon temporal differences in bolus entry and exit (ie, bolus entries progressing from proximal to distal indicate antegrade bolus movement while bolus entries progressing from distal to proximal indicate retrograde bolus movement) (",
"      <a class=\"graphic graphic_waveform graphicRef56477 \" href=\"UTD.htm?26/32/27151\">",
"       waveform 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Principles of MII'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Combined MII-EM offers the opportunity to simultaneously evaluate esophageal contractions and bolus transit without the use of radiation. Some of the findings challenge current existing criteria that define effectiveness of esophageal body function. Future studies are warranted to evaluate the prognostic values of pressure and bolus transit abnormalities and also to continue to incorporate high resolution manometry with impedance measurements. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Combined multichannel intraluminal impedance and pH (MII-pH)'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Combined MII-pH testing brings a shift in GER testing paradigm. In MII-pH studies reflux presence, distribution and clearing is primarily detected by MII and simply characterized as acid versus non-acid based upon pH change and as liquid, gas, or mixed based upon MII. MII determines refluxate clearance time while pH measures acid clearance time. MII-pH has become an important clinical tool, particularly to assess gastroesophageal reflux in the postprandial period, in patients with persistent symptoms on proton pump inhibitor (PPI) therapy, and those with atypical symptoms. In these situations it has great potential to direct therapy to additional pharmacologic approaches, surgery, or perhaps even endoscopic modification of reflux. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Combined multichannel intraluminal impedance and pH (MII-pH)'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?17/18/17706?source=see_link\">",
"       \"Approach to refractory gastroesophageal reflux disease in adults\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?41/57/42905?source=see_link\">",
"       \"Surgical management of gastroesophageal reflux in adults\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?25/5/25688?source=see_link\">",
"       \"Endoscopic therapy for gastroesophageal reflux disease: Sewing and full-thickness plication techniques\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/40/26247/abstract/1\">",
"      Tutuian R, Vela MF, Balaji NS, et al. Esophageal function testing with combined multichannel intraluminal impedance and manometry: multicenter study in healthy volunteers. Clin Gastroenterol Hepatol 2003; 1:174.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/40/26247/abstract/2\">",
"      Koya DL, Agrawal A, Freeman JE, Castell DO. Impedance detected abnormal bolus transit in patients with normal esophageal manometry. Sensitive indicator of esophageal functional abnormality? Dis Esophagus 2008; 21:563.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/40/26247/abstract/3\">",
"      Sifrim D, Dupont L, Blondeau K, et al. Weakly acidic reflux in patients with chronic unexplained cough during 24 hour pressure, pH, and impedance monitoring. Gut 2005; 54:449.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/40/26247/abstract/4\">",
"      Spechler SJ, Castell DO. Classification of oesophageal motility abnormalities. Gut 2001; 49:145.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/40/26247/abstract/5\">",
"      Tutuian R, Castell DO. Combined multichannel intraluminal impedance and manometry clarifies esophageal function abnormalities: study in 350 patients. Am J Gastroenterol 2004; 99:1011.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/40/26247/abstract/6\">",
"      Conchillo JM, Nguyen NQ, Samsom M, et al. Multichannel intraluminal impedance monitoring in the evaluation of patients with non-obstructive Dysphagia. Am J Gastroenterol 2005; 100:2624.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/40/26247/abstract/7\">",
"      Tutuian R, Castell DO. Clarification of the esophageal function defect in patients with manometric ineffective esophageal motility: studies using combined impedance-manometry. Clin Gastroenterol Hepatol 2004; 2:230.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/40/26247/abstract/8\">",
"      Tutuian R, Mainie I, Agrawal A, et al. Symptom and function heterogenicity among patients with distal esophageal spasm: studies using combined impedance-manometry. Am J Gastroenterol 2006; 101:464.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/40/26247/abstract/9\">",
"      Yigit T, Quiroga E, Oelschlager B. Multichannel intraluminal impedance for the assessment of post-fundoplication dysphagia. Dis Esophagus 2006; 19:382.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/40/26247/abstract/10\">",
"      Wilson JA, Mainie I, Tutuian R, et al. Multichannel intraluminal impedance and esophageal manometry data for unrestricted swallowing: establishing normal values. Dis Esophagus 2008; 21:51.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/40/26247/abstract/11\">",
"      Sifrim D, Castell D, Dent J, Kahrilas PJ. Gastro-oesophageal reflux monitoring: review and consensus report on detection and definitions of acid, non-acid, and gas reflux. Gut 2004; 53:1024.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/40/26247/abstract/12\">",
"      Hirano I, Richter JE, Practice Parameters Committee of the American College of Gastroenterology. ACG practice guidelines: esophageal reflux testing. Am J Gastroenterol 2007; 102:668.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/40/26247/abstract/13\">",
"      Pritchett JM, Aslam M, Slaughter JC, et al. Efficacy of esophageal impedance/pH monitoring in patients with refractory gastroesophageal reflux disease, on and off therapy. Clin Gastroenterol Hepatol 2009; 7:743.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/40/26247/abstract/14\">",
"      Rosen R, Nurko S. The importance of multichannel intraluminal impedance in the evaluation of children with persistent respiratory symptoms. Am J Gastroenterol 2004; 99:2452.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/40/26247/abstract/15\">",
"      Ford CN. Evaluation and management of laryngopharyngeal reflux. JAMA 2005; 294:1534.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/40/26247/abstract/16\">",
"      Oelschlager BK, Quiroga E, Isch JA, Cuenca-Abente F. Gastroesophageal and pharyngeal reflux detection using impedance and 24-hour pH monitoring in asymptomatic subjects: defining the normal environment. J Gastrointest Surg 2006; 10:54.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/40/26247/abstract/17\">",
"      Shay S, Tutuian R, Sifrim D, et al. Twenty-four hour ambulatory simultaneous impedance and pH monitoring: a multicenter report of normal values from 60 healthy volunteers. Am J Gastroenterol 2004; 99:1037.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/40/26247/abstract/18\">",
"      Bredenoord AJ, Weusten BL, Timmer R, Smout AJ. Reproducibility of multichannel intraluminal electrical impedance monitoring of gastroesophageal reflux. Am J Gastroenterol 2005; 100:265.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/40/26247/abstract/19\">",
"      Vela MF, Camacho-Lobato L, Srinivasan R, et al. Simultaneous intraesophageal impedance and pH measurement of acid and nonacid gastroesophageal reflux: effect of omeprazole. Gastroenterology 2001; 120:1599.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/40/26247/abstract/20\">",
"      Tutuian, R, Mainie, I, Agrawal, A, et al. Normal values for ambulatory 24-h combined impedance-pH monitoring on acid suppressive therapy. Gastroenterology 2006; 130 Suppl 2:A171.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/40/26247/abstract/21\">",
"      Zerbib F, Roman S, Bruley Des Varannes S, et al. Normal Values of Pharyngeal and Esophageal 24-Hour pH Impedance in Individuals on and off Therapy and Interobserver Reproducibility. Clin Gastroenterol Hepatol 2013; 11:366.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/40/26247/abstract/22\">",
"      Mainie I, Tutuian R, Shay S, et al. Acid and non-acid reflux in patients with persistent symptoms despite acid suppressive therapy: a multicentre study using combined ambulatory impedance-pH monitoring. Gut 2006; 55:1398.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/40/26247/abstract/23\">",
"      Zerbib F, Roman S, Ropert A, et al. Esophageal pH-impedance monitoring and symptom analysis in GERD: a study in patients off and on therapy. Am J Gastroenterol 2006; 101:1956.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/40/26247/abstract/24\">",
"      Tutuian R, Mainie I, Agrawal A, et al. Nonacid reflux in patients with chronic cough on acid-suppressive therapy. Chest 2006; 130:386.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/40/26247/abstract/25\">",
"      Mainie I, Tutuian R, Agrawal A, et al. Combined multichannel intraluminal impedance-pH monitoring to select patients with persistent gastro-oesophageal reflux for laparoscopic Nissen fundoplication. Br J Surg 2006; 93:1483.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/40/26247/abstract/26\">",
"      Sharma N, Agrawal A, Freeman J, et al. An analysis of persistent symptoms in acid-suppressed patients undergoing impedance-pH monitoring. Clin Gastroenterol Hepatol 2008; 6:521.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/40/26247/abstract/27\">",
"      Kline MM, Ewing M, Simpson N, Laine L. The utility of intraluminal impedance in patients with gastroesophageal reflux disease-like symptoms but normal endoscopy and 24-hour pH testing. Clin Gastroenterol Hepatol 2008; 6:880.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/40/26247/abstract/28\">",
"      Tutuian R, Vela MF, Hill EG, et al. Characteristics of symptomatic reflux episodes on Acid suppressive therapy. Am J Gastroenterol 2008; 103:1090.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/40/26247/abstract/29\">",
"      Savarino E, Zentilin P, Tutuian R, et al. The role of nonacid reflux in NERD: lessons learned from impedance-pH monitoring in 150 patients off therapy. Am J Gastroenterol 2008; 103:2685.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/40/26247/abstract/30\">",
"      Hemmink GJ, Bredenoord AJ, Weusten BL, et al. Esophageal pH-impedance monitoring in patients with therapy-resistant reflux symptoms: 'on' or 'off' proton pump inhibitor? Am J Gastroenterol 2008; 103:2446.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2248 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-203.80.222.8-5CA963D2D9-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_40_26247=[""].join("\n");
var outline_f25_40_26247=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H16\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      PRINCIPLES OF MII",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      COMBINED MULTICHANNEL INTRALUMINAL IMPEDANCE AND MANOMETRY (MII-EM)",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Indications",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Procedure",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Data analysis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      COMBINED MULTICHANNEL INTRALUMINAL IMPEDANCE AND PH (MII-PH)",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Indications",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Procedure",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Data analysis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - GER composition and proximal extent",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - GER content: Acid, non-acid, weakly acidic, weakly alkaline reflux",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Combined MII-pH parameters",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Overall study interpretation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Influence on management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"GAST/2248\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/2248|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?24/50/25390\" title=\"figure 1\">",
"      ConventionaL vs impedance",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?4/10/4256\" title=\"figure 2\">",
"      MII pH monitoring",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/2248|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?4/42/4779\" title=\"table 1\">",
"      Pressure versus transit",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?4/5/4188\" title=\"table 2\">",
"      Normal values impedance pH",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/2248|Waveform\">",
"      <a href=\"#\" title=\"WAVEFORMS\">",
"       WAVEFORMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"UTD.htm?26/32/27151\" title=\"waveform 1\">",
"      Detection of bolus movement",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/18/17706?source=related_link\">",
"      Approach to refractory gastroesophageal reflux disease in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/5/25688?source=related_link\">",
"      Endoscopic therapy for gastroesophageal reflux disease: Sewing and full-thickness plication techniques",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/57/42905?source=related_link\">",
"      Surgical management of gastroesophageal reflux in adults",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f25_40_26248="Pathophysiology and prevention of peritonitis in peritoneal dialysis";
var content_f25_40_26248=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Pathophysiology and prevention of peritonitis in peritoneal dialysis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?25/40/26248/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?25/40/26248/contributors\">",
"     John M Burkart, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?25/40/26248/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?25/40/26248/contributors\">",
"     Thomas A Golper, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?25/40/26248/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?25/40/26248/contributors\">",
"     Alice M Sheridan, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?25/40/26248/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Oct 18, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Peritonitis is one of the major complications of continuous ambulatory peritoneal dialysis (PD) and remains the primary reason why patients switch from PD to hemodialysis [",
"    <a class=\"abstract\" href=\"UTD.htm?25/40/26248/abstract/1\">",
"     1",
"    </a>",
"    ]. A review of the factors responsible for peritonitis in this setting and the modalities that can be used to reduce the frequency of this complication are presented here.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     PATHOPHYSIOLOGY AND CAUSES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Peritonitis associated with PD is most often due to contamination with pathogenic skin bacteria, with Staphylococcus epidermidis and S. aureus accounting for the majority of cases. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/11/17594?source=see_link\">",
"     \"Microbiology and therapy of peritonitis in continuous peritoneal dialysis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The intact peritoneum and the defense mechanisms of the mesothelium are probably the most important barriers to the development of peritonitis in PD patients. The incidence of systemic bacteremia in association with PD peritonitis is extremely low (less than one percent) in contrast to the reported 30 percent with surgical peritonitis [",
"    <a class=\"abstract\" href=\"UTD.htm?25/40/26248/abstract/2\">",
"     2",
"    </a>",
"    ] and 39 to 76 percent of spontaneous peritonitis in cirrhotic patients with ascites [",
"    <a class=\"abstract\" href=\"UTD.htm?25/40/26248/abstract/3,4\">",
"     3,4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A number of factors contribute to the development of peritonitis in this setting even when the patient is maximally skilled with the dialysis technique:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The patient on continuous ambulatory peritoneal dialysis (CAPD) usually connects and disconnects from the transfer set many times a day and therefore must perform a large number of sterile exchanges per year; it would be naive to assume that bacterial contamination does not occur at times. In comparison, a patient on continuous cycling peritoneal dialysis (CCPD) needs to connect or disconnect from the transfer set far fewer times, and the peritonitis rate is predicted to be lower than that in patients on CAPD (see below).",
"     </li>",
"     <li>",
"      The continuous presence of nonphysiologic fluid in the peritoneal cavity can impair host defenses. Standard dialysis fluids have a high glucose concentration, are hyperosmolar, have a low pH, and markedly dilute resident peritoneal macrophage and cytokine levels. Newer peritoneal dialysis fluids containing glucose polymers (such as",
"      <a class=\"drug drug_general\" href=\"UTD.htm?43/36/44612?source=see_link\">",
"       icodextrin",
"      </a>",
"      ) may be relatively less harmful to neutrophil and macrophage function. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?18/12/18632?source=see_link\">",
"       \"Peritoneal dialysis solutions\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Macrophages and cytokines that are activated during a potential infection are constantly removed during each exchange of dialysis fluids. As a result, a relatively small inoculum of bacteria, as often occurs with a touch contamination, can readily induce peritonitis in a PD patient; in contrast, a similar inoculation during surgical laparotomy seldom causes peritonitis [",
"      <a class=\"abstract\" href=\"UTD.htm?25/40/26248/abstract/5,6\">",
"       5,6",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Mesothelial surfaces have extraordinary host defense mechanisms when the surfaces are allowed close proximity to each other. These defense mechanisms are compromised by the presence of dialysis solution.",
"     </li>",
"     <li>",
"      The chronic indwelling catheter bridges both a sterile and nonsterile environment. Bacteria can track along the catheter and its tunnel. In addition, the catheter itself can be a nidus of retained microbes directly growing into the material (fungi) or through the creation of",
"      <span class=\"nowrap\">",
"       biofilm/slime",
"      </span>",
"      layers, under which the bacteria are protected from host defenses or antibiotics (see below). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?2/60/3018?source=see_link\">",
"       \"Tunnel and peritoneal catheter exit site infections in continuous peritoneal dialysis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The normal healthy peritoneal mesothelial cells play an important role in orchestrating host",
"      <span class=\"nowrap\">",
"       defense/peritoneal",
"      </span>",
"      inflammation and fibrosis. The function of these mesothelial cells may be altered over time.",
"     </li>",
"     <li>",
"      Seasonal variation in peritonitis with an increased risk in hot and humid months or climates, suggests a catheter or technique-related underlying cause of many episodes [",
"      <a class=\"abstract\" href=\"UTD.htm?25/40/26248/abstract/7\">",
"       7",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Sources of contamination",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are several sources of bacterial peritonitis in CAPD:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Intraluminal (touch contamination)",
"     </li>",
"     <li>",
"      Periluminal (catheter-related infection)",
"     </li>",
"     <li>",
"      Transvisceral migration due to intraabdominal pathology (eg, bowel leak)",
"     </li>",
"     <li>",
"      Hematogenous",
"     </li>",
"     <li>",
"      Vaginal leak, which is very rare",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Prior to the use of Y systems (see below), the most common cause of peritonitis in CAPD patients was thought to be touch contamination during the spike. The connection devices developed based upon the principle of \"flush before fill\" have significantly reduced the incidence of peritonitis due to touch contamination.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H428817003\">",
"    <span class=\"h2\">",
"     Exit site infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Catheter exit site infection has been associated with peritonitis [",
"    <a class=\"abstract\" href=\"UTD.htm?25/40/26248/abstract/8-10\">",
"     8-10",
"    </a>",
"    ]. Perhaps the best data are from a secondary analysis of a randomized trial that compared two antimicrobial ointments among 203 stable PD patients [",
"    <a class=\"abstract\" href=\"UTD.htm?25/40/26248/abstract/9\">",
"     9",
"    </a>",
"    ]. Over 18 months there were 44 exit site infections and 87 peritonitis episodes. Patients who had an exit site infection were much more likely to develop peritonitis within 30 days, even if exit site infection was appropriately treated. The risk of peritonitis decreased over time with hazard ratios of 11.1, 5.3, and 4.9 at 15, 45 and 60 days. Surprisingly, in this study, the organisms that caused peritonitis were most often unrelated to those that caused the exit site infection, suggesting that the mechanism of increased susceptibility to peritonitis is not straightforward. However, this observation needs to be confirmed in a larger clinical trial. Regardless of the mechanism by which exit site infections lead to peritonitis, these data support the need for aggressive prevention and treatment of exit site infections [",
"    <a class=\"abstract\" href=\"UTD.htm?25/40/26248/abstract/11\">",
"     11",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/60/3018?source=see_link&amp;anchor=H15#H15\">",
"     \"Tunnel and peritoneal catheter exit site infections in continuous peritoneal dialysis\", section on 'Initial antibiotic therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Biofilms",
"    </span>",
"    &nbsp;&mdash;&nbsp;Biofilms on the catheter may contribute to relapsing or recurrent infection and to antibiotic resistance. In addition, in vitro studies suggest that higher levels of and multiple antibiotics are needed to eradicate recurrent peritonitis due to biofilms [",
"    <a class=\"abstract\" href=\"UTD.htm?25/40/26248/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Despite these experimental observations, the clinical significance of biofilms remains uncertain. A large prospective study, for example, demonstrated biofilms in peritoneal catheters removed from PD patients; cultures of scrapings from these biofilms were often positive for S. aureus or S. epidermidis [",
"    <a class=\"abstract\" href=\"UTD.htm?25/40/26248/abstract/13\">",
"     13",
"    </a>",
"    ]. There was, however, no clear relationship to clinical peritonitis [",
"    <a class=\"abstract\" href=\"UTD.htm?25/40/26248/abstract/14\">",
"     14",
"    </a>",
"    ]. Other studies also showed that biofilms can be present without any evidence of infection [",
"    <a class=\"abstract\" href=\"UTD.htm?25/40/26248/abstract/15,16\">",
"     15,16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Nevertheless, biofilms may contribute to relapsing or recurrent peritonitis [",
"    <a class=\"abstract\" href=\"UTD.htm?25/40/26248/abstract/17,18\">",
"     17,18",
"    </a>",
"    ]. If this was true, the reappearance of the same organism would be expected to occur among patients with multiple episodes of peritonitis. To best examine this possibility, nearly 200 patients initiating PD between 1990 to 2000 were enrolled in a study because they had experienced more than one episode of culture-positive peritonitis and complete data were available concerning cultured organisms [",
"    <a class=\"abstract\" href=\"UTD.htm?25/40/26248/abstract/18\">",
"     18",
"    </a>",
"    ]. Reported results were as follows:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Approximately 80 percent (157 patients) had at least one repeat infection with the same organism.",
"     </li>",
"     <li>",
"      More than 50 percent of the peritonitis episodes among 124 patients were caused by the same organism.",
"     </li>",
"     <li>",
"      59 of 90 patients (65 percent) of those with more than four infectious episodes had at least half or more of their episodes caused by the same organism.",
"     </li>",
"     <li>",
"      Among 67 patients with catheter changes and subsequent peritonitis, only 10 developed repeat infections with the same organism after the catheter change.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Another report found that patients with multiple episodes of peritonitis were likely to have stable biofilms, positive biofilm cultures, and a high incidence of catheter loss [",
"    <a class=\"abstract\" href=\"UTD.htm?25/40/26248/abstract/17\">",
"     17",
"    </a>",
"    ]. Troublesome organisms that notoriously form biofilms in this setting are Staphylococci and Pseudomonas [",
"    <a class=\"abstract\" href=\"UTD.htm?25/40/26248/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Summary",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although more data are required, evidence generally supports the hypothesis that biofilms may be associated with recurrent or relapsing peritonitis in some PD patients.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     PREVENTION",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Proper training",
"    </span>",
"    &nbsp;&mdash;&nbsp;All patients must be trained in aseptic techniques and instructed in the definition of and proper response to contamination [",
"    <a class=\"abstract\" href=\"UTD.htm?25/40/26248/abstract/20,21\">",
"     20,21",
"    </a>",
"    ]. After a known break in technique, the working group for the 2005 International Society of Peritoneal Dialysis (ISPD) noted that a two day course of antibiotics is administered by most nephrologists [",
"    <a class=\"abstract\" href=\"UTD.htm?25/40/26248/abstract/20\">",
"     20",
"    </a>",
"    ]. At our center, we change the patient's transfer set and typically prescribe two days of antibiotics (one-half of time oral cephalosporin and one-half of time intraperitoneal cephalosporin). If the contamination was noted after an exchange was started, we recommend seven days of antibiotics.",
"   </p>",
"   <p>",
"    The benefits of training as well as retraining were reported in a study of new patients who were randomly assigned to either standard or enhanced training (adult learning) [",
"    <a class=\"abstract\" href=\"UTD.htm?25/40/26248/abstract/22\">",
"     22",
"    </a>",
"    ]. At two years, enhanced training was associated with significantly fewer exit site infections as well as a trend toward a decreased peritonitis rate.",
"   </p>",
"   <p>",
"    A related issue is whether training nurses' experience has an impact upon peritonitis rates. In a single center observational study, there was a negative association between trainers' length of time in practice and incidence of Gram positive peritonitis among incident patients [",
"    <a class=\"abstract\" href=\"UTD.htm?25/40/26248/abstract/23\">",
"     23",
"    </a>",
"    ]. This suggests that continued active learning for trainers may help prevent peritonitis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Prophylactic antibiotic administration for procedures",
"    </span>",
"    &nbsp;&mdash;&nbsp;The administration of an antibiotic just prior to peritoneal catheter placement may decrease the incidence of wound infection and peritonitis. This is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/63/6136?source=see_link&amp;anchor=H8#H8\">",
"     \"Placement and maintenance of the peritoneal dialysis catheter\", section on 'Antibiotic prophylaxis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The working group for the 2005 International Society of Peritoneal dialysis also recommend that antibiotic prophylaxis may be administered for the following procedures [",
"    <a class=\"abstract\" href=\"UTD.htm?25/40/26248/abstract/20\">",
"     20",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Two hours prior to extensive dental procedures, a single oral dose of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?41/10/42152?source=see_link\">",
"       amoxicillin",
"      </a>",
"      (two grams) is considered a reasonable option.",
"     </li>",
"     <li>",
"      Among patients undergoing colonoscopy with polypectomy, the intravenous administration of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?12/51/13112?source=see_link\">",
"       ampicillin",
"      </a>",
"      (one gram) plus a single dose of an aminoglycoside (with or without",
"      <a class=\"drug drug_general\" href=\"UTD.htm?19/38/20065?source=see_link\">",
"       metronidazole",
"      </a>",
"      ) immediately prior to the procedure may help prevent peritonitis.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In addition, the working group also recommended that the abdomen should also be emptied of fluid prior to any procedure involving the abdomen or pelvis [",
"    <a class=\"abstract\" href=\"UTD.htm?25/40/26248/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Y and double bag systems",
"    </span>",
"    &nbsp;&mdash;&nbsp;The first modification in peritoneal dialysis that lowered the rate of peritonitis was the development of wearable (collapsible) dialysate bags. The second important modification of the standard technique was the introduction of the Y set [",
"    <a class=\"abstract\" href=\"UTD.htm?25/40/26248/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The standard spike systems require the patient to sequentially drain the peritoneal cavity, disconnect the spent dialysis solution, connect or \"spike\" a new bag of dialysate, and then infuse the new dialysate into the peritoneal cavity. There were two disadvantages with this system:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Any possible microbial contamination of the spike had the potential to be infused into the abdominal cavity.",
"     </li>",
"     <li>",
"      The patient needed to carry the empty bag until the dialysate was drained and discarded.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The Y systems were designed to overcome these problems. Initial Y systems had drain tubing in the shape of a Y. One of the arms of the Y has a preattached drain bag (",
"    <a class=\"graphic graphic_figure graphicRef57532 \" href=\"UTD.htm?29/27/30142\">",
"     figure 1",
"    </a>",
"    ). The patient connects the bag with the fresh dialysis solution to the other arm, and the base of the Y to the Tenckhoff catheter. The first step after spike is to flush out microbes that contaminated the spike by draining a small volume of fresh dialysis solution into the drain bag. The peritoneal cavity is then drained before the new dialysis solution is instilled. This \"flush before fill\" sequence, in contrast to the standard spike, flushes any possible contamination of the spike away from the peritoneal cavity into the drain bag.",
"   </p>",
"   <p>",
"    Multiple reports confirmed a reduction in peritonitis risk with single use systems that incorporate the Y system design [",
"    <a class=\"abstract\" href=\"UTD.htm?25/40/26248/abstract/25-31\">",
"     25-31",
"    </a>",
"    ]. This was perhaps best shown in a systematic review of seven trials consisting of 485 patients in which the use of the Y set, compared with the standard spike system, was associated with a significantly lower risk of peritonitis (RR of 0.64, 95% CI 0.53-0.77) [",
"    <a class=\"abstract\" href=\"UTD.htm?25/40/26248/abstract/31\">",
"     31",
"    </a>",
"    ]; a similar benefit with the Y system in terms of the peritonitis rate (RR of 0.49, 95% CI 0.40-0.61) was reported upon analysis of eight trials and 7417 patient-months.",
"   </p>",
"   <p>",
"    Some, but not all [",
"    <a class=\"abstract\" href=\"UTD.htm?25/40/26248/abstract/32\">",
"     32",
"    </a>",
"    ], studies suggest that subsequent Y systems, in which both dialysis solutions and drain bags are preattached (eg, double bag systems), may be associated with lower peritonitis rates since they more effectively flush out possible contamination during attachment (",
"    <a class=\"graphic graphic_figure graphicRef64131 \" href=\"UTD.htm?7/7/7293\">",
"     figure 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?25/40/26248/abstract/21,30,32-38\">",
"     21,30,32-38",
"    </a>",
"    ]. As examples:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In one report, this technique led to decrease in peritonitis rate from 1.7 to 0.7 episodes per year, with a decrease in the occurrence of infections caused by skin organisms [",
"      <a class=\"abstract\" href=\"UTD.htm?25/40/26248/abstract/34\">",
"       34",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a second study of 147 patients who were randomly assigned to a twin double bag system, a Y-set, or a conventional system, the average peritonitis free interval was highest in the twin bag system group (24.8 months versus 12.0 and 6.1 months for the Y-set and conventional system groups, respectively, p&lt;0.001) [",
"      <a class=\"abstract\" href=\"UTD.htm?25/40/26248/abstract/37\">",
"       37",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    However, a systematic review of randomized, prospective studies found no statistically significant difference with double bag and Y systems concerning peritonitis rates (RR 0.90, 95% CI 0.49-1.66) and",
"    <span class=\"nowrap\">",
"     exit-site/tunnel",
"    </span>",
"    infection rates (RR 1.04, 95% CI 0.52-2.06) [",
"    <a class=\"abstract\" href=\"UTD.htm?25/40/26248/abstract/31\">",
"     31",
"    </a>",
"    ]. Despite this, there was a trend in favor of double bag systems for experiencing peritonitis episodes (RR 0.59, CI 0.35-1.01), which was based upon data from three trials consisting of 292 patients [",
"    <a class=\"abstract\" href=\"UTD.htm?25/40/26248/abstract/32,33,37\">",
"     32,33,37",
"    </a>",
"    ]. There is limited evidence that different double bag systems may not be associated with the same peritonitis rates [",
"    <a class=\"abstract\" href=\"UTD.htm?25/40/26248/abstract/39\">",
"     39",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    As a result, the 2005 European Best Practice Guidelines recommend the use of double-bag systems [",
"    <a class=\"abstract\" href=\"UTD.htm?25/40/26248/abstract/40\">",
"     40",
"    </a>",
"    ]. If these are not available, the guidelines suggest the use of any alternative Y system versus any spike system.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Different PD systems",
"    </span>",
"    &nbsp;&mdash;&nbsp;The exact difference in peritonitis rates with CAPD versus CCPD is unclear. Most studies have found that the rate is lower with CCPD than that with CAPD (presumably due to fewer required connections and disconnections), while others have reported that it is higher or the same [",
"    <a class=\"abstract\" href=\"UTD.htm?25/40/26248/abstract/21,38,41-47\">",
"     21,38,41-47",
"    </a>",
"    ]. Reasons for these varying results may include changes in CAPD technology from older standard spike systems (increased rate) to disconnect Y sets (decreased rate), center or geographic differences, and others. As examples:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a survey of all renal units in Scotland between 1999 to 2002, peritonitis rates for automatic peritoneal dialysis and CAPD were approximately the same, with respective rates being one episode occurring every 20.3 and 18.6 months [",
"      <a class=\"abstract\" href=\"UTD.htm?25/40/26248/abstract/38\">",
"       38",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A retrospective study of nearly 12,000 patients in the United States reported that the rate of peritonitis was minimally but significantly lower with CAPD than with CCPD (RR of 0.939, 95% CI 0.883-0.998) [",
"      <a class=\"abstract\" href=\"UTD.htm?25/40/26248/abstract/47\">",
"       47",
"      </a>",
"      ]. Since information related to CAPD connection technology was not available, it is unclear whether the lower CAPD rates were associated with the increasing use of newer techniques.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A single center review of trends in peritonitis rates showed that with flush before fill technology and the use of twin bags in CAPD patients, peritonitis rates in cycler patients were actually higher [",
"    <a class=\"abstract\" href=\"UTD.htm?25/40/26248/abstract/48\">",
"     48",
"    </a>",
"    ]. It was thought to be due to the need to \"spike\" the connection and that a reduction in peritonitis rates was observed in these patients when they used an assist device to help make this connection.",
"   </p>",
"   <p>",
"    Further study is required to better understand the possible differences in peritonitis rates between different PD systems.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Staphylococcus aureus nasal carriage",
"    </span>",
"    &nbsp;&mdash;&nbsp;The primary reservoir for S. aureus is the anterior nares [",
"    <a class=\"abstract\" href=\"UTD.htm?25/40/26248/abstract/49\">",
"     49",
"    </a>",
"    ]. Furthermore, nasal carriers of S. aureus are at increased risk to develop S. aureus exit site infections, tunnel infections, peritonitis, and possibly peritonitis [",
"    <a class=\"abstract\" href=\"UTD.htm?25/40/26248/abstract/50,51\">",
"     50,51",
"    </a>",
"    ]. One landmark report, for example, found that nasal carriers were four times more likely to develop exit site infections than noncarriers; the overall peritonitis rates were not different between the groups, but all cases of S.aureus peritonitis occurred in the carriers [",
"    <a class=\"abstract\" href=\"UTD.htm?25/40/26248/abstract/50\">",
"     50",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A discussion of the treatment of S. aureus nasal carriage and its effect upon peritoneal dialysis infections is presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/60/3018?source=see_link\">",
"     \"Tunnel and peritoneal catheter exit site infections in continuous peritoneal dialysis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Treatment of catheter infections",
"    </span>",
"    &nbsp;&mdash;&nbsp;An important cause of peritonitis in continuous peritoneal dialysis is extension of infection from the peritoneal dialysis catheter. This is particularly true for infections caused by S. aureus and Pseudomonas aeruginosa. Thus, prompt and effective treatment of catheter related infections is required. This is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/60/3018?source=see_link\">",
"     \"Tunnel and peritoneal catheter exit site infections in continuous peritoneal dialysis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Secondary bacterial peritonitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Not all causes of bacterial peritonitis in a patient treated with peritoneal dialysis are related to the catheter. What has been called secondary or enteric peritonitis can be induced by underlying pathology of the gastrointestinal tract, resulting in significant morbidity and mortality [",
"    <a class=\"abstract\" href=\"UTD.htm?25/40/26248/abstract/52,53\">",
"     52,53",
"    </a>",
"    ]. These conditions include cholecystitis, appendicitis, ruptured diverticulum, the treatment of severe constipation, and perforation during endoscopy [",
"    <a class=\"abstract\" href=\"UTD.htm?25/40/26248/abstract/54\">",
"     54",
"    </a>",
"    ]. Methods to prevent secondary peritonitis are unknown, but may include the avoidance of constipation and evacuation of the gastrointestinal tract prior to endoscopy [",
"    <a class=\"abstract\" href=\"UTD.htm?25/40/26248/abstract/20,53\">",
"     20,53",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Fungal peritonitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Prevention of fungal peritonitis is presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/27/8631?source=see_link\">",
"     \"Fungal peritonitis in continuous peritoneal dialysis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Catheter removal after renal transplantation",
"    </span>",
"    &nbsp;&mdash;&nbsp;The optimal timing of peritoneal dialysis catheter removal after renal transplantation is unclear. Unless otherwise indicated and despite an enhanced risk of peritonitis, some clinicians wait three to four months after surgery since a significant number of patients require the resumption of either temporary or permanent dialysis after transplantation. However, many patients at high-risk for peritonitis may benefit from earlier catheter removal. As an example, one retrospective study of 232 peritoneal dialysis patients found that a significantly enhanced incidence of peritonitis occurred in those with the following clinical characteristics [",
"    <a class=\"abstract\" href=\"UTD.htm?25/40/26248/abstract/55\">",
"     55",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      An increased number of peritonitis episodes prior to surgery (median of three)",
"     </li>",
"     <li>",
"      Previous peritonitis due to Staphylococcus aureus",
"     </li>",
"     <li>",
"      Male gender",
"     </li>",
"     <li>",
"      Technical problems at surgery",
"     </li>",
"     <li>",
"      Greater than two rejection episodes",
"     </li>",
"     <li>",
"      Permanent graft non-function",
"     </li>",
"     <li>",
"      Urinary leak",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    We typically remove the catheter",
"    <strong>",
"     within one month",
"    </strong>",
"    after surgery unless there is a high index of suspicion for the need for dialysis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Beyond the Basics topic (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?14/10/14501?source=see_link\">",
"       \"Patient information: Peritoneal dialysis (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;We suggest the following regimen to minimize the risk of peritonitis in patients treated with PD:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      All patients must be taught proper techniques to decrease the risk of infection.",
"     </li>",
"     <li>",
"      We recommend the administration of an antibiotic, such as cephalosporin, just prior to peritoneal catheter placement to decrease the incidence of wound infection and peritonitis. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?5/63/6136?source=see_link&amp;anchor=H8#H8\">",
"       \"Placement and maintenance of the peritoneal dialysis catheter\", section on 'Antibiotic prophylaxis'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Close attention to catheter implantation technique is needed. Improper catheter placement predisposes to catheter infections.",
"     </li>",
"     <li>",
"      All patients should use Y systems or cyclers and, if cost is not an issue, Y and double bag systems are recommended to further minimize the likelihood of contamination. Standard spike systems should",
"      <strong>",
"       not",
"      </strong>",
"      be utilized.",
"     </li>",
"     <li>",
"      In patients with recurrent peritonitis, one needs to review their technique, rule out exit site or catheter biofilm problems [",
"      <a class=\"abstract\" href=\"UTD.htm?25/40/26248/abstract/56\">",
"       56",
"      </a>",
"      ], or consider the possibility that the patient is a nasal carrier for S. aureus.",
"     </li>",
"     <li>",
"      The prevention and treatment of catheter infections is discussed separately. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?2/60/3018?source=see_link\">",
"       \"Tunnel and peritoneal catheter exit site infections in continuous peritoneal dialysis\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/40/26248/abstract/1\">",
"      Voinescu CG, Khanna R. Peritonitis in peritoneal dialysis. Int J Artif Organs 2002; 25:249.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/40/26248/abstract/2\">",
"      Lorber B, Swenson RM. The bacteriology of intra-abdominal infections. Surg Clin North Am 1975; 55:1349.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/40/26248/abstract/3\">",
"      Correia JP, Conn HO. Spontaneous bacterial peritonitis in cirrhosis: endemic or epidemic? Med Clin North Am 1975; 59:963.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/40/26248/abstract/4\">",
"      Weinstein MP, Iannini PB, Stratton CW, Eickhoff TC. Spontaneous bacterial peritonitis. A review of 28 cases with emphasis on improved survival and factors influencing prognosis. Am J Med 1978; 64:592.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/40/26248/abstract/5\">",
"      Williams JD. Biocompatibility in peritoneal dialysis: definitions and mechanisms. Perit Dial Int 1995; 15:S5.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/40/26248/abstract/6\">",
"      Brulez HF, Verbrugh HA. First-line defense mechanisms in the peritoneal cavity during peritoneal dialysis. Perit Dial Int 1995; 15:S24.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/40/26248/abstract/7\">",
"      Szeto CC, Chow KM, Wong TY, et al. Influence of climate on the incidence of peritoneal dialysis-related peritonitis. Perit Dial Int 2003; 23:580.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/40/26248/abstract/8\">",
"      Gupta B, Bernardini J, Piraino B. Peritonitis associated with exit site and tunnel infections. Am J Kidney Dis 1996; 28:415.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/40/26248/abstract/9\">",
"      van Diepen AT, Tomlinson GA, Jassal SV. The association between exit site infection and subsequent peritonitis among peritoneal dialysis patients. Clin J Am Soc Nephrol 2012; 7:1266.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/40/26248/abstract/10\">",
"      Szeto CC, Chow KM, Kwan BC, et al. Staphylococcus aureus peritonitis complicates peritoneal dialysis: review of 245 consecutive cases. Clin J Am Soc Nephrol 2007; 2:245.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/40/26248/abstract/11\">",
"      Blake PG. Getting excited about exit sites in peritoneal dialysis? Clin J Am Soc Nephrol 2012; 7:1206.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/40/26248/abstract/12\">",
"      Anwar H, Dasgupta MK, Costerton JW. Testing the susceptibility of bacteria in biofilms to antibacterial agents. Antimicrob Agents Chemother 1990; 34:2043.",
"     </a>",
"    </li>",
"    <li>",
"     Dasgupta, MK, Ulan, RA, Bettcher, KB, et al. Effects of exit site infection and peritonitis on the distribution of biofilm-encased adherent bacterial microcolonies (BABM) on Tenckhoff (T) catheters in patients undergoing continuous ambulatory peritoneal dialysis (CAPD). In: Advances in Continuous Ambulatory Peritoneal Dialysis, Khanna, R, Nolph, KD, Prowant, BF, et al (Eds), University of Toronto Press, Toronto, 1986, 6:102.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/40/26248/abstract/14\">",
"      Dasgupta, MK, Bettcher, KB, Ulan, RA, et al. Relationship of adherent bacterial biofilms to peritonitis in chronic ambulatory peritoneal dialysis. Perit Dial Bull 1987; 7:168.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/40/26248/abstract/15\">",
"      Verger, C, Chesneau, AM, Thibault, M, et al. Biofilm on the Tenckhoff catheter: A negligible source of contamination. Perit Dial Bull 1987; 7:178.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/40/26248/abstract/16\">",
"      Swartz R, Messana J, Holmes C, Williams J. Biofilm formation on peritoneal catheters does not require the presence of infection. ASAIO Trans 1991; 37:626.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/40/26248/abstract/17\">",
"      Dasgupta MK, Kowalewaska-Grochowska K, Costerton JW. Biofilm and peritonitis in peritoneal dialysis. Perit Dial Int 1993; 13 Suppl 2:S322.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/40/26248/abstract/18\">",
"      Finkelstein ES, Jekel J, Troidle L, et al. Patterns of infection in patients maintained on long-term peritoneal dialysis therapy with multiple episodes of peritonitis. Am J Kidney Dis 2002; 39:1278.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/40/26248/abstract/19\">",
"      Reid G, Khoury AE, Preston CA, Costerton JW. Influence of dextrose dialysis solutions on adhesion of Staphylococcus aureus and Pseudomonas aeruginosa to three catheter surfaces. Am J Nephrol 1994; 14:37.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/40/26248/abstract/20\">",
"      Piraino B, Bailie GR, Bernardini J, et al. Peritoneal dialysis-related infections recommendations: 2005 update. Perit Dial Int 2005; 25:107.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/40/26248/abstract/21\">",
"      Mactier R. Peritonitis is still the achilles' heel of peritoneal dialysis. Perit Dial Int 2009; 29:262.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/40/26248/abstract/22\">",
"      Hall G, Bogan A, Dreis S, et al. New directions in peritoneal dialysis patient training. Nephrol Nurs J 2004; 31:149.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/40/26248/abstract/23\">",
"      Chow KM, Szeto CC, Law MC, et al. Influence of peritoneal dialysis training nurses' experience on peritonitis rates. Clin J Am Soc Nephrol 2007; 2:647.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/40/26248/abstract/24\">",
"      Buoncristiani, U, Cozzari, M, Quintaliani, G, et al. Abatement of exogenous peritonitis risk using the Perugia CAPD system. Dial Transplant 1983; 12:14.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/40/26248/abstract/25\">",
"      Burkart JM, Hylander B, Durnell-Figel T, Roberts D. Comparison of peritonitis rates during long-term use of standard spike versus Ultraset in continuous ambulatory peritoneal dialysis (CAPD). Perit Dial Int 1990; 10:41.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/40/26248/abstract/26\">",
"      Maiorca R, Cantaluppi A, Cancarini GC, et al. Prospective controlled trial of a Y-connector and disinfectant to prevent peritonitis in continuous ambulatory peritoneal dialysis. Lancet 1983; 2:642.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/40/26248/abstract/27\">",
"      Scalamogna A, De Vecchi A, Castelnovo C, et al. Long-term incidence of peritonitis in CAPD patients treated by the Y set technique: experience in a single center. Nephron 1990; 55:24.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/40/26248/abstract/28\">",
"      Port FK, Held PJ, Nolph KD, et al. Risk of peritonitis and technique failure by CAPD connection technique: a national study. Kidney Int 1992; 42:967.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/40/26248/abstract/29\">",
"      Peritonitis in continuous ambulatory peritoneal dialysis (CAPD): a multi-centre randomized clinical trial comparing the Y connector disinfectant system to standard systems. Canadian CAPD Clinical Trials Group. Perit Dial Int 1989; 9:159.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/40/26248/abstract/30\">",
"      Daly CD, Campbell MK, MacLeod AM, et al. Do the Y-set and double-bag systems reduce the incidence of CAPD peritonitis? A systematic review of randomized controlled trials. Nephrol Dial Transplant 2001; 16:341.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/40/26248/abstract/31\">",
"      Strippoli GF, Tong A, Johnson D, et al. Catheter-related interventions to prevent peritonitis in peritoneal dialysis: a systematic review of randomized, controlled trials. J Am Soc Nephrol 2004; 15:2735.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/40/26248/abstract/32\">",
"      Li PK, Szeto CC, Law MC, et al. Comparison of double-bag and Y-set disconnect systems in continuous ambulatory peritoneal dialysis: a randomized prospective multicenter study. Am J Kidney Dis 1999; 33:535.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/40/26248/abstract/33\">",
"      Harris DC, Yuill EJ, Byth K, et al. Twin- versus single-bag disconnect systems: infection rates and cost of continuous ambulatory peritoneal dialysis. J Am Soc Nephrol 1996; 7:2392.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/40/26248/abstract/34\">",
"      Kiernan L, Kliger A, Gorban-Brennan N, et al. Comparison of continuous ambulatory peritoneal dialysis-related infections with different \"Y-tubing\" exchange systems. J Am Soc Nephrol 1995; 5:1835.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/40/26248/abstract/35\">",
"      Balteau PR, Peluso FP, Coles GA, et al. Design and testing of the Baxter Integrated Disconnect Systems (IDS). Perit Dial Int 1991; 11:131.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/40/26248/abstract/36\">",
"      Honkanen, E, Kala, AR, Gronhagen-Riska, C. Divergent etiologies of CAPD peritonitis in integrated double bag and traditional systems? In: Advances in Continuous Ambulatory Peritoneal Dialysis, Khanna, R, Nolph, KD, Prowant, BF, et al (Eds), University of Toronto Press, Toronto, 1991; 7:129.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/40/26248/abstract/37\">",
"      Monte&oacute;n F, Correa-Rotter R, Paniagua R, et al. Prevention of peritonitis with disconnect systems in CAPD: a randomized controlled trial. The Mexican Nephrology Collaborative Study Group. Kidney Int 1998; 54:2123.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/40/26248/abstract/38\">",
"      Kavanagh D, Prescott GJ, Mactier RA. Peritoneal dialysis-associated peritonitis in Scotland (1999-2002). Nephrol Dial Transplant 2004; 19:2584.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/40/26248/abstract/39\">",
"      Wong HS, Ong LM, Lim TO, et al. A randomized, multicenter, open-label trial to determine peritonitis rate, product defect, and technique survival between ANDY-Disc and UltraBag in patients on CAPD. Am J Kidney Dis 2006; 48:464.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/40/26248/abstract/40\">",
"      European Best Practice Guidelines for peritoneal dialysis. Nephrol Dial Transplant 2005; 20(Suppl 9):3.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/40/26248/abstract/41\">",
"      Burkart JM, Jordan JR, Durnell TA, Case LD. Comparison of exit-site infections in disconnect versus nondisconnect systems for peritoneal dialysis. Perit Dial Int 1992; 12:317.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/40/26248/abstract/42\">",
"      Holley JL, Bernardini J, Piraino B. Continuous cycling peritoneal dialysis is associated with lower rates of catheter infections than continuous ambulatory peritoneal dialysis. Am J Kidney Dis 1990; 16:133.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/40/26248/abstract/43\">",
"      Korbet SM, Vonesh EF, Firanek CA. Peritonitis in an urban peritoneal dialysis program: an analysis of infecting pathogens. Am J Kidney Dis 1995; 26:47.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/40/26248/abstract/44\">",
"      Rodr&iacute;guez-Carmona A, P&eacute;rez Font&aacute;n M, Garc&iacute;a Falc&oacute;n T, et al. A comparative analysis on the incidence of peritonitis and exit-site infection in CAPD and automated peritoneal dialysis. Perit Dial Int 1999; 19:253.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/40/26248/abstract/45\">",
"      Locatelli AJ, Marcos GM, G&oacute;mez MG, et al. Comparing peritonitis in continuous ambulatory peritoneal dialysis patients versus automated peritoneal dialysis patients. Adv Perit Dial 1999; 15:193.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/40/26248/abstract/46\">",
"      Huang JW, Hung KY, Yen CJ, et al. Comparison of infectious complications in peritoneal dialysis patients using either a twin-bag system or automated peritoneal dialysis. Nephrol Dial Transplant 2001; 16:604.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/40/26248/abstract/47\">",
"      Oo TN, Roberts TL, Collins AJ. A comparison of peritonitis rates from the United States Renal Data System database: CAPD versus continuous cycling peritoneal dialysis patients. Am J Kidney Dis 2005; 45:372.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/40/26248/abstract/48\">",
"      Bender, FH, Bernardini, J, Piraino, B. Prevention of infectious complications in peritoneal dialysis: best demonstrated practices. Kidney Int 2006; 70:S44.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/40/26248/abstract/49\">",
"      WHITE A, SMITH J. NASAL RESERVOIR AS THE SOURCE OF EXTRANASAL STAPHYLOCOCCI. Antimicrob Agents Chemother (Bethesda) 1963; 161:679.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/40/26248/abstract/50\">",
"      Luzar MA, Coles GA, Faller B, et al. Staphylococcus aureus nasal carriage and infection in patients on continuous ambulatory peritoneal dialysis. N Engl J Med 1990; 322:505.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/40/26248/abstract/51\">",
"      Nouwen J, Schouten J, Schneebergen P, et al. Staphylococcus aureus carriage patterns and the risk of infections associated with continuous peritoneal dialysis. J Clin Microbiol 2006; 44:2233.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/40/26248/abstract/52\">",
"      Tzamaloukas AH, Obermiller LE, Gibel LJ, et al. Peritonitis associated with intra-abdominal pathology in continuous ambulatory peritoneal dialysis patients. Perit Dial Int 1993; 13 Suppl 2:S335.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/40/26248/abstract/53\">",
"      Piraino B. Prevention of peritonitis. Perit Dial Int 1998; 18:244.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/40/26248/abstract/54\">",
"      Singharetnam W, Holley JL. Acute treatment of constipation may lead to transmural migration of bacteria resulting in gram-negative, polymicrobial, or fungal peritonitis. Perit Dial Int 1996; 16:423.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/40/26248/abstract/55\">",
"      Bakir N, Surachno S, Sluiter WJ, Struijk DG. Peritonitis in peritoneal dialysis patients after renal transplantation. Nephrol Dial Transplant 1998; 13:3178.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/40/26248/abstract/56\">",
"      Teitelbaum I, Burkart J. Peritoneal dialysis. Am J Kidney Dis 2003; 42:1082.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1867 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-61.55.141.10-F6FDDAB425-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_40_26248=[""].join("\n");
var outline_f25_40_26248=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H17\" id=\"summRecButton\">",
"      <span>",
"       RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      PATHOPHYSIOLOGY AND CAUSES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Sources of contamination",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H428817003\">",
"      Exit site infection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Biofilms",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Summary",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      PREVENTION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Proper training",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Prophylactic antibiotic administration for procedures",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Y and double bag systems",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Different PD systems",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Staphylococcus aureus nasal carriage",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Treatment of catheter infections",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Secondary bacterial peritonitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Fungal peritonitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Catheter removal after renal transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"NEPH/1867\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEPH/1867|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?29/27/30142\" title=\"figure 1\">",
"      Y system for peritoneal dialysis initial",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?7/7/7293\" title=\"figure 2\">",
"      Y system for peritoneal dialysis modified",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/27/8631?source=related_link\">",
"      Fungal peritonitis in continuous peritoneal dialysis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/11/17594?source=related_link\">",
"      Microbiology and therapy of peritonitis in continuous peritoneal dialysis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?14/10/14501?source=related_link\">",
"      Patient information: Peritoneal dialysis (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/12/18632?source=related_link\">",
"      Peritoneal dialysis solutions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/63/6136?source=related_link\">",
"      Placement and maintenance of the peritoneal dialysis catheter",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/60/3018?source=related_link\">",
"      Tunnel and peritoneal catheter exit site infections in continuous peritoneal dialysis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f25_40_26249="Cutaneous warts";
var content_f25_40_26249=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Cutaneous warts",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?25/40/26249/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?25/40/26249/contributors\">",
"     Beth G Goldstein, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?25/40/26249/contributors\">",
"     Adam O Goldstein, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?25/40/26249/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?25/40/26249/contributors\">",
"     Robert P Dellavalle, MD, PhD, MSPH",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?25/40/26249/contributors\">",
"     Moise L Levy, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?25/40/26249/contributors\">",
"     Ted Rosen, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?25/40/26249/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?25/40/26249/contributors\">",
"     Abena O Ofori, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?25/40/26249/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 3, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Human papillomaviruses (HPV) infect epithelial tissues of skin and mucous membranes [",
"    <a class=\"abstract\" href=\"UTD.htm?25/40/26249/abstract/1\">",
"     1",
"    </a>",
"    ]. The most common clinical manifestation of these viruses is warts (verrucae). There are over 150 distinct HPV subtypes; some tend to infect specific body sites and produce characteristic proliferative lesions at those sites. As an example, HPV type 1 commonly infects the soles of the feet and produces plantar warts, while HPV types 6 and 11 infect the anogenital area and cause anogenital warts. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/38/23144?source=see_link\">",
"     \"Condylomata acuminata (anogenital warts)\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    HPV subtypes have a variable potential to cause malignant change. However, the common cutaneous warts discussed here are rarely linked with HPV-associated carcinoma. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/53/26455?source=see_link\">",
"     \"Virology of human papillomavirus infections and the link to cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY AND TRANSMISSION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cutaneous verrucae occur most commonly in children and young adults [",
"    <a class=\"abstract\" href=\"UTD.htm?25/40/26249/abstract/2\">",
"     2",
"    </a>",
"    ]. They are also more common among certain occupations such as handlers of meat, poultry, and fish. Predisposing conditions for either more extensive or recalcitrant involvement include atopic dermatitis and any condition in which there is decreased cell-mediated immunity (eg, AIDS, organ transplantation) [",
"    <a class=\"abstract\" href=\"UTD.htm?25/40/26249/abstract/3,4\">",
"     3,4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Infection with HPV occurs by skin-to-skin contact, with maceration or sites of trauma (Koebner phenomenon) predisposing patients to inoculation. Latent HPV infection also may occur in normal skin. The reservoir for HPV appears to be individuals with clinical or subclinical infection, and possibly viral particles on inanimate objects. The incubation period following exposure is approximately two to six months.",
"   </p>",
"   <p>",
"    Spontaneous remission of warts occurs in up to two-thirds of patients within two years [",
"    <a class=\"abstract\" href=\"UTD.htm?25/40/26249/abstract/5\">",
"     5",
"    </a>",
"    ]. Warts in patients with intact cellular immunity are the most likely to regress without therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?25/40/26249/abstract/5,6\">",
"     5,6",
"    </a>",
"    ]. Recurrence is common.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     CLINICAL FEATURES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Verrucae can have several different forms based upon location (genital, plantar, and palmar warts) and morphology (flat, mosaic, and filiform warts) (",
"    <a class=\"graphic graphic_picture graphicRef72086 graphicRef51139 graphicRef58825 graphicRef70615 graphicRef56924 graphicRef72268 graphicRef53424 graphicRef62168 graphicRef66188 \" href=\"UTD.htm?43/38/44650\">",
"     picture 1A-I",
"    </a>",
"    ). Lesions may occur singly, in groups, or as coalescing lesions forming plaques. Mosaic warts are plaques of coalescing plantar or palmar warts.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of verrucae is based upon clinical appearance. If there is doubt, a no. 15 blade can be used to scrape off any hyperkeratotic debris and reveal thrombosed capillaries, often called seeds. If dermatoscopic examination is performed, these may appear as homogenous black to red dots and globules [",
"    <a class=\"abstract\" href=\"UTD.htm?25/40/26249/abstract/7,8\">",
"     7,8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The wart also will obscure normal skin markings, also known as dermatoglyphics. Rarely, a shave biopsy is indicated to confirm the diagnosis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Differential diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The differential diagnosis of verrucae includes the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Lichen planus and lichen nitidus &ndash;",
"      </strong>",
"      The flat-topped papules of lichen planus and globoid papules of lichen nitidus may be confused with verruca plana (flat warts). Look for the oral lacy lesions of lichen planus, symmetric distribution, and Wickham's striae.",
"     </li>",
"     <li>",
"      <strong>",
"       Seborrheic keratosis &ndash;",
"      </strong>",
"      Seborrheic keratoses have a stuck on appearance, with horn cysts visible on close examination. They are often pigmented. Dermoscopy can be useful for diagnosis. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?0/34/553?source=see_link\">",
"       \"Overview of benign lesions of the skin\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?0/34/553?source=see_link&amp;anchor=H1101421989#H1101421989\">",
"       \"Overview of benign lesions of the skin\", section on 'Seborrheic keratosis'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Acrochordon &ndash;",
"      </strong>",
"      Acrochordons, or skin tags, are pedunculated flesh-colored papules that lack the roughness of warts. Filiform verruca may be pedunculated but have a characteristic filiform appearance.",
"     </li>",
"     <li>",
"      <strong>",
"       Clavus &ndash;",
"      </strong>",
"      Commonly called a corn, a clavus may obscure normal skin lines but lacks evidence of thrombosed capillaries, or \"seeds,\" after scraping with a no. 15 blade.",
"     </li>",
"     <li>",
"      <strong>",
"       Squamous cell carcinoma &ndash;",
"      </strong>",
"      A diagnosis of squamous cell carcinoma should be considered when lesions have irregular growth, ulceration, or resist therapy, particularly in sun-exposed areas or in immunosuppressed patients.",
"     </li>",
"     <li>",
"      <strong>",
"       Traumatic black heel &ndash;",
"      </strong>",
"      Dried dark erythrocytes deposited in the epidermis of the heel after trauma (black heel) can appear similar to the black dots seen with plantar warts. The black specks of black heel can be removed by superficial paring that usually does not cause bleeding, and black heel does not disrupt skin lines.",
"     </li>",
"     <li>",
"      <strong>",
"       Amelanotic melanoma &ndash;",
"      </strong>",
"      Although extremely rare, lesions that are treatment resistant or atypical, particularly on the palms or soles, should be monitored closely. A biopsy may be required",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The type and aggressiveness of therapy for verrucae will depend upon the type of wart, its location, the degree of symptoms, the patient's cooperation, the patient&rsquo;s desires, and the underlying immune status. Current therapies for HPV are not specific for the virus. Some work by enhancing innate immunity or by local chemotherapeutic effect, but the majority work by tissue destruction, with the goal of destroying the virus-containing epidermis and preserving as much uninvolved tissue as possible. The least painful methods should be used initially, especially in young children. More aggressive or destructive therapies should be reserved for areas where scarring is not a consideration or for numerous, large, recalcitrant, or highly symptomatic lesions.",
"   </p>",
"   <p>",
"    As mentioned above, spontaneous regression occurs in as many as two-thirds of warts within two years; observation is an option for all patients. However, if treatment is pursued, it is far easier to treat smaller, fewer warts early than to wait until lesions enlarge or multiply. New warts may also appear while others are regressing, and most patients desire treatment.",
"   </p>",
"   <p>",
"    It is important to remember when treating verrucae that the virus is microscopic and, although the skin may look normal after treatment, there often is virus still present in the remaining tissue. If any infected tissue remains after treatment, the wart may recur. &nbsp;",
"   </p>",
"   <p>",
"    Therapy may take several weeks or even months; patience and perseverance are essential. Never guarantee patients that the initial removal of a wart will be the definitive treatment.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9145981\">",
"    <span class=\"h2\">",
"     Choice of therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;High quality studies of therapeutic interventions for cutaneous warts are limited, complicating definitive recommendations on the best approach to therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?25/40/26249/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Generalizations based on the limited available data and clinical experience can be made regarding choice of therapy:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Common, plantar, and palmar warts are most commonly treated with salicylic acid or liquid nitrogen. Liquid nitrogen is often avoided in young children because of its potential for causing pain. The role of duct tape as an adjunct to salicylic acid therapy is uncertain. Bichloracetic acid,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?7/39/7794?source=see_link\">",
"       trichloroacetic acid",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?7/57/8083?source=see_link\">",
"       cantharidin",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?19/59/20406?source=see_link\">",
"       imiquimod",
"      </a>",
"      , and topical and intralesional immunotherapy are examples of additional modes of therapy. (See",
"      <a class=\"local\" href=\"#H17\">",
"       'Imiquimod'",
"      </a>",
"      below and",
"      <a class=\"local\" href=\"#H18\">",
"       'Intralesional immunotherapy'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      Flat warts are most often treated with cryotherapy, or topical applications of 5-fluorouracil,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?19/59/20406?source=see_link\">",
"       imiquimod",
"      </a>",
"      , or tretinoin.",
"     </li>",
"     <li>",
"      Filiform warts are most often treated with snip or shave excision followed by hemostasis, as needed. An alternative method that has been used in clinical practice for small filiform warts is contact freezing of the wart. This is usually performed by grasping the base of the wart with forceps that have been briefly dipped in liquid nitrogen.",
"     </li>",
"     <li>",
"      Because a scar on the sole of the foot can be painful and is irreversible, only severe, recalcitrant plantar lesions should be considered for surgical treatment and usually then in consultation with a dermatologist.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A summary of the various therapies currently used to treat warts is provided below.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Salicylic acid",
"    </span>",
"    &nbsp;&mdash;&nbsp;Salicylic acid is an effective therapy for warts that can be used in both adults and children. A 2012 meta-analysis of randomized trials that evaluated treatments for warts found that salicylic acid was superior to placebo for clearance of warts (relative risk [RR] 1.56, 95% CI 1.20-2.03) [",
"    <a class=\"abstract\" href=\"UTD.htm?25/40/26249/abstract/9\">",
"     9",
"    </a>",
"    ]. Reports of the likelihood of clearance of warts following salicylic acid therapy have varied widely, ranging from 0 percent to more than 80 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?25/40/26249/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A number of salicylic acid preparations are available without a prescription. These preparations should not be used in patients with peripheral neuropathy because of the inability to judge the extent of tissue damage resulting from therapy and a risk for poor healing.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Potent preparations, such as 40 percent plasters (Mediplast or Duofilm patch), usually are reserved for thicker areas (eg, palms, soles, extremities); they are particularly useful for plantar warts. The plaster is best applied to the wart and a few millimeters of surrounding skin, taped into place with duct or athletic tape and kept dry for 48 to 72 hours. The patch is then removed, the wart pared down, and the process repeated. The patch must be taped securely in place because it destroys all skin it contacts. If it gets wet, it must be reapplied.",
"     </li>",
"     <li>",
"      Lesser strength preparations are used for the digits of young children and for thinner warts in adults. Two liquid forms, salicylic acid 17 percent (Occlusal HP, Duoplant, Compound W, Duofilm, Wart-off) and salicylic acid 27.5 percent in a film-forming base (Virasal) allow easy application to multiple areas and are useful for common, plantar, palmar, and flat warts. Salicylic acid may also be combined with other agents to attempt to achieve synergistic therapeutic results. For example, salicylic acid 16.7 percent plus lactic acid 17.7 percent (Viranol) and salicylic acid 17 percent premixed with 2 percent 5-fluorouracil (WartPeel) are available for topical treatment of warts.",
"     </li>",
"     <li>",
"      Two other patches, salicylic acid 15 percent in karaya gum base (Trans Ver Sal) and salicylic acid 21 percent (Trans Plantar) are useful for isolated thicker lesions that allow for secure overnight taping of discs into place. Instruct patients to trim the patch to a size slightly larger than the lesion.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    All products come with instructions for application. Patients generally should be advised to apply the patch or liquid at bedtime after soaking the affected area in warm water for 10 to 20 minutes.",
"   </p>",
"   <p>",
"    Adequate paring of hyperkeratosis is an essential component of successful treatment. Paring is done with a nail file (included with some patches) or pumice stone by the patient in between treatments,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    with a scalpel blade in the office immediately before cryotherapy or application of topical agents.",
"   </p>",
"   <p>",
"    Irritation, when it occurs, is usually a sign that the treatment is effective and will result in sloughing of tissue with dead wart virus. Medication is used less often in very painful areas; balancing therapeutic responses and patient discomfort can be difficult. The response to therapy is assessed after two to three weeks. Treatment is often continued for one to two weeks after clinical removal of the verruca to help reduce recurrence and ensure complete removal of any residual virus.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3140176\">",
"    <span class=\"h2\">",
"     Liquid nitrogen",
"    </span>",
"    &nbsp;&mdash;&nbsp;Liquid nitrogen therapy is useful in older children and adults but is often poorly tolerated due to pain when used for younger children. Although a statistically significant benefit of liquid nitrogen cryosurgery over placebo was not detected in a 2012 meta-analysis of randomized trials (RR 1.45, 95% CI 0.65-3.23), the meta-analysis did not find a significant difference in efficacy between this treatment and salicylic acid, which appeared to be more effective than placebo (see",
"    <a class=\"local\" href=\"#H8\">",
"     'Salicylic acid'",
"    </a>",
"    above) [",
"    <a class=\"abstract\" href=\"UTD.htm?25/40/26249/abstract/9\">",
"     9",
"    </a>",
"    ]. Cure rates from liquid nitrogen cryosurgery reported in randomized trials range from 14 percent to more than 90 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?25/40/26249/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Liquid nitrogen must be used cautiously on the digits, especially where nerves are located, to prevent severe pain and possible neuropathy, and to avoid over-freezing in the periungual region, which can result in permanent nail dystrophy. Cryosurgery is also ill-suited to treat small facial flat warts due to the propensity to cause dyschromia.",
"   </p>",
"   <p>",
"    Anesthesia (with 1 percent",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/34/35360?source=see_link\">",
"     lidocaine",
"    </a>",
"    or EMLA cream) is not necessary in all patients prior to liquid nitrogen therapy, although it may be helpful for those with large lesions. Liquid nitrogen is applied so that the visibly frozen area includes the lesion and 2 mm of the surrounding normal tissue and the frozen appearance disappears within 30 to 60 seconds after application for common, plantar, or palmar warts, and within 10 seconds or less for flat warts. Two freeze-thaw cycles may lead to improved resolution at three months when lesions are very thick or when freezing plantar warts [",
"    <a class=\"abstract\" href=\"UTD.htm?25/40/26249/abstract/10\">",
"     10",
"    </a>",
"    ]. It is always better to under-freeze than over-freeze if one is unsure about the initial freeze duration. Some clinicians combine liquid nitrogen therapy with curettage, using the liquid nitrogen as an anesthetic agent. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/51/31543?source=see_link&amp;anchor=H19#H19\">",
"     \"Dermatologic procedures\", section on 'Cryosurgery'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The patient response to liquid nitrogen varies from minimal erythema to hemorrhagic blistering with pain and tenderness. Patients should be warned of these possible normal reactions; plain petrolatum is applied to the blistered skin after it pops. Hypopigmentation may occur in the area treated; thus, dark skinned patients should be treated cautiously with cryotherapy.",
"   </p>",
"   <p>",
"    Healing typically occurs within four to seven days. We typically instruct patients to apply salicylic acid for at least seven more days to peel off more skin in an attempt to prevent recurrences. However, a benefit of this additional intervention is not proven [",
"    <a class=\"abstract\" href=\"UTD.htm?25/40/26249/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Schedule patients for a return visit in two to three weeks to assess therapy; consider repeating a lighter application of liquid nitrogen to treated sites, even if normal tissue is present. Seeing patients back on a weekly basis for repeat therapy leads to more rapid resolution of warts, but it does not lead to higher overall success and it causes more pain [",
"    <a class=\"abstract\" href=\"UTD.htm?25/40/26249/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Duct tape",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is conflicting evidence about the effectiveness of covering warts with duct tape. Although one trial in children found superiority of treatment with standard duct tape to cryotherapy [",
"    <a class=\"abstract\" href=\"UTD.htm?25/40/26249/abstract/12\">",
"     12",
"    </a>",
"    ], a meta-analysis of two placebo-controlled randomized trials failed to find a statistically significant difference between the efficacy of clear duct tape and placebo (RR 1.43, 95% CI 0.51-4.05) [",
"    <a class=\"abstract\" href=\"UTD.htm?25/40/26249/abstract/9\">",
"     9",
"    </a>",
"    ]. Descriptions of these three trials are provided below. [",
"    <a class=\"abstract\" href=\"UTD.htm?25/40/26249/abstract/12-14\">",
"     12-14",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A study of 61 children and adolescents (ages 3 to 22) concluded that covering warts with duct tape was more effective than cryotherapy [",
"      <a class=\"abstract\" href=\"UTD.htm?25/40/26249/abstract/12\">",
"       12",
"      </a>",
"      ]. Treatment involved keeping the wart covered with duct tape for cycles lasting six days and then removing the tape, soaking the wart, debriding the wart with an emery board or pumice stone, and then leaving the wart uncovered on the sixth night; the duct tape was reapplied the next morning. Treatment was continued until wart resolution or for a maximum of two months.",
"      <br/>",
"      <br/>",
"      Resolution rates were significantly higher with duct tape than with cryotherapy (85 versus 60 percent). The majority of warts that resolved with duct tape did so within 28 days of treatment; warts were unlikely to resolve if no response was seen within two weeks. There were nine patients lost to follow-up, and blinding of evaluators was limited. The study included patients with warts in various locations, including finger and plantar warts, but excluded periungual warts because of concerns about nail dystrophy in the cryotherapy arm of the study.",
"     </li>",
"     <li>",
"      In contrast, a somewhat more rigorous study in 103 children (ages 4 to 12) found no statistically significant benefits with duct tape [",
"      <a class=\"abstract\" href=\"UTD.htm?25/40/26249/abstract/13\">",
"       13",
"      </a>",
"      ]. Patients were treated with either a clear brand of duct tape according to the protocol above, or with a corn pad (a ring of material surrounding the wart, intended as a placebo) one night per week; both groups also performed soaking and debridement one night per week as per the protocol above. The evaluator was blinded to treatment for most patients, and no patients were lost to follow-up. After six weeks, rates of wart resolution were similar in the duct tape and corn pad groups (16 versus 6 percent, p = 0.12) and much lower than the rates seen in the earlier trial.",
"     </li>",
"     <li>",
"      A similar trial comparing a clear brand of duct tape with a control treatment with a moleskin pad in 90 adults also found no difference in the rate of wart resolution at the end of two months (21 versus 22 percent) [",
"      <a class=\"abstract\" href=\"UTD.htm?25/40/26249/abstract/14\">",
"       14",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Participants in the latter two trials that used clear duct tape apparently found the duct tape to be much more difficult to keep applied. The researchers in the adult trial were initially informed by the manufacturer that the clear duct tape had the same adhesive as their standard silver duct tape; however they later learned that silver duct tape from that manufacturer uses a rubber-based adhesive and clear duct tape an acrylic-based adhesive [",
"    <a class=\"abstract\" href=\"UTD.htm?25/40/26249/abstract/14\">",
"     14",
"    </a>",
"    ]. The trial that used clear duct tape in children also used duct tape made by the same manufacturer [",
"    <a class=\"abstract\" href=\"UTD.htm?25/40/26249/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    It is possible that the decreased stickiness of clear duct tape directly reduced efficacy, or that the type of adhesive is related to the efficacy of duct tape. Alternatively, the less rigorous design of the earlier trial could have led to a false conclusion of benefit.",
"   </p>",
"   <p>",
"    In summary, it clearly remains uncertain whether duct tape is an effective treatment for warts. In patients who are treated with duct tape, it would make sense to choose a silver brand that is adequately sticky to remain on the skin. In nondiabetic patients with no peripheral artery disease and no neuropathy who are free from skin erosions, duct tape can be combined with salicylic acid applied to the wart itself and not the surrounding skin (see",
"    <a class=\"local\" href=\"#H8\">",
"     'Salicylic acid'",
"    </a>",
"    above).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Cantharidin",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?7/57/8083?source=see_link\">",
"     Cantharidin",
"    </a>",
"    0.7 percent is an extract of a blistering insect. It is typically used in resistant cases in conjunction with or before salicylic acid preparations. It may be particularly useful for patients with multiple lesions and in young children because application is painless in the office. However, pain may occur 2 to 24 hours after application, and repeat applications within 10 to 14 days are occasionally necessary. A mixture of cantharidin 1 percent plus podophyllin 5 percent and salicylic acid 30 percent can be used in patients with thick warts, but should be used with caution on the digits [",
"    <a class=\"abstract\" href=\"UTD.htm?25/40/26249/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?7/57/8083?source=see_link\">",
"     Cantharidin",
"    </a>",
"    is applied carefully in the office to individual lesions and then covered with clear tape (eg, Blenderm). Use of Mastisol to help secure the tape increases the potency and prevents the medication from touching normal skin. Blistering will occur within 2 to 24 hours, after which time the tape should be removed and the medication washed off with soap and water. Plain petrolatum is applied to open areas twice daily.",
"   </p>",
"   <p>",
"    Blistering can be very uncomfortable, and the chemotoxic response varies among patients; some have swelling with significant pain, while others may have no response at all. Although the application itself is painless,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/38/15978?source=see_link\">",
"     ibuprofen",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/27/15802?source=see_link\">",
"     acetaminophen",
"    </a>",
"    with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/0/35848?source=see_link\">",
"     codeine",
"    </a>",
"    is suggested for pain relief from the blisters that form; opioids may be needed in some patients.",
"   </p>",
"   <p>",
"    After healing has occurred in five to ten days, it is essential to treat the base of the lesion with a salicylic acid preparation for an additional five to seven days to prevent recurrences around the edges.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?7/57/8083?source=see_link\">",
"     Cantharidin",
"    </a>",
"    is not currently approved by the US FDA, but it is on the FDA's proposed Bulk Substances List, which allows physicians to administer drugs compounded with cantharidin. It is available in many other countries, including Canada, and it is safe when used appropriately [",
"    <a class=\"abstract\" href=\"UTD.htm?25/40/26249/abstract/16\">",
"     16",
"    </a>",
"    ]. To avoid accidental ingestion by children, or severe blistering if applied incorrectly to the skin, cantharidin should only be applied in a physician's office.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Bichloracetic acid or Trichloroacetic acid",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bichloracetic and trichloroacetic acids are useful for warts on the palms or the soles. Either agent may be applied to pared warts with a wooden toothpick every 7 to 10 days. Application of salicylic acid preparations between visits quickens the response time.",
"   </p>",
"   <p>",
"    At the end of therapy when lesions are thin, the medication may cause burning and stinging. Pretreatment with EMLA is helpful for thin lesions.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Curettage and desiccation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Curettage and desiccation are not necessarily more effective than other methods but may be useful for isolated lesions. The major problems are pain from anesthetic injection (pretreatment with EMLA cream may help ease the pain of the injection), dyschromia, and atrophic or hypertrophic scarring. The procedure is never performed as first-line therapy or, if possible, at all on the soles of the feet due to the propensity to develop persistently painful scars at this anatomical site.",
"   </p>",
"   <p>",
"    The procedure is performed as follows:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Numb the area with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/34/35360?source=see_link\">",
"       lidocaine",
"      </a>",
"      1 percent plain if the warts are on the digits, lidocaine 1 percent with epinephrine 1:100,000 if elsewhere.",
"     </li>",
"     <li>",
"      Desiccate verruca, scrape with a no. 3, 4, or 5 curette, then desiccate the base. May repeat curettage and desiccation twice.",
"     </li>",
"     <li>",
"      Give wound care education and explain about recurrence and scarring. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?30/51/31543?source=see_link&amp;anchor=H30#H30\">",
"       \"Dermatologic procedures\", section on 'Wound care'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     5-Fluorouracil",
"    </span>",
"    &nbsp;&mdash;&nbsp;5-fluorouracil (Efudex 5 percent cream or 5 percent solution; Fluoroplex 1 percent [30 g]) can be used to treat flat warts [",
"    <a class=\"abstract\" href=\"UTD.htm?25/40/26249/abstract/17-19\">",
"     17-19",
"    </a>",
"    ]. The cream is applied to affected areas twice daily for three to five weeks. Therapy with 5-fluorouracil causes an inflammatory response at the site of application. Local sun protection is essential because the cutaneous reaction may be exacerbated by sun exposure (phototoxicity) [",
"    <a class=\"abstract\" href=\"UTD.htm?25/40/26249/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Tretinoin",
"    </span>",
"    &nbsp;&mdash;&nbsp;Tretinoin (0.05 percent, 0.1 percent cream; 0.01 percent, 0.025 percent gel) is useful for flat warts, but improvement may take several weeks. It is applied once or twice a day, with a goal of mild scaling and mild irritation. The highest strength tolerated should be used. As with 5-fluorouracil, sun protection is important. Protect the normal surrounding skin with a barrier cream (eg, Vaseline or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/53/15187?source=see_link\">",
"     zinc oxide",
"    </a>",
"    )",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Snip or shave excision",
"    </span>",
"    &nbsp;&mdash;&nbsp;Snip or shave excision is used for filiform warts. The area is anesthetized with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/34/35360?source=see_link\">",
"     lidocaine",
"    </a>",
"    1 percent, then the wart is removed with either scissors (snip excision) or a no. 15 scalpel blade or half of a double-edged razor blade (shave excisions). Hemostasis can be achieved with cautery or aluminum chloride.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Cimetidine",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/54/2921?source=see_link\">",
"     Cimetidine",
"    </a>",
"    , an H2 receptor antagonist, has been used to treat recalcitrant warts based upon the theory that H2 receptors are present on T-suppressor cells, and blocking the receptors may therefore result in an increase in cell-mediated immunity. Uncontrolled studies suggested that cimetidine therapy (30 to 50",
"    <span class=\"nowrap\">",
"     mg/kg/day",
"    </span>",
"    in four divided doses for up to 3 months) may be effective [",
"    <a class=\"abstract\" href=\"UTD.htm?25/40/26249/abstract/21,22\">",
"     21,22",
"    </a>",
"    ]. In contrast, a placebo-controlled double-blind study found that cimetidine therapy was no more effective than placebo, although the number of patients was small and the ability to detect a statistical difference may have been insufficient [",
"    <a class=\"abstract\" href=\"UTD.htm?25/40/26249/abstract/23\">",
"     23",
"    </a>",
"    ]. A second double-blind study found that cimetidine combined with levamisole caused regression of severe recalcitrant warts in 18 of 21 (86 percent) treated patients [",
"    <a class=\"abstract\" href=\"UTD.htm?25/40/26249/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Imiquimod",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/59/20406?source=see_link\">",
"     Imiquimod",
"    </a>",
"    is a topical immunomodulator that is believed to act by local cytokine induction. Although more commonly used for anogenital warts, imiquimod 5 percent cream can be used to treat nongenital warts as well [",
"    <a class=\"abstract\" href=\"UTD.htm?25/40/26249/abstract/25,26\">",
"     25,26",
"    </a>",
"    ]. Small studies and case series suggest that imiquimod can successfully treat recalcitrant warts in at least some patients, however there is a wide range of reported rates of clearance [",
"    <a class=\"abstract\" href=\"UTD.htm?25/40/26249/abstract/27-30\">",
"     27-30",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/59/20406?source=see_link\">",
"     Imiquimod",
"    </a>",
"    is nonscarring and it is painless to apply. Local reactions are common and can be significant, and there are rare reports of systemic side effects. Imiquimod is expensive compared with many other therapies for warts.",
"   </p>",
"   <p>",
"    We typically find",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/59/20406?source=see_link\">",
"     imiquimod",
"    </a>",
"    useful for:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Pediatric patients with multiple lesions that are unresponsive to occlusion therapy, salicylic acid therapy, cryotherapy, and bichloroacetic acid therapy or who do not tolerate such therapy",
"     </li>",
"     <li>",
"      Patients of any age with facial lesions",
"     </li>",
"     <li>",
"      Recalcitrant lesions, following removal of overlying hyperkeratosis",
"     </li>",
"     <li>",
"      Lesions where scarring is a concern",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    It can also be used as adjunctive therapy when other therapies are not sufficiently effective when used alone. We recommend using",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/59/20406?source=see_link\">",
"     imiquimod",
"    </a>",
"    prior to consideration of intralesional",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/15/39159?source=see_link\">",
"     bleomycin",
"    </a>",
"    or laser therapy for recalcitrant warts.",
"   </p>",
"   <p>",
"    Various",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/59/20406?source=see_link\">",
"     imiquimod",
"    </a>",
"    regimens have been used and none has been extensively studied. We typically use the following regimen in areas where scarring is not an issue:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Debride the lesions with a metal nail file, emery board, or pumice stone to remove dead tissue prior to each application; soaking the lesions for 20 to 30 minutes prior to debridement is helpful",
"     </li>",
"     <li>",
"      Apply a salicylic acid preparation alternating with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?19/59/20406?source=see_link\">",
"       imiquimod",
"      </a>",
"      cream 5 percent; each should be applied at bedtime",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?19/59/20406?source=see_link\">",
"       Imiquimod",
"      </a>",
"      should be applied very sparingly and covered with a bandage or similar covering",
"     </li>",
"     <li>",
"      Remove the medication with soap and water in the morning",
"     </li>",
"     <li>",
"      If the lesions are dry they can be left uncovered during the day; if the lesions are exudative or open, apply a topical antibiotic such as",
"      <a class=\"drug drug_general\" href=\"UTD.htm?6/20/6469?source=see_link\">",
"       bacitracin",
"      </a>",
"      and cover",
"     </li>",
"     <li>",
"      If lesions become painful, therapy should be held until they become asymptomatic at which point application should be resumed at less frequent intervals (ie,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?19/59/20406?source=see_link\">",
"       imiquimod",
"      </a>",
"      or salicylic acid every three to four nights)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    For the face or other areas where scarring is a concern, the",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/59/20406?source=see_link\">",
"     imiquimod",
"    </a>",
"    can be used in a similar regimen alone, instead of alternating with salicylic acid. In these areas, debridement should be gentle, with a goal of removing the white hyperkeratotic skin prior to each application. Debridement is not necessary if clinically evident hyperkeratosis is absent (eg, flat warts).",
"   </p>",
"   <p>",
"    Two lower concentrations of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/59/20406?source=see_link\">",
"     imiquimod",
"    </a>",
"    (3.75 and 2.5 percent creams) are also available. However, the comparative efficacy of these concentrations of imiquimod to the 5 percent cream in cutaneous warts is unknown, and the incidence of adverse effects has not been directly compared. Data from studies in anogenital warts suggest that the incidence of adverse effects with use of the 3.75 percent and 2.5 percent formulations may be similar to or lower than the rate of adverse effects associated with application of imiquimod 5 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?25/40/26249/abstract/31\">",
"     31",
"    </a>",
"    ]. Additional studies are necessary to determine whether the 3.75 and 2.5 percent concentrations should be favored for the treatment of cutaneous warts in sensitive areas.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Intralesional immunotherapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Intralesional immunotherapy with skin test antigens (ie, mumps, Candida, or Trichophyton antigens) may lead to the resolution both of the injected wart and other warts that were not injected [",
"    <a class=\"abstract\" href=\"UTD.htm?25/40/26249/abstract/32,33\">",
"     32,33",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A trial in 201 patients with warts who demonstrated at least a 5 mm response to skin testing with at least one of the above antigens randomly assigned patients to receive injection of 0.3 mL of an antigen that produced a skin test response, such an antigen plus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/56/29576?source=see_link\">",
"     interferon alfa-2b",
"    </a>",
"    , interferon alone, or saline [",
"    <a class=\"abstract\" href=\"UTD.htm?25/40/26249/abstract/34\">",
"     34",
"    </a>",
"    ]. Patients received the injection every three weeks until the wart was completely cleared or for a maximum of five injections.",
"   </p>",
"   <p>",
"    Patients treated with skin test antigens had significantly greater resolution of the injected wart than those treated with interferon alone or saline (60 versus 26 and 22 percent, respectively). Additionally, more patients with multiple warts experienced complete resolution of at least one wart other than the injected wart (49 versus 9 and 19 percent).",
"   </p>",
"   <p>",
"    Although the results of this study appear to show benefit, it used an unblinded assessment of outcome, performed an unplanned interim analysis that led to stopping the trial because of a lack of availability of mumps antigen, and changed the protocol of two arms of the trial to replace granulocyte-macrophage colony-stimulating factor (GM-CSF) injection with interferon injection because of severe side effects with GM-CSF. Additionally, there appeared to be an increased rate of fever and myalgias in patients treated with immunotherapy, particularly in the group treated with both antigen and interferon.",
"   </p>",
"   <p>",
"    Intralesional immunotherapy is nonscarring and is much less expensive than",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/59/20406?source=see_link\">",
"     imiquimod",
"    </a>",
"    . We typically find intralesional immunotherapy useful for:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Pediatric patients with multiple lesions that are unresponsive to occlusion therapy, salicylic acid therapy, cryotherapy, and bichloroacetic acid therapy or who do not tolerate such therapy",
"     </li>",
"     <li>",
"      Patients of any age with facial lesions",
"     </li>",
"     <li>",
"      Recalcitrant lesions",
"     </li>",
"     <li>",
"      Lesions where scarring is a concern",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    We typically use candida antigen and inject 0.3 mL intradermally and as superficially as possible into the largest lesion so as to achieve maximal delivery into virally infected skin; such a location should decrease the pain of injection. Treatment should be used in conjunction with occlusion",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    salicylic acid with debridement. Injection can be repeated every four weeks. It can also be used in combination with cryotherapy or other destructive modalities.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6256858\">",
"    <span class=\"h2\">",
"     Topical immunotherapy with contact allergens",
"    </span>",
"    &nbsp;&mdash;&nbsp;Based upon limited data, contact allergens, such as squaric acid dibutylester (SADBE), dinitrochlorobenzene (DNCB), and diphenylcyclopropenone (DPCP), appear to be effective for the treatment of cutaneous warts. Topical immunotherapy should be performed by clinicians with experience in this procedure. Treatment is usually administered by a dermatologist.",
"   </p>",
"   <p>",
"    Similar to the use of these agents for alopecia areata, treatment begins with sensitization of the patient to the contact allergen through application of the sensitizer to a small unaffected area (eg, 4 x 4 cm area on the medial upper arm). Approximately two weeks after sensitization, the clinician begins a series of applications of the contact allergen to the wart with a lower concentration of the agent. The concentration is subsequently titrated upward to obtain and maintain a mild contact dermatitis in the treatment area. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/14/4330?source=see_link&amp;anchor=H13#H13\">",
"     \"Management of alopecia areata\", section on 'Topical immunotherapy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Among these agents, only DNCB has been evaluated in randomized trials. A meta-analysis of two small randomized trials with a total of 80 patients suggested that DNCB is more effective than placebo (RR 2.12, 95% CI 1.38-3.26) [",
"    <a class=\"abstract\" href=\"UTD.htm?25/40/26249/abstract/9\">",
"     9",
"    </a>",
"    ]. However, concern for the mutagenic potential of DNCB has led to the infrequent use of this agent [",
"    <a class=\"abstract\" href=\"UTD.htm?25/40/26249/abstract/35,36\">",
"     35,36",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Regimens used for SADBE have varied widely [",
"    <a class=\"abstract\" href=\"UTD.htm?25/40/26249/abstract/35,37-40\">",
"     35,37-40",
"    </a>",
"    ]. Sensitization is typically performed with a 1 to 3% concentration of SADBE, and treatment is usually begun with concentrations of 0.01% or higher. The frequency of clinician application of SADBE ranges from every few days to every few weeks. The efficacy of SADBE is supported by an uncontrolled study of 568 adults and children with multiple and resistant warts in which sensitization with 3% SADBE was followed by twice weekly clinician applications of serial dilutions of SADBE (0.03 to 3%) for up to 10 weeks [",
"    <a class=\"abstract\" href=\"UTD.htm?25/40/26249/abstract/39\">",
"     39",
"    </a>",
"    ]. Of the 443 patients who completed the study, 382 had complete resolution of warts (86 percent). The average time to resolution of periungual or subungual warts, flat warts, and multiple common warts were 10, 8, and 6 weeks, respectively. Based upon a separate retrospective study of 61 children with warts, a treatment regimen in which SADBE is applied more frequently by patients (or parents) at home may be an effective and safe alternative to clinician-administered treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?25/40/26249/abstract/35\">",
"     35",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There are multiple reports of successful treatment of warts with DPCP, many of which include warts that were refractory to other therapies [",
"    <a class=\"abstract\" href=\"UTD.htm?25/40/26249/abstract/41-52\">",
"     41-52",
"    </a>",
"    ]. Treatment is often performed with sensitization with 1 to 3% DPCP followed by applications of DPCP every one to three weeks with initial concentrations in the range of 0.001 to 3%. An uncontrolled prospective study of 134 adolescents and adults with refractory palmoplantar or periungual warts found that among 111 patients who completed the study (treatment with DPCP once weekly for eight weeks and a follow-up period of four months), 49 (44 percent) achieved a complete response and 18 (16 percent) had partial improvement by the end of follow-up [",
"    <a class=\"abstract\" href=\"UTD.htm?25/40/26249/abstract/48\">",
"     48",
"    </a>",
"    ]. Two retrospective studies have reported higher rates of clearance among patients who have complied with treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?25/40/26249/abstract/44,46\">",
"     44,46",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In addition, successful treatment of warts with DPCP has been reported in immunosuppressed patients [",
"    <a class=\"abstract\" href=\"UTD.htm?25/40/26249/abstract/53\">",
"     53",
"    </a>",
"    ]. However, treatment may be less likely to be effective in this population than in immunocompetent patients [",
"    <a class=\"abstract\" href=\"UTD.htm?25/40/26249/abstract/53\">",
"     53",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Erythema, itching, pigment changes, blistering, and local or diffuse eczematous eruptions are potential side effects of topical immunotherapy with contact allergens [",
"    <a class=\"abstract\" href=\"UTD.htm?25/40/26249/abstract/54\">",
"     54",
"    </a>",
"    ]. Treatment of warts with DPCP has also been linked to the development of urticaria [",
"    <a class=\"abstract\" href=\"UTD.htm?25/40/26249/abstract/55-57\">",
"     55-57",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    SADBE and DPCP are typically purchased from a chemical distributor and the solutions for application are subsequently prepared by a pharmacist or the clinician. Proper storage is important for the use of DPCP and SADBE. DPCP should not be exposed to light and SADBE must be kept refrigerated.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2085174\">",
"    <span class=\"h2\">",
"     Other",
"    </span>",
"    &nbsp;&mdash;&nbsp;Examples of additional therapies that have been utilized for cutaneous warts include intralesional",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/15/39159?source=see_link\">",
"     bleomycin",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?25/40/26249/abstract/58,59\">",
"     58,59",
"    </a>",
"    ], ablative laser therapy (carbon dioxide or pulsed dye vascular) [",
"    <a class=\"abstract\" href=\"UTD.htm?25/40/26249/abstract/60-62\">",
"     60-62",
"    </a>",
"    ], topical treatment with extemporaneously compounded 1 to 3%",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/2/20517?source=see_link\">",
"     cidofovir",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?25/40/26249/abstract/63\">",
"     63",
"    </a>",
"    ], intralesional cidofovir [",
"    <a class=\"abstract\" href=\"UTD.htm?25/40/26249/abstract/64,65\">",
"     64,65",
"    </a>",
"    ], oral administration of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/1/39958?source=see_link\">",
"     acitretin",
"    </a>",
"    or superpharmacologic doses of zinc [",
"    <a class=\"abstract\" href=\"UTD.htm?25/40/26249/abstract/66,67\">",
"     66,67",
"    </a>",
"    ], photodynamic therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?25/40/26249/abstract/68,69\">",
"     68,69",
"    </a>",
"    ], and topical viable Bacillus Calmette-Gu&eacute;rin [",
"    <a class=\"abstract\" href=\"UTD.htm?25/40/26249/abstract/70\">",
"     70",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Resolution of cutaneous warts after administration of the quadrivalent HPV vaccine has been documented in several patients [",
"    <a class=\"abstract\" href=\"UTD.htm?25/40/26249/abstract/71,72\">",
"     71,72",
"    </a>",
"    ]. However, the efficacy of this intervention for warts remains to be proven. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/17/19738?source=see_link&amp;anchor=H5967752#H5967752\">",
"     \"Recommendations for the use of human papillomavirus vaccines\", section on 'Available vaccines'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Botanical products have also been proposed for the treatment of warts, but the evidence to support the use of such agents is scant.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h1\">",
"     PREVENTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Many patients ask how they can avoid getting new warts or avoid spreading the ones they currently have. While no good clinical trials have been performed on wart prevention, measures that would limit contact with the causal vector, human papillomavirus, or which would limit the chances of infection once exposed, are reasonable to discuss with patients.",
"   </p>",
"   <p>",
"    To help avoid exposure, patients should avoid touching warts on themselves or others. Using slippers or other footwear in public showers may cut down on the chance of transmission [",
"    <a class=\"abstract\" href=\"UTD.htm?25/40/26249/abstract/73\">",
"     73",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Tools used for paring down warts (eg, nail file, pumice stone, etc.) should not be used on normal skin or nails, and should not be shared with others. Similarly, hair-bearing areas with warts should be shaved with electric razors or not at all.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?11/5/11346?source=see_link\">",
"       \"Patient information: Skin warts (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?25/16/25857?source=see_link\">",
"       \"Patient information: Skin warts (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The type and aggressiveness of therapy for verrucae will depend upon the type of wart, its location, the degree of symptoms, and the patient's cooperation and immune status.",
"     </li>",
"     <li>",
"      The least painful methods should be used initially, especially in young children. More destructive therapies should be reserved for areas where scarring is not a consideration or for recalcitrant lesions.",
"     </li>",
"     <li>",
"      Spontaneous regression occurs in as many as two-thirds of warts within two years; observation is an option for all patients. However, it is far easier to treat smaller, fewer warts early than to wait until lesions enlarge or multiply.",
"     </li>",
"     <li>",
"      It is important to remember when treating verrucae that the virus is microscopic and although the skin may look normal after treatment, there often is virus still present in the remaining tissue. If infected tissue remains, warts may recur.",
"     </li>",
"     <li>",
"      Therapy may take several weeks or even months; patience and perseverance are essential.",
"     </li>",
"     <li>",
"      Tools used for paring down warts (eg, nail file, pumice stone, etc.) should not be used on normal skin or nails or by other people, so as to avoid spreading warts. Similarly, hair-bearing areas with warts should be shaved with electric razors or not at all.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Although alternatives are discussed in detail above, we recommend the following as initial therapies:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In children old enough to comply with the therapy, treat common, plantar, and palmar warts with salicylic acid&nbsp;(see",
"      <a class=\"local\" href=\"#H8\">",
"       'Salicylic acid'",
"      </a>",
"      above).",
"     </li>",
"     <li>",
"      In light-skinned adults with common, plantar, or palmar warts treat patients who want a rapid response to therapy with liquid nitrogen (see",
"      <a class=\"local\" href=\"#H3140176\">",
"       'Liquid nitrogen'",
"      </a>",
"      above). For dark-skinned adults and those who wish to avoid the discomfort of liquid nitrogen, treat with salicylic acid&nbsp;(see",
"      <a class=\"local\" href=\"#H8\">",
"       'Salicylic acid'",
"      </a>",
"      above).",
"     </li>",
"     <li>",
"      The role of duct tape as an adjunct to salicylic acid therapy is uncertain; it can be tried in selected patients interested in the therapy. There are few adverse effects with duct tape other than some local irritation and difficulty with compliance. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Duct tape'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Treat filiform warts with snip or shave excision (see",
"      <a class=\"local\" href=\"#H15\">",
"       'Snip or shave excision'",
"      </a>",
"      above).",
"     </li>",
"     <li>",
"      In light-skinned patients, treat flat warts with liquid nitrogen (see",
"      <a class=\"local\" href=\"#H3140176\">",
"       'Liquid nitrogen'",
"      </a>",
"      above). In dark-skinned patients treat flat warts with 5-fluorouracil or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?19/59/20406?source=see_link\">",
"       imiquimod",
"      </a>",
"      &nbsp;(see",
"      <a class=\"local\" href=\"#H13\">",
"       '5-Fluorouracil'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H17\">",
"       'Imiquimod'",
"      </a>",
"      above).",
"     </li>",
"     <li>",
"      In patients with facial lesions or other lesions where scarring is a concern, treat with topical",
"      <a class=\"drug drug_general\" href=\"UTD.htm?19/59/20406?source=see_link\">",
"       imiquimod",
"      </a>",
"      or intralesional injection of candida antigen (see",
"      <a class=\"local\" href=\"#H17\">",
"       'Imiquimod'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H18\">",
"       'Intralesional immunotherapy'",
"      </a>",
"      above).",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     Bonnez W, Reichman RC. Papillomaviruses. In: and Practice of Infectious Diseases, 5th ed, Mandell GL, Bennett JE, Dolin R (Eds), Churchill Livingstone, Philadelphia 2000. p.1630.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/40/26249/abstract/2\">",
"      Kilkenny M, Marks R. The descriptive epidemiology of warts in the community. Australas J Dermatol 1996; 37:80.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/40/26249/abstract/3\">",
"      Barbosa P. Plantar verrucae and HIV infection. Clin Podiatr Med Surg 1998; 15:317.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/40/26249/abstract/4\">",
"      Viac J, Thivolet J, Chardonnet Y. Specific immunity in patients suffering from recurring warts before and after repetitive intradermal tests with human papilloma virus. Br J Dermatol 1977; 97:365.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/40/26249/abstract/5\">",
"      Pyrh&ouml;nen S, Johansson E. Regression of warts. An immunological study. Lancet 1975; 1:592.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/40/26249/abstract/6\">",
"      Rogozinski TT, Jablonska S, Jarzabek-Chorzelska M. Role of cell-mediated immunity in spontaneous regression of plane warts. Int J Dermatol 1988; 27:322.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/40/26249/abstract/7\">",
"      Bae JM, Kang H, Kim HO, Park YM. Differential diagnosis of plantar wart from corn, callus and healed wart with the aid of dermoscopy. Br J Dermatol 2009; 160:220.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/40/26249/abstract/8\">",
"      Lee DY, Park JH, Lee JH, et al. The use of dermoscopy for the diagnosis of plantar wart. J Eur Acad Dermatol Venereol 2009; 23:726.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/40/26249/abstract/9\">",
"      Kwok CS, Gibbs S, Bennett C, et al. Topical treatments for cutaneous warts. Cochrane Database Syst Rev 2012; 9:CD001781.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/40/26249/abstract/10\">",
"      Berth-Jones J, Bourke J, Eglitis H, et al. Value of a second freeze-thaw cycle in cryotherapy of common warts. Br J Dermatol 1994; 131:883.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/40/26249/abstract/11\">",
"      Bourke JF, Berth-Jones J, Hutchinson PE. Cryotherapy of common viral warts at intervals of 1, 2 and 3 weeks. Br J Dermatol 1995; 132:433.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/40/26249/abstract/12\">",
"      Focht DR 3rd, Spicer C, Fairchok MP. The efficacy of duct tape vs cryotherapy in the treatment of verruca vulgaris (the common wart). Arch Pediatr Adolesc Med 2002; 156:971.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/40/26249/abstract/13\">",
"      de Haen M, Spigt MG, van Uden CJ, et al. Efficacy of duct tape vs placebo in the treatment of verruca vulgaris (warts) in primary school children. Arch Pediatr Adolesc Med 2006; 160:1121.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/40/26249/abstract/14\">",
"      Wenner R, Askari SK, Cham PM, et al. Duct tape for the treatment of common warts in adults: a double-blind randomized controlled trial. Arch Dermatol 2007; 143:309.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/40/26249/abstract/15\">",
"      Coskey RJ. Treatment of plantar warts in children with a salicylic acid-podophyllin-cantharidin product. Pediatr Dermatol 1984; 2:71.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/40/26249/abstract/16\">",
"      Moed L, Shwayder TA, Chang MW. Cantharidin revisited: a blistering defense of an ancient medicine. Arch Dermatol 2001; 137:1357.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/40/26249/abstract/17\">",
"      Lee S, Kim JG, Chun SI. Treatment of verruca plana with 5% 5-fluorouracil ointment. Dermatologica 1980; 160:383.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/40/26249/abstract/18\">",
"      Hursthouse MW. A controlled trial on the use of topical 5-fluorouracil on viral warts. Br J Dermatol 1975; 92:93.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/40/26249/abstract/19\">",
"      Goncalves JC. 5-Fluorouracil in the treatment of common warts of the hands. A double-blind study. Br J Dermatol 1975; 92:89.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/40/26249/abstract/20\">",
"      Goette DK. Topical chemotherapy with 5-fluorouracil. A review. J Am Acad Dermatol 1981; 4:633.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/40/26249/abstract/21\">",
"      Glass AT, Solomon BA. Cimetidine therapy for recalcitrant warts in adults. Arch Dermatol 1996; 132:680.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/40/26249/abstract/22\">",
"      Orlow SJ, Paller A. Cimetidine therapy for multiple viral warts in children. J Am Acad Dermatol 1993; 28:794.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/40/26249/abstract/23\">",
"      Yilmaz E, Alpsoy E, Basaran E. Cimetidine therapy for warts: a placebo-controlled, double-blind study. J Am Acad Dermatol 1996; 34:1005.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/40/26249/abstract/24\">",
"      Parsad D, Saini R, Negi KS. Comparison of combination of cimetidine and levamisole with cimetidine alone in the treatment of recalcitrant warts. Australas J Dermatol 1999; 40:93.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/40/26249/abstract/25\">",
"      Gupta AK, Cherman AM, Tyring SK. Viral and nonviral uses of imiquimod: a review. J Cutan Med Surg 2004; 8:338.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/40/26249/abstract/26\">",
"      Muzio G, Massone C, Rebora A. Treatment of non-genital warts with topical imiquimod 5% cream. Eur J Dermatol 2002; 12:347.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/40/26249/abstract/27\">",
"      Harwood CA, Perrett CM, Brown VL, et al. Imiquimod cream 5% for recalcitrant cutaneous warts in immunosuppressed individuals. Br J Dermatol 2005; 152:122.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/40/26249/abstract/28\">",
"      Micali G, Dall'Oglio F, Nasca MR. An open label evaluation of the efficacy of imiquimod 5% cream in the treatment of recalcitrant subungual and periungual cutaneous warts. J Dermatolog Treat 2003; 14:233.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/40/26249/abstract/29\">",
"      Hengge UR, Esser S, Schultewolter T, et al. Self-administered topical 5% imiquimod for the treatment of common warts and molluscum contagiosum. Br J Dermatol 2000; 143:1026.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/40/26249/abstract/30\">",
"      Grussendorf-Conen EI, Jacobs S. Efficacy of imiquimod 5% cream in the treatment of recalcitrant warts in children. Pediatr Dermatol 2002; 19:263.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/40/26249/abstract/31\">",
"      Baker DA, Ferris DG, Martens MG, et al. Imiquimod 3.75% cream applied daily to treat anogenital warts: combined results from women in two randomized, placebo-controlled studies. Infect Dis Obstet Gynecol 2011; 2011:806105.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/40/26249/abstract/32\">",
"      Johnson SM, Roberson PK, Horn TD. Intralesional injection of mumps or Candida skin test antigens: a novel immunotherapy for warts. Arch Dermatol 2001; 137:451.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/40/26249/abstract/33\">",
"      Clifton MM, Johnson SM, Roberson PK, et al. Immunotherapy for recalcitrant warts in children using intralesional mumps or Candida antigens. Pediatr Dermatol 2003; 20:268.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/40/26249/abstract/34\">",
"      Horn TD, Johnson SM, Helm RM, Roberson PK. Intralesional immunotherapy of warts with mumps, Candida, and Trichophyton skin test antigens: a single-blinded, randomized, and controlled trial. Arch Dermatol 2005; 141:589.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/40/26249/abstract/35\">",
"      Silverberg NB, Lim JK, Paller AS, Mancini AJ. Squaric acid immunotherapy for warts in children. J Am Acad Dermatol 2000; 42:803.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/40/26249/abstract/36\">",
"      Wilkerson MG, Connor TH, Wilkin JK. Dinitrochlorobenzene is inherently mutagenic in the presence of trace mutagenic contaminants. Arch Dermatol 1988; 124:396.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/40/26249/abstract/37\">",
"      Lee AN, Mallory SB. Contact immunotherapy with squaric acid dibutylester for the treatment of recalcitrant warts. J Am Acad Dermatol 1999; 41:595.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/40/26249/abstract/38\">",
"      Iijima S, Otsuka F. Contact immunotherapy with squaric acid dibutylester for warts [corrected]. Dermatology 1993; 187:115.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/40/26249/abstract/39\">",
"      Micali G, Dall'Oglio F, Tedeschi A, et al. Treatment of cutaneous warts with squaric acid dibutylester: a decade of experience. Arch Dermatol 2000; 136:557.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/40/26249/abstract/40\">",
"      Hama N, Hatamochi A, Hayashi S, et al. Usefulness of topical immunotherapy with squaric acid dibutylester for refractory common warts on the face and neck. J Dermatol 2009; 36:660.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/40/26249/abstract/41\">",
"      Choi MH, Seo SH, Kim IH, Son SW. Comparative study on the sustained efficacy of diphencyprone immunotherapy versus cryotherapy in viral warts. Pediatr Dermatol 2008; 25:398.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/40/26249/abstract/42\">",
"      Aghaei S. Treatment of disseminated facial warts through contact immunotherapy with diphenylcyclopropenone (DPCP). Dermatol Online J 2006; 12:10.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/40/26249/abstract/43\">",
"      Pollock B, Highet AS. An interesting response to diphencyprone (DPC) sensitization on facial warts: review of DPC treatment for viral warts. J Dermatolog Treat 2002; 13:47.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/40/26249/abstract/44\">",
"      Upitis JA, Krol A. The use of diphenylcyclopropenone in the treatment of recalcitrant warts. J Cutan Med Surg 2002; 6:214.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/40/26249/abstract/45\">",
"      Haedersdal M, Selvaag E, Petersen CS. Immunotherapy with diphenylcyclopropenone of recalcitrant warts: a retrospective analysis. Acta Derm Venereol 2000; 80:217.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/40/26249/abstract/46\">",
"      Buckley DA, Keane FM, Munn SE, et al. Recalcitrant viral warts treated by diphencyprone immunotherapy. Br J Dermatol 1999; 141:292.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/40/26249/abstract/47\">",
"      Weisshaar E, Neumann HJ, Gollnick H. Successful treatment of disseminated facial verrucae with contact immunotherapy. Eur J Dermatol 1998; 8:488.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/40/26249/abstract/48\">",
"      Rampen FH, Steijlen PM. Diphencyprone in the management of refractory palmoplantar and periungual warts: an open study. Dermatology 1996; 193:236.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/40/26249/abstract/49\">",
"      van der Steen P, van de Kerkhof P, der Kinderen D, et al. Clinical and immunohistochemical responses of plantar warts to topical immunotherapy with diphenylcyclopropenone. J Dermatol 1991; 18:330.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/40/26249/abstract/50\">",
"      Naylor MF, Neldner KH, Yarbrough GK, et al. Contact immunotherapy of resistant warts. J Am Acad Dermatol 1988; 19:679.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/40/26249/abstract/51\">",
"      Orecchia G, Douville H, Santagostino L, Rabbiosi G. Treatment of multiple relapsing warts with diphenciprone. Dermatologica 1988; 177:225.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/40/26249/abstract/52\">",
"      Choi JW, Cho S, Lee JH. Does immunotherapy of viral warts provide beneficial effects when it is combined with conventional therapy? Ann Dermatol 2011; 23:282.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/40/26249/abstract/53\">",
"      Audrain H, Siddiqui H, Buckley DA. Diphencyprone immunotherapy for viral warts in immunosuppressed patients. Br J Dermatol 2012.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/40/26249/abstract/54\">",
"      Dasher DA, Burkhart CN, Morrell DS. Immunotherapy for childhood warts. Pediatr Ann 2009; 38:373.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/40/26249/abstract/55\">",
"      Choi JE, Seo SH, Kim IH, Son SW. Prospective study of urticaria after diphencyprone therapy in patients with viral warts. Int J Dermatol 2007; 46:1313.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/40/26249/abstract/56\">",
"      Culp BL, Wells MJ. Generalized urticaria with use of diphencyprone in the treatment of warts. J Drugs Dermatol 2007; 6:529.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/40/26249/abstract/57\">",
"      Short KA, Higgins EM. Urticaria as a side-effect of diphencyprone therapy for resistant viral warts. Br J Dermatol 2005; 152:583.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/40/26249/abstract/58\">",
"      Munn SE, Higgins E, Marshall M, Clement M. A new method of intralesional bleomycin therapy in the treatment of recalcitrant warts. Br J Dermatol 1996; 135:969.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/40/26249/abstract/59\">",
"      Salk R, Douglas TS. Intralesional bleomycin sulfate injection for the treatment of verruca plantaris. J Am Podiatr Med Assoc 2006; 96:220.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/40/26249/abstract/60\">",
"      Robson KJ, Cunningham NM, Kruzan KL, et al. Pulsed-dye laser versus conventional therapy in the treatment of warts: a prospective randomized trial. J Am Acad Dermatol 2000; 43:275.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/40/26249/abstract/61\">",
"      Ross BS, Levine VJ, Nehal K, et al. Pulsed dye laser treatment of warts: an update. Dermatol Surg 1999; 25:377.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/40/26249/abstract/62\">",
"      Sloan K, Haberman H, Lynde CW. Carbon dioxide laser-treatment of resistant verrucae vulgaris: retrospective analysis. J Cutan Med Surg 1998; 2:142.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/40/26249/abstract/63\">",
"      Field S, Irvine AD, Kirby B. The treatment of viral warts with topical cidofovir 1%: our experience of seven paediatric patients. Br J Dermatol 2009; 160:223.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/40/26249/abstract/64\">",
"      Broganelli P, Chiaretta A, Fragnelli B, Bernengo MG. Intralesional cidofovir for the treatment of multiple and recalcitrant cutaneous viral warts. Dermatol Ther 2012; 25:468.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/40/26249/abstract/65\">",
"      Blouin MM, Cloutier R, No&euml;l R. Intralesional cidofovir in the treatment of cutaneous warts in a renal transplant patient. J Cutan Med Surg 2012; 16:462.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/40/26249/abstract/66\">",
"      Simone CD, Capizzi R, Carbone A, et al. Use of acitretin in a case of giant common warts in an HIV-infected patient. Eur J Dermatol 2008; 18:346.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/40/26249/abstract/67\">",
"      Stefani M, Bottino G, Fontenelle E, Azulay DR. [Efficacy comparison between cimetidine and zinc sulphate in the treatment of multiple and recalcitrant warts]. An Bras Dermatol 2009; 84:23.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/40/26249/abstract/68\">",
"      Lin MY, Xiang LH. Topical 5-aminolevulinic acid photodynamic therapy for recalcitrant facial flat wart in Chinese subjects. J Dermatol 2008; 35:658.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/40/26249/abstract/69\">",
"      Schroeter CA, Kaas L, Waterval JJ, et al. Successful treatment of periungual warts using photodynamic therapy: a pilot study. J Eur Acad Dermatol Venereol 2007; 21:1170.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/40/26249/abstract/70\">",
"      Salem A, Nofal A, Hosny D. Treatment of common and plane warts in children with topical viable Bacillus Calmette-Guerin. Pediatr Dermatol 2013; 30:60.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/40/26249/abstract/71\">",
"      Daniel BS, Murrell DF. Complete resolution of chronic multiple verruca vulgaris treated with quadrivalent human papillomavirus vaccine. JAMA Dermatol 2013; 149:370.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/40/26249/abstract/72\">",
"      Venugopal SS, Murrell DF. Recalcitrant cutaneous warts treated with recombinant quadrivalent human papillomavirus vaccine (types 6, 11, 16, and 18) in a developmentally delayed, 31-year-old white man. Arch Dermatol 2010; 146:475.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/40/26249/abstract/73\">",
"      Johnson LW. Communal showers and the risk of plantar warts. J Fam Pract 1995; 40:136.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 4029 Version 15.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-118.195.65.243-8D13A6BE0D-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_40_26249=[""].join("\n");
var outline_f25_40_26249=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H23\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EPIDEMIOLOGY AND TRANSMISSION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      CLINICAL FEATURES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Differential diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9145981\">",
"      Choice of therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Salicylic acid",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3140176\">",
"      Liquid nitrogen",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Duct tape",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Cantharidin",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Bichloracetic acid or Trichloroacetic acid",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Curettage and desiccation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      5-Fluorouracil",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Tretinoin",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Snip or shave excision",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Cimetidine",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Imiquimod",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Intralesional immunotherapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6256858\">",
"      Topical immunotherapy with contact allergens",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2085174\">",
"      Other",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      PREVENTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DERM/4029\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DERM/4029|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?28/18/28962\" title=\"picture 1A\">",
"      Flat warts forehead",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?17/53/18262\" title=\"picture 1B\">",
"      Flat warts linear",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?8/22/8546\" title=\"picture 1C\">",
"      Verruca vulgaris - finger",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?33/28/34241\" title=\"picture 1D\">",
"      Verruca vulgaris - hand",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?11/7/11376\" title=\"picture 1E\">",
"      Verruca vulgaris",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?26/51/27454\" title=\"picture 1F\">",
"      Periungual warts",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?21/34/22053\" title=\"picture 1G\">",
"      Plantar warts close view",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?15/40/16003\" title=\"picture 1H\">",
"      Plantar verrucae",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?43/14/44258\" title=\"picture 1I\">",
"      Filiform wart",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/38/23144?source=related_link\">",
"      Condylomata acuminata (anogenital warts)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/51/31543?source=related_link\">",
"      Dermatologic procedures",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/14/4330?source=related_link\">",
"      Management of alopecia areata",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/34/553?source=related_link\">",
"      Overview of benign lesions of the skin",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?25/16/25857?source=related_link\">",
"      Patient information: Skin warts (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?11/5/11346?source=related_link\">",
"      Patient information: Skin warts (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/17/19738?source=related_link\">",
"      Recommendations for the use of human papillomavirus vaccines",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/53/26455?source=related_link\">",
"      Virology of human papillomavirus infections and the link to cancer",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f25_40_26250="New onset diabetes after transplant (NODAT) in renal transplant recipients";
var content_f25_40_26250=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   New onset diabetes after transplant (NODAT) in renal transplant recipients",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?25/40/26250/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?25/40/26250/contributors\">",
"     Garry S Tobin, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?25/40/26250/contributors\">",
"     Christina Klein, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?25/40/26250/contributors\">",
"     Daniel C Brennan, MD, FACP",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?25/40/26250/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?25/40/26250/contributors\">",
"     Barbara Murphy, MB, BAO, BCh, FRCPI",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?25/40/26250/contributors\">",
"     David M Nathan, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?25/40/26250/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?25/40/26250/contributors\">",
"     Alice M Sheridan, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?25/40/26250/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 18, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Diabetes occurs in a substantial number of patients following renal transplantation. New onset diabetes after transplant (NODAT) is associated with increased mortality and morbidity, and in particular, higher rates of cardiovascular disease and infection which are the leading causes of death in renal transplant recipients.",
"   </p>",
"   <p>",
"    This topic reviews the epidemiology, risk factors and clinical implications of NODAT, as well as recommendations for screening and management. Issues relating to renal transplantation and combined kidney-pancreas transplantation in patients with preexisting diabetes are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/39/36472?source=see_link\">",
"     \"Renal transplantation in diabetic nephropathy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/19/41272?source=see_link\">",
"     \"Benefits and complications associated with kidney-pancreas transplantation in diabetes mellitus\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/16/7434?source=see_link\">",
"     \"Patient selection for and immunologic issues relating to kidney-pancreas transplantation in diabetes mellitus\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     DEFINITION",
"    </span>",
"    &nbsp;&mdash;&nbsp;International consensus guidelines regarding the definition of new-onset diabetes mellitus after transplantation were published in 2003 [",
"    <a class=\"abstract\" href=\"UTD.htm?25/40/26250/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. This diagnostic clarification was important, as the use of various definitions prior to this publication made it difficult to assess the incidence of NODAT or the importance of different risk factors. (See",
"    <a class=\"local\" href=\"#H3\">",
"     'Incidence'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H4\">",
"     'Risk factors'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Except for the glycated hemoglobin (HbA1c), which should NOT be used before three months post-transplantation, these guidelines use standard WHO and ADA criteria for diagnosis of diabetes mellitus and impaired glucose tolerance [",
"    <a class=\"abstract\" href=\"UTD.htm?25/40/26250/abstract/3\">",
"     3",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/54/38758?source=see_link&amp;anchor=H3#H3\">",
"     \"Diagnosis of diabetes mellitus\", section on 'Diagnostic criteria'",
"    </a>",
"    .) The HbA1C is not recommended before three months following transplantation because the test may not be valid until new hemoglobin has been synthesized and glycated for the appropriate period in the diabetogenic post-transplant setting [",
"    <a class=\"abstract\" href=\"UTD.htm?25/40/26250/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Diabetes mellitus after transplantation may be diagnosed at any time after transplantation by any of the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Symptoms of diabetes plus random plasma glucose &ge;200",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (11.1",
"      <span class=\"nowrap\">",
"       mmol/L).",
"      </span>",
"      Symptoms include polyuria, polydipsia, and unexplained weight loss.",
"     </li>",
"     <li>",
"      Fasting plasma glucose &ge;126",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (7.0",
"      <span class=\"nowrap\">",
"       mmol/L).",
"      </span>",
"      Fasting is defined as no caloric intake for at least eight hours.",
"     </li>",
"     <li>",
"      Two-hour plasma glucose &ge;200",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (11.1",
"      <span class=\"nowrap\">",
"       mmol/L)",
"      </span>",
"      during an oral glucose tolerance test. The test should be performed as described by the WHO, using a glucose load containing the equivalent of 75 g anhydrous glucose dissolved in water.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Subdiabetic hyperglycemia, also called &ldquo;pre-diabetes&rdquo; includes impaired fasting glucose",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    impaired glucose tolerance and is diagnosed by a fasting plasma glucose between 100 and 125",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (5.6 and 6.9",
"    <span class=\"nowrap\">",
"     mmol/L)",
"    </span>",
"    or a two-hour plasma glucose between 140 and 199",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (7.8 and 11.0",
"    <span class=\"nowrap\">",
"     mmol/L)",
"    </span>",
"    during an oral glucose tolerance test, respectively, according to ADA guidelines. Of note, the normal range of fasting plasma glucose differs according to ADA and WHO criteria; an abnormal fasting glucose is defined as &ge;100",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (5.6",
"    <span class=\"nowrap\">",
"     mmol/L)",
"    </span>",
"    by the ADA and &ge;110",
"    <span class=\"nowrap\">",
"     mg/dl",
"    </span>",
"    (6.1",
"    <span class=\"nowrap\">",
"     mmol/L)",
"    </span>",
"    by the WHO. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/54/38758?source=see_link&amp;anchor=H3#H3\">",
"     \"Diagnosis of diabetes mellitus\", section on 'Diagnostic criteria'",
"    </a>",
"    .) Among transplant recipients, the lower threshold advocated by the ADA is more sensitive in identifying patients at risk for NODAT [",
"    <a class=\"abstract\" href=\"UTD.htm?25/40/26250/abstract/4\">",
"     4",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H35235284\">",
"     'Posttransplant screening'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The two-hour oral glucose tolerance test is more sensitive than the fasting blood glucose for detecting subdiabetic hyperglycemia [",
"    <a class=\"abstract\" href=\"UTD.htm?25/40/26250/abstract/5,6\">",
"     5,6",
"    </a>",
"    ]. However, the oral glucose tolerance test is somewhat impractical, associated with expense, and the results generally do not alter transplant candidacy or post transplant management. Thus we do not recommend that it be used for screening or management pre or post transplant. (See",
"    <a class=\"local\" href=\"#H23\">",
"     'Management'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    An abnormal fasting blood glucose obtained on routine screening should be confirmed on another day [",
"    <a class=\"abstract\" href=\"UTD.htm?25/40/26250/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     INCIDENCE",
"    </span>",
"    &nbsp;&mdash;&nbsp;The reported incidence of NODAT is variable and must be interpreted in the context of definition used, time from transplant, study population, and immunosuppressive agents used for individual studies. Studies that were published prior to the development of the consensus definition described above reported rates ranging from 7 to 46 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?25/40/26250/abstract/7-10\">",
"     7-10",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H2\">",
"     'Definition'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Several more recent studies have provided incidence estimates of NODAT defined by the 2003 international consensus guidelines including the use of the oral glucose tolerance test [",
"    <a class=\"abstract\" href=\"UTD.htm?25/40/26250/abstract/4,5,11-13\">",
"     4,5,11-13",
"    </a>",
"    ]. A substantial number of patients who were classified as having NODAT in these reports became normoglycemic without any medical therapy suggesting that their hyperglycemia was transient and that incidence was overestimated in these reports. However, even transient perioperative hyperglycemia may suggest a higher risk for the future development of NODAT. (See",
"    <a class=\"local\" href=\"#H5971847\">",
"     'Impaired glucose tolerance and perioperative hyperglycemia'",
"    </a>",
"    below.). Overall, studies that use the current criteria for diagnosis suggest that approximately one-third of non-diabetic kidney transplant recipients develop persistently impaired glucose metabolism by six months post-transplantation [",
"    <a class=\"abstract\" href=\"UTD.htm?25/40/26250/abstract/4,5,13\">",
"     4,5,13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The incidence of NODAT is higher among transplant recipients than the incidence of new-onset diabetes among dialysis patients. As an example, in a comparative analysis new-onset diabetes was lower among dialysis patients on a transplant wait-list compared to transplant recipients who were receiving either",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/14/32992?source=see_link\">",
"     tacrolimus",
"    </a>",
"    (6 versus 18 and 30 percent, respectively) [",
"    <a class=\"abstract\" href=\"UTD.htm?25/40/26250/abstract/14\">",
"     14",
"    </a>",
"    ]. The higher incidence of NODAT among recipients receiving tacrolimus compared to cyclosporine has been noted in other studies and is ascribed to the more toxic effect of tacrolimus on islet cells. (See",
"    <a class=\"local\" href=\"#H14\">",
"     'Calcineurin inhibitors'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     RISK FACTORS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Many of the same risk factors that predispose non-transplant patients to diabetes mellitus have been identified as risk factors for its development after transplantation. Such common risk factors include age, obesity, African American race and Hispanic ethnicity, family history and impaired glucose tolerance. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/24/9610?source=see_link\">",
"     \"Risk factors for type 2 diabetes mellitus\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In addition, some risk factors are unique to the transplant population. These include specific agents used for immunosuppression, HLA mismatch, donor gender, and type of underlying renal disease [",
"    <a class=\"abstract\" href=\"UTD.htm?25/40/26250/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Impaired glucose tolerance prior to transplant [",
"    <a class=\"abstract\" href=\"UTD.htm?25/40/26250/abstract/16\">",
"     16",
"    </a>",
"    ] and hyperglycemia in the immediate peri-operative period [",
"    <a class=\"abstract\" href=\"UTD.htm?25/40/26250/abstract/11,17\">",
"     11,17",
"    </a>",
"    ] may identify patients at higher risk for the development of NODAT. (See",
"    <a class=\"local\" href=\"#H5971847\">",
"     'Impaired glucose tolerance and perioperative hyperglycemia'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Increased age",
"    </span>",
"    &nbsp;&mdash;&nbsp;Increasing age is associated with increasing risk for NODAT [",
"    <a class=\"abstract\" href=\"UTD.htm?25/40/26250/abstract/7,9,18-26\">",
"     7,9,18-26",
"    </a>",
"    ]. Age older than 40 to 45 years is most frequently cited as the threshold level that is associated with a markedly increased risk [",
"    <a class=\"abstract\" href=\"UTD.htm?25/40/26250/abstract/1,10\">",
"     1,10",
"    </a>",
"    ]. An analysis of US Medicare kidney transplant recipients found that age 60 or over was associated with a relative risk of 2.6 for the development of NODAT versus that observed with younger patients [",
"    <a class=\"abstract\" href=\"UTD.htm?25/40/26250/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Obesity",
"    </span>",
"    &nbsp;&mdash;&nbsp;Obesity independently correlates with the development of NODAT [",
"    <a class=\"abstract\" href=\"UTD.htm?25/40/26250/abstract/9,18,19,23,25-29\">",
"     9,18,19,23,25-29",
"    </a>",
"    ]. In a survey of almost 12,000 Medicare transplant recipients, a body mass index &ge;30 was the second strongest risk factor (RR 1.73) (after age greater than 60 years) for NODAT [",
"    <a class=\"abstract\" href=\"UTD.htm?25/40/26250/abstract/9\">",
"     9",
"    </a>",
"    ]. An analysis of 15,309 patients using the",
"    <span class=\"nowrap\">",
"     OPTN/UNOS",
"    </span>",
"    database found that the risk of NODAT increased 1.4-fold for those with a BMI of 25 to 30 and nearly doubled if the BMI was &gt;30 [",
"    <a class=\"abstract\" href=\"UTD.htm?25/40/26250/abstract/25\">",
"     25",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Obesity is a potentially important risk factor since it is theoretically modifiable [",
"    <a class=\"abstract\" href=\"UTD.htm?25/40/26250/abstract/27\">",
"     27",
"    </a>",
"    ]. Since the transplant population is increasingly obese, the risk of NODAT may be increasing over time. As an example, an analysis of all US kidney transplant recipients since 1987 found an increase in the percentage of overweight recipients, with the incidence of obesity paralleling that of the general population [",
"    <a class=\"abstract\" href=\"UTD.htm?25/40/26250/abstract/30\">",
"     30",
"    </a>",
"    ]; two-thirds of patients had a body mass index &ge;25.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Race and ethnicity",
"    </span>",
"    &nbsp;&mdash;&nbsp;African-Americans and Hispanics have an increased risk of NODAT. In one study, the incidence of NODAT was much higher among blacks (20 percent) and Hispanics (21 percent) than among Asian-Americans (5 percent) and whites (4 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?25/40/26250/abstract/21\">",
"     21",
"    </a>",
"    ]. Other reports have found a similarly increased risk for African-Americans [",
"    <a class=\"abstract\" href=\"UTD.htm?25/40/26250/abstract/9-11,25,30\">",
"     9-11,25,30",
"    </a>",
"    ]. The association between Hispanics and increased risk of NODAT has been less consistently observed but has been seen even with early steroid discontinuation [",
"    <a class=\"abstract\" href=\"UTD.htm?25/40/26250/abstract/9,26,30,31\">",
"     9,26,30,31",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    African-Americans may be especially susceptible to NODAT when",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/14/32992?source=see_link\">",
"     tacrolimus",
"    </a>",
"    is used, with one study reporting an incidence of 37 and 8 percent among those treated with tacrolimus and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    , respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?25/40/26250/abstract/32\">",
"     32",
"    </a>",
"    ]. This may be due to the requirement for African Americans to use relatively higher doses of tacrolimus than non-African Americans to attain therapeutic blood levels, with higher doses contributing to the increased risk.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Family history",
"    </span>",
"    &nbsp;&mdash;&nbsp;A family history of diabetes has been identified as an independent risk factor for the development of NODAT [",
"    <a class=\"abstract\" href=\"UTD.htm?25/40/26250/abstract/21,33\">",
"     21,33",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     HLA matching and donor characteristics",
"    </span>",
"    &nbsp;&mdash;&nbsp;Increased HLA mismatching, DR mismatch, and, specifically, the B27 phenotype, have been associated with an increased risk of NODAT, although there is inconsistency regarding risk with specific HLA types [",
"    <a class=\"abstract\" href=\"UTD.htm?25/40/26250/abstract/1,9,33\">",
"     1,9,33",
"    </a>",
"    ]. Male and deceased-donor allografts have also been associated with NODAT in some studies [",
"    <a class=\"abstract\" href=\"UTD.htm?25/40/26250/abstract/9,18,21,33\">",
"     9,18,21,33",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hepatitis C Virus (HCV) infection correlates with both pre- and post-transplant diabetes [",
"    <a class=\"abstract\" href=\"UTD.htm?25/40/26250/abstract/9,24-26,34-37\">",
"     9,24-26,34-37",
"    </a>",
"    ]. A 2005 meta-analysis of ten studies of 2,502 patients found that anti-HCV positive patients were nearly four times more likely to have NODAT compared with uninfected individuals [",
"    <a class=\"abstract\" href=\"UTD.htm?25/40/26250/abstract/36\">",
"     36",
"    </a>",
"    ]. In addition, at least one group has shown decreased incidence of NODAT with treatment of hepatitis C infection prior to transplantation [",
"    <a class=\"abstract\" href=\"UTD.htm?25/40/26250/abstract/38\">",
"     38",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The relationship between HCV infection and NODAT may be heightened with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/14/32992?source=see_link\">",
"     tacrolimus",
"    </a>",
"    versus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    -based immunosuppression. Proposed mechanisms include HCV-induced islet cell dysfunction, insulin resistance due to liver dysfunction, and abnormalities in glucose metabolism [",
"    <a class=\"abstract\" href=\"UTD.htm?25/40/26250/abstract/39\">",
"     39",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Cytomegalovirus infection has also been reported to increase the risk of NODAT [",
"    <a class=\"abstract\" href=\"UTD.htm?25/40/26250/abstract/40,41\">",
"     40,41",
"    </a>",
"    ]. In one study, an asymptomatic CMV infection was associated with a lower median insulin release and a fourfold increased risk of NODAT [",
"    <a class=\"abstract\" href=\"UTD.htm?25/40/26250/abstract/41\">",
"     41",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Medications",
"    </span>",
"    &nbsp;&mdash;&nbsp;Antirejection medications that contribute to NODAT include glucocorticoids, calcineurin inhibitors, and MTOR inhibitors.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Glucocorticoids",
"    </span>",
"    &nbsp;&mdash;&nbsp;The chronic use of glucocorticoids leads to hyperglycemia among some patients. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/47/27386?source=see_link\">",
"     \"Major side effects of systemic glucocorticoids\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A study of Medicaid non-transplant recipients attempted to quantitate the risk of overt glucocorticoid-induced diabetes [",
"    <a class=\"abstract\" href=\"UTD.htm?25/40/26250/abstract/42\">",
"     42",
"    </a>",
"    ]. Patients treated with less than 10",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    (or an equivalent) had a 1.8-fold increased risk of initiating diabetes medication therapy; the risk rose proportionately with the corticosteroid dose.",
"   </p>",
"   <p>",
"    NODAT rates are now significantly lower than those reported several decades ago (46 percent in 1979) [",
"    <a class=\"abstract\" href=\"UTD.htm?25/40/26250/abstract/7\">",
"     7",
"    </a>",
"    ]. This is due to the markedly reduced daily steroid dose [",
"    <a class=\"abstract\" href=\"UTD.htm?25/40/26250/abstract/7,33,43,44\">",
"     7,33,43,44",
"    </a>",
"    ]. In one study of 173 consecutive patients, for example, both univariate and multivariate linear regression analysis revealed a significant relationship between the 2-hr serum glucose level and the",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/48/33536?source=see_link\">",
"     prednisolone",
"    </a>",
"    dose [",
"    <a class=\"abstract\" href=\"UTD.htm?25/40/26250/abstract/33\">",
"     33",
"    </a>",
"    ]. The risk of developing NODAT was 5 percent per 0.01",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day of increase in prednisolone dose.",
"   </p>",
"   <p>",
"    However in another small study, although insulin sensitivity increased among patients who had",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/48/33536?source=see_link\">",
"     prednisolone",
"    </a>",
"    decreased from 16 to 9 mg daily, complete withdrawal of glucocorticoids did not significantly affect insulin sensitivity [",
"    <a class=\"abstract\" href=\"UTD.htm?25/40/26250/abstract/45\">",
"     45",
"    </a>",
"    ]. In the single large randomized control trial of steroid withdrawal in kidney transplant patients, the overall incidence of NODAT requiring therapy at 5 years was similar between patients in the steroid withdrawal arm versus the steroid continuation arm although the proportion of patients requiring insulin was lower in the steroid withdrawal arm (4 versus 12 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?25/40/26250/abstract/46\">",
"     46",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A significant percentage of patients suffer a rejection episode following steroid withdrawal requiring reinstitution of steroid therapy thus adjustment of immunosuppression therapy aimed at improving glucose tolerance must be weighed against the risk of allograft rejection. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/4/21577?source=see_link\">",
"     \"Withdrawal or avoidance of glucocorticoids after renal transplantation\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Pulsed high-dose therapy for acute rejection also appears to be a particularly strong risk factor for NODAT [",
"    <a class=\"abstract\" href=\"UTD.htm?25/40/26250/abstract/47\">",
"     47",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Calcineurin inhibitors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Both",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/14/32992?source=see_link\">",
"     tacrolimus",
"    </a>",
"    increase the risk of NODAT [",
"    <a class=\"abstract\" href=\"UTD.htm?25/40/26250/abstract/27\">",
"     27",
"    </a>",
"    ]. Compared with cyclosporine, tacrolimus has usually been observed to be more diabetogenic [",
"    <a class=\"abstract\" href=\"UTD.htm?25/40/26250/abstract/8,9,11,12,14,24-26,48-50\">",
"     8,9,11,12,14,24-26,48-50",
"    </a>",
"    ]. The following is a survey of some of these studies:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A 2004 meta-analysis found that insulin-treated diabetes mellitus occurred in 9.8 percent of renal transplant recipients on",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/14/32992?source=see_link\">",
"       tacrolimus",
"      </a>",
"      versus 2.7 percent of those on",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"       cyclosporine",
"      </a>",
"      -based regimens [",
"      <a class=\"abstract\" href=\"UTD.htm?25/40/26250/abstract/8\">",
"       8",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In the ELITE study, higher rates of NODAT developed at one year in patients receiving low-dose",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/14/32992?source=see_link\">",
"       tacrolimus",
"      </a>",
"      (8.4 percent) versus those receiving standard-dose",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"       cyclosporine",
"      </a>",
"      (6 percent), low-dose cyclosporine (4.2 percent), and low-dose",
"      <a class=\"drug drug_general\" href=\"UTD.htm?5/39/5753?source=see_link\">",
"       sirolimus",
"      </a>",
"      (6.6 percent) [",
"      <a class=\"abstract\" href=\"UTD.htm?25/40/26250/abstract/50\">",
"       50",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a randomized prospective study of 682 de novo kidney transplant recipients, the six-month incidence of NODAT or impaired fasting glucose was higher among those randomized to",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/14/32992?source=see_link\">",
"       tacrolimus",
"      </a>",
"      versus the group given",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"       cyclosporine",
"      </a>",
"      (34 versus 26 percent) [",
"      <a class=\"abstract\" href=\"UTD.htm?25/40/26250/abstract/12\">",
"       12",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A retrospective study of 8839 patients found a higher risk of NODAT with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/14/32992?source=see_link\">",
"       tacrolimus",
"      </a>",
"      compared with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"       cyclosporine",
"      </a>",
"      when these agents were used with various doses of corticosteroids [",
"      <a class=\"abstract\" href=\"UTD.htm?25/40/26250/abstract/51\">",
"       51",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Not all data, however, confirm the increased risk of NODAT with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/14/32992?source=see_link\">",
"     tacrolimus",
"    </a>",
"    over that with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?25/40/26250/abstract/52\">",
"     52",
"    </a>",
"    ]. Differences in the definition of diabetes among studies and different doses and levels may underlie some of the inconsistency in the literature.",
"   </p>",
"   <p>",
"    Increased",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/14/32992?source=see_link\">",
"     tacrolimus",
"    </a>",
"    levels have particularly strong associations with impaired glucose tolerance and NODAT. In one study, levels higher than 15",
"    <span class=\"nowrap\">",
"     ng/mL",
"    </span>",
"    were significantly associated with the development at one year of glucose intolerance (15 percent) and NODAT (32 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?25/40/26250/abstract/23\">",
"     23",
"    </a>",
"    ]. An increased incidence of NODAT seen after the introduction of the microemulsion formula of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    also suggests that an increased exposure to this drug also has clinically apparent effects on glucose tolerance [",
"    <a class=\"abstract\" href=\"UTD.htm?25/40/26250/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Both calcineurin inhibitors cause reversible toxicity to islet cells and may directly affect transcriptional regulation of insulin expression [",
"    <a class=\"abstract\" href=\"UTD.htm?25/40/26250/abstract/53\">",
"     53",
"    </a>",
"    ]. Some evidence suggests",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/14/32992?source=see_link\">",
"     tacrolimus",
"    </a>",
"    causes more severe swelling and vacuolization of islet cells [",
"    <a class=\"abstract\" href=\"UTD.htm?25/40/26250/abstract/54\">",
"     54",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Sirolimus",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/39/5753?source=see_link\">",
"     Sirolimus",
"    </a>",
"    is diabetogenic [",
"    <a class=\"abstract\" href=\"UTD.htm?25/40/26250/abstract/11,55,56\">",
"     11,55,56",
"    </a>",
"    ]. Conversion to sirolimus from",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/14/32992?source=see_link\">",
"     tacrolimus",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    has been associated with a significant worsening rather than an improvement in insulin resistance [",
"    <a class=\"abstract\" href=\"UTD.htm?25/40/26250/abstract/55\">",
"     55",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Other agents",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/3/38967?source=see_link\">",
"     Azathioprine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/29/4569?source=see_link\">",
"     mycophenolate",
"    </a>",
"    mofetil (MMF) do not have independent diabetogenic effects. In one large retrospective study, the use of azathioprine and MMF were actually associated with a decreased risk of NODAT (16 and 22 percent, respectively) [",
"    <a class=\"abstract\" href=\"UTD.htm?25/40/26250/abstract/9\">",
"     9",
"    </a>",
"    ]. This benefit may be due to the ability to permit the use of lower doses of corticosteroids, although this is unproven.",
"   </p>",
"   <p>",
"    Although the evidence is weak, the administration of statins and use of angiotensin receptor blockers or angiotensin converting enzyme inhibitors may be associated with a decreased risk of NODAT [",
"    <a class=\"abstract\" href=\"UTD.htm?25/40/26250/abstract/57\">",
"     57",
"    </a>",
"    ]. The underlying mechanisms for these observations are unclear.",
"   </p>",
"   <p>",
"    Long-term use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/58/5034?source=see_link\">",
"     trimethoprim-sulfamethoxazole",
"    </a>",
"    for prophylaxis for pneumocystis and bacterial infections may also reduce NODAT through a sulfonyl urea-like action.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Immunosuppressive combination regimens",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diabetogenic effects of immunosuppressive combination regimens have been compared:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In at least two studies, the combination of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/14/32992?source=see_link\">",
"       tacrolimus",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/3/38967?source=see_link\">",
"       azathioprine",
"      </a>",
"      was associated with higher rates of NODAT compared with tacrolimus with MMF or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"       cyclosporine",
"      </a>",
"      with MMF [",
"      <a class=\"abstract\" href=\"UTD.htm?25/40/26250/abstract/52,58\">",
"       52,58",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In another study, patients treated with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/14/32992?source=see_link\">",
"       tacrolimus",
"      </a>",
"      and MMF had lower rates of NODAT when compared with those taking tacrolimus and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?5/39/5753?source=see_link\">",
"       sirolimus",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"       cyclosporine",
"      </a>",
"      and sirolimus (14 versus 17 and 33 percent, respectively) [",
"      <a class=\"abstract\" href=\"UTD.htm?25/40/26250/abstract/59\">",
"       59",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The combination of either calcineurin inhibitor with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?5/39/5753?source=see_link\">",
"       sirolimus",
"      </a>",
"      may be particularly diabetogenic compared with the combination of a calcineurin inhibitor with MMF [",
"      <a class=\"abstract\" href=\"UTD.htm?25/40/26250/abstract/26\">",
"       26",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2159061289\">",
"    <span class=\"h2\">",
"     Underlying renal disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Polycystic kidney disease may confer an increased risk of NODAT, although this has not been consistently observed [",
"    <a class=\"abstract\" href=\"UTD.htm?25/40/26250/abstract/26,60-63\">",
"     26,60-63",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5971847\">",
"    <span class=\"h2\">",
"     Impaired glucose tolerance and perioperative hyperglycemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pre-operative impaired glucose tolerance generally identifies transplant candidates who are at higher risk for the development of NODAT. This was supported by one study in which impaired glucose tolerance was identified in 18 percent of nondiabetic patients prior to transplantation. Among 31 patients who developed NODAT after transplantation, 16 (52 percent) had impaired glucose tolerance pretransplant [",
"    <a class=\"abstract\" href=\"UTD.htm?25/40/26250/abstract/16\">",
"     16",
"    </a>",
"    ]: in multivariate analysis pretransplant impaired glucose tolerance was associated with the development of NODAT (relative risk of 2.4, 95% CI 1.1-5.3).",
"   </p>",
"   <p>",
"    In addition to increasing the risk of NODAT, impaired glucose tolerance has been associated with increased long term risk of cardiac and peripheral vascular disease in renal transplant recipients [",
"    <a class=\"abstract\" href=\"UTD.htm?25/40/26250/abstract/64\">",
"     64",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Other studies that have examined the incidence of impaired glucose tolerance and NODAT using serial oral glucose tolerance tests suggest that the majority of patients developing persistent NODAT can be identified within three months of transplantation and conversely, that patients with a normal oral glucose tolerance test 3 to 12 months post-transplant are at low risk for developing late NODAT [",
"    <a class=\"abstract\" href=\"UTD.htm?25/40/26250/abstract/5,29\">",
"     5,29",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Peri-operative hyperglycemia is also associated with development of NODAT [",
"    <a class=\"abstract\" href=\"UTD.htm?25/40/26250/abstract/11,17\">",
"     11,17",
"    </a>",
"    ]. In one retrospective study, among 349 patients who developed hyperglycemia during the transplantation hospitalization, 102 (29 percent) developed NODAT within the first year after transplantation [",
"    <a class=\"abstract\" href=\"UTD.htm?25/40/26250/abstract/17\">",
"     17",
"    </a>",
"    ]. By contrast, only 1 of 28 patients (4 percent) who did not have perioperative hyperglycemia developed NODAT. The risk of NODAT was highest among patients who required insulin.",
"   </p>",
"   <p>",
"    This was also shown in one study cited above [",
"    <a class=\"abstract\" href=\"UTD.htm?25/40/26250/abstract/11\">",
"     11",
"    </a>",
"    ], in which, among 23 patients who developed transient peri-operative hyperglycemia, 11 (48 percent) developed persistent hyperglycemia after 6 to 12 months of normoglycemia.",
"   </p>",
"   <p>",
"    Although the incidence and relevance of perioperative hyperglycemia depend upon specific center immunosuppressive protocols (ie, steroid administration), perioperative hyperglycemia may allow the identification of patients at increased risk for NODAT.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     CLINICAL IMPACT",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Patient survival",
"    </span>",
"    &nbsp;&mdash;&nbsp;The development of NODAT has an adverse effect upon patient survival [",
"    <a class=\"abstract\" href=\"UTD.htm?25/40/26250/abstract/9,18-20,47,64-69\">",
"     9,18-20,47,64-69",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In one study, one-year patient survival was 83 and 98 percent in those with and without NODAT, respectively [",
"      <a class=\"abstract\" href=\"UTD.htm?25/40/26250/abstract/18\">",
"       18",
"      </a>",
"      ]. A subsequent report found that five-year survival with NODAT was 87 versus 93 percent among non-diabetic patients [",
"      <a class=\"abstract\" href=\"UTD.htm?25/40/26250/abstract/21\">",
"       21",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Other investigators have reported that mean patient survival post-transplantation was lower with NODAT (8.1 versus 11.0 years) [",
"      <a class=\"abstract\" href=\"UTD.htm?25/40/26250/abstract/66\">",
"       66",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The development of NODAT correlates with increased cardiovascular mortality, which is the most prevalent cause of poor long-term survival [",
"    <a class=\"abstract\" href=\"UTD.htm?25/40/26250/abstract/9,70-74\">",
"     9,70-74",
"    </a>",
"    ]. The increased relative risk for death from cardiovascular disease ranges from 1.5 to 3 among those who develop NODAT versus those without diabetes [",
"    <a class=\"abstract\" href=\"UTD.htm?25/40/26250/abstract/9,71,73\">",
"     9,71,73",
"    </a>",
"    ]. Some of the excess risk is associated with coexistence of other cardiovascular risk factors, particularly increased age and dyslipidemia [",
"    <a class=\"abstract\" href=\"UTD.htm?25/40/26250/abstract/73\">",
"     73",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The effect of new-onset post-transplant diabetes mellitus on cardiovascular or overall mortality may not be as great as that of pretransplant diabetes, at least at 1.5 years. This was suggested by a large cohort study that examined outcomes of 37,448 recipients who had survived for longer than one year with a functioning transplant [",
"    <a class=\"abstract\" href=\"UTD.htm?25/40/26250/abstract/75\">",
"     75",
"    </a>",
"    ]. Recipients were stratified according to the absence or presence of diabetes and occurrence of acute rejection at one year following transplant. At a median followup of 1.5 years, pretransplant diabetes but not new-onset diabetes was associated with higher all-cause and cardiovascular mortality. This study is limited by the short duration of followup; 1.5 years may not be sufficient to show an adverse affect of new-onset diabetes [",
"    <a class=\"abstract\" href=\"UTD.htm?25/40/26250/abstract/76\">",
"     76",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Allograft survival",
"    </span>",
"    &nbsp;&mdash;&nbsp;NODAT decreases long-term allograft survival. In one study, for example, graft survival at 12 years was 48 and 70 percent in those with and without NODAT, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?25/40/26250/abstract/77\">",
"     77",
"    </a>",
"    ]; this was associated with a relative risk of loss of 3.72.",
"   </p>",
"   <p>",
"    Most, if not all of the adverse effect on allograft survival is due to the increase in mortality associated with NODAT. As an example, in a retrospective analysis of 27,707 transplant recipients, NODAT was associated with increased risk for allograft failure from any cause but not for death-censored graft loss (or graft loss without death) [",
"    <a class=\"abstract\" href=\"UTD.htm?25/40/26250/abstract/68\">",
"     68",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, another large retrospective study suggested that NODAT was associated with increased risk for both overall allograft failure and for death-censored allograft failure [",
"    <a class=\"abstract\" href=\"UTD.htm?25/40/26250/abstract/9\">",
"     9",
"    </a>",
"    ]. Unlike the study cited above however [",
"    <a class=\"abstract\" href=\"UTD.htm?25/40/26250/abstract/68\">",
"     68",
"    </a>",
"    ], this study did not control for acute rejection in the multivariate analysis [",
"    <a class=\"abstract\" href=\"UTD.htm?25/40/26250/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The mechanism by which NODAT may decrease allograft survival independent of increased mortality is not clear. Some have suggested that the recurrence of diabetic nephropathy may contribute to the increased rate of graft failure without death [",
"    <a class=\"abstract\" href=\"UTD.htm?25/40/26250/abstract/78\">",
"     78",
"    </a>",
"    ]. Another possibility is that efforts to decrease diabetogenic immunosuppressive therapy in order to prevent NODAT and its complications may increase rates of rejection [",
"    <a class=\"abstract\" href=\"UTD.htm?25/40/26250/abstract/77\">",
"     77",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, the effect of diabetes on death censored allograft loss is less than that of acute rejection. This was demonstrated in the study cited above that showed that acute rejection, but not diabetes, was associated with higher death-censored transplant failure at a median followup of 1.5 years [",
"    <a class=\"abstract\" href=\"UTD.htm?25/40/26250/abstract/75\">",
"     75",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H19\">",
"     'Patient survival'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Although limited by the short followup time, this large study suggests that acute rejection is the most significant potentially modifiable factor in allograft survival and underlines the importance of maintaining adequate immunosuppression to prevent rejection, even at the expense of the development of new-onset diabetes [",
"    <a class=\"abstract\" href=\"UTD.htm?25/40/26250/abstract/76\">",
"     76",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Infections",
"    </span>",
"    &nbsp;&mdash;&nbsp;NODAT has been associated with an increased risk for infection and sepsis, with hyperglycemia possibly altering the immune response [",
"    <a class=\"abstract\" href=\"UTD.htm?25/40/26250/abstract/18,21,67,77,79\">",
"     18,21,67,77,79",
"    </a>",
"    ]. Urinary tract infection, pneumonia, and cytomegalovirus have also been reported to occur at increased rates with diabetes [",
"    <a class=\"abstract\" href=\"UTD.htm?25/40/26250/abstract/18,21,67\">",
"     18,21,67",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Diabetic complications",
"    </span>",
"    &nbsp;&mdash;&nbsp;Complications observed in non-transplant patients with diabetes are also observed in those who develop NODAT. This was shown in a retrospective study of 4105 patients who developed NODAT by three years post-transplantation [",
"    <a class=\"abstract\" href=\"UTD.htm?25/40/26250/abstract/80\">",
"     80",
"    </a>",
"    ]. Ketoacidosis, hyperosmolarity, ophthalmic complications, neurologic complications, and",
"    <span class=\"nowrap\">",
"     hypoglycemia/shock",
"    </span>",
"    occurred in 8.1, 3.2, 8.3, 16.2, and 7.3 percent of patients, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?25/40/26250/abstract/80\">",
"     80",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h1\">",
"     MANAGEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Management includes pretransplant evaluation, regular posttransplantation monitoring of all patients, consideration of immunosuppressant therapy modification based on impaired glucose tolerance, and therapy of diabetes mellitus [",
"    <a class=\"abstract\" href=\"UTD.htm?25/40/26250/abstract/1\">",
"     1",
"    </a>",
"    ]. Aggressive management of other cardiovascular risk factors such as hypertension and dyslipidemia is also warranted.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H35235261\">",
"    <span class=\"h2\">",
"     Pretransplant screening",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pretransplant assessment should include screening for risk factors for NODAT, and for a history of gestational diabetes. All patients should be screened with a fasting plasma glucose, for other evidence of the metabolic syndrome, and other cardiovascular risk factors. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/11/32954?source=see_link\">",
"     \"The metabolic syndrome (insulin resistance syndrome or syndrome X)\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/8/39048?source=see_link\">",
"     \"Estimation of cardiovascular risk in an individual patient without known cardiovascular disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    All patients should be counseled regarding their risk of NODAT and lifestyle modifications aimed at decreasing this risk [",
"    <a class=\"abstract\" href=\"UTD.htm?25/40/26250/abstract/15,81\">",
"     15,81",
"    </a>",
"    ]. Individuals at high risk should be referred to a dietitian. We generally do not screen transplant candidates with an oral glucose tolerance test, although an abnormal test may be predictive of the development of NODAT since the test results would not alter transplantation candidacy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H35235284\">",
"    <span class=\"h2\">",
"     Posttransplant screening",
"    </span>",
"    &nbsp;&mdash;&nbsp;All patients, whether or not they have a pre-identified increased risk, should have a fasting blood glucose measured weekly during the first four weeks posttransplant, then at three and six months post-transplant, and then yearly. A hemoglobin A1c can be checked after three months post-transplant, particularly if it is difficult to obtain fasting plasma-glucose levels.",
"   </p>",
"   <p>",
"    Among patients who have HBA1C greater than 6 percent, we recommend home blood sugar monitoring and assessment of a HbA1C quarterly. We do not recommend additional therapy beyond diet and exercise until the HBA1C is &gt;7 percent.",
"   </p>",
"   <p>",
"    Home blood sugar monitoring should be performed in those with perioperative hyperglycemia, particularly for those with blood sugars &ge;200 or those requiring insulin administration, since such patients are at higher risk for NODAT. Initially blood glucose should be checked 4 times daily; before each meal and before bed. However, monitoring a two-hour post prandial blood glucose may be a better indicator of diabetes and its control. (See",
"    <a class=\"local\" href=\"#H5971847\">",
"     'Impaired glucose tolerance and perioperative hyperglycemia'",
"    </a>",
"    above.).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;The rationale for treating patients with NODAT is derived from studies of nontransplanted patients. Improved glycemic control decreases the risk of microvascular complications in patients with type 2 diabetes. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/35/43577?source=see_link&amp;anchor=H2#H2\">",
"     \"Initial management of blood glucose in type 2 diabetes mellitus\", section on 'Treatment goals'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Additionally, among transplanted patients with diabetes, achieving goal fasting blood glucose may reduce the increased prevalence of rejection [",
"    <a class=\"abstract\" href=\"UTD.htm?25/40/26250/abstract/82\">",
"     82",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A stepwise approach is recommended for treatment of NODAT, starting with non-pharmacologic therapy, including diet, weight reduction and exercise, followed by oral monotherapy, oral combination therapy, and finally insulin, providing metabolic decompensation has not occurred (which would require earlier insulin initiation) [",
"    <a class=\"abstract\" href=\"UTD.htm?25/40/26250/abstract/1\">",
"     1",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/35/43577?source=see_link\">",
"     \"Initial management of blood glucose in type 2 diabetes mellitus\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients with subdiabetic hyperglycemia or NODAT should also have aggressive interventions aimed at decreasing cardiovascular risk, such as lipid and blood pressure control.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     Aspirin",
"    </a>",
"    may be indicated to further reduce cardiovascular risk. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/23/16761?source=see_link\">",
"     \"Hypertension after renal transplantation\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/54/29546?source=see_link\">",
"     \"Lipid abnormalities after renal transplantation\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h3\">",
"     Adjustment of immunosuppression",
"    </span>",
"    &nbsp;&mdash;&nbsp;Adjustment of immunosuppression therapy aimed at improving glucose tolerance may be considered among patients with NODAT. However the potential benefit of altering immunosuppressive agents must be weighed against the risk of allograft rejection.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H216879\">",
"    <span class=\"h4\">",
"     Glucocorticoids",
"    </span>",
"    &nbsp;&mdash;&nbsp;The glucocorticoid dose should be decreased as soon as possible, but complete steroid withdrawal is not recommended [",
"    <a class=\"abstract\" href=\"UTD.htm?25/40/26250/abstract/1\">",
"     1",
"    </a>",
"    ].",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/48/33536?source=see_link\">",
"     Prednisolone",
"    </a>",
"    dose reduction to 5",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    at one year has been associated with a decrease in glucose intolerance from 55 to 34 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?25/40/26250/abstract/44\">",
"     44",
"    </a>",
"    ]. Although complete steroid withdrawal can reduce the incidence of NODAT, a significant percentage of patients suffer a rejection episode requiring reinstitution of steroid therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?25/40/26250/abstract/83\">",
"     83",
"    </a>",
"    ]. One study also found no improvement in insulin sensitivity when dropping from 5 mg to complete prednisolone withdrawal [",
"    <a class=\"abstract\" href=\"UTD.htm?25/40/26250/abstract/45\">",
"     45",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H13\">",
"     'Glucocorticoids'",
"    </a>",
"    above.)",
"    <br/>",
"    <br/>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H216886\">",
"    <span class=\"h4\">",
"     Tacrolimus",
"    </span>",
"    &nbsp;&mdash;&nbsp;Compared with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    , the use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/14/32992?source=see_link\">",
"     tacrolimus",
"    </a>",
"    is associated with higher rates of NODAT, particularly with tacrolimus trough levels &gt;15",
"    <span class=\"nowrap\">",
"     ng/mL",
"    </span>",
"    in the first month post-transplant. (See",
"    <a class=\"local\" href=\"#H14\">",
"     'Calcineurin inhibitors'",
"    </a>",
"    above.) Thus, in affected patients, consideration should be given to reducing the tacrolimus dose.",
"   </p>",
"   <p>",
"    We generally do not switch affected patients from",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/14/32992?source=see_link\">",
"     tacrolimus",
"    </a>",
"    to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    unless there are other tacrolimus related side effects, since the effect of tacrolimus on glucose tolerance may be reversible even if the agent is not discontinued. In one study, for example, 70 percent of white patients and 20 percent of African-Americans were able to discontinue insulin without discontinuing tacrolimus or steroids [",
"    <a class=\"abstract\" href=\"UTD.htm?25/40/26250/abstract/32\">",
"     32",
"    </a>",
"    ]. In addition, one large review reported an improved graft survival with tacrolimus therapy, despite the increased rate of NODAT seen with tacrolimus and the association of NODAT with decreased graft survival [",
"    <a class=\"abstract\" href=\"UTD.htm?25/40/26250/abstract/9\">",
"     9",
"    </a>",
"    ]. Another registry analysis of the USRDS database of nearly 50,000 patients transplanted between January 1998 and December 2002, (during which time the time tacrolimus and cyclosporin had equal market share) showed that diabetes was associated with worse patient and graft survival but no differences based on whether tacrolimus or cyclosporine was used despite a higher incidence of NODAT among those who received tacrolimus [",
"    <a class=\"abstract\" href=\"UTD.htm?25/40/26250/abstract/84\">",
"     84",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, some data in liver transplant patients suggests that switching from",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/14/32992?source=see_link\">",
"     tacrolimus",
"    </a>",
"    to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    may improve glucose control and return normal glucose tolerance, while simply decreasing tacrolimus was not beneficial [",
"    <a class=\"abstract\" href=\"UTD.htm?25/40/26250/abstract/85\">",
"     85",
"    </a>",
"    ]. Thus, switching to cyclosporine may be considered among patients in whom diabetes is difficult to control [",
"    <a class=\"abstract\" href=\"UTD.htm?25/40/26250/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Conversion to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/39/5753?source=see_link\">",
"     sirolimus",
"    </a>",
"    is not recommended. Sirolimus may worsen insulin resistance [",
"    <a class=\"abstract\" href=\"UTD.htm?25/40/26250/abstract/55\">",
"     55",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h3\">",
"     Oral therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Drug selection should consider efficacy, side effects and costs. Limited information exists regarding use of newer oral agents to treat glucocorticoid- or immunosuppression-related diabetes. Glucocorticoid-induced diabetes, even with low dose therapy, is characterized by fasting blood sugars only slightly above baseline, but more markedly increased postprandial blood glucose and reduced insulin sensitivity [",
"    <a class=\"abstract\" href=\"UTD.htm?25/40/26250/abstract/86\">",
"     86",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The following discussion of oral therapy emphasizes those aspects specific to renal transplant recipients. General discussions of the use of these agents are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/26/38312?source=see_link\">",
"     \"Metformin in the treatment of diabetes mellitus\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/50/21290?source=see_link\">",
"     \"Thiazolidinediones in the treatment of diabetes mellitus\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/46/35559?source=see_link\">",
"     \"Sulfonylureas and meglitinides in the treatment of diabetes mellitus\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/0/3078?source=see_link\">",
"     \"Alpha-glucosidase inhibitors and lipase inhibitors for treatment of diabetes mellitus\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/35/43577?source=see_link\">",
"     \"Initial management of blood glucose in type 2 diabetes mellitus\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/19/28986?source=see_link\">",
"     \"Management of persistent hyperglycemia in type 2 diabetes mellitus\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    We generally start oral treatment with sulfonylureas given the extensive experience with these agents and their relatively low cost [",
"    <a class=\"abstract\" href=\"UTD.htm?25/40/26250/abstract/87\">",
"     87",
"    </a>",
"    ]. However, some experts would choose meglitinides such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/25/4503?source=see_link\">",
"     repaglinide",
"    </a>",
"    (Prandin) before sulfonylureas are used, since sulfonylureas may have potential toxicity in the setting of renal dysfunction. Among the sulfonylureas,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/28/40391?source=see_link\">",
"     glipizide",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/39/8823?source=see_link\">",
"     glimepiride",
"    </a>",
"    are preferred to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/6/29800?source=see_link\">",
"     glyburide",
"    </a>",
"    when the glomerular filtration rate (GFR) is less than 50",
"    <span class=\"nowrap\">",
"     mL/min,",
"    </span>",
"    because glyburide may accumulate with renal insufficiency resulting in hypoglycemia. We usually begin with glipizide at 2.5 to 5 mg orally daily and then advance to 10 mg twice per day as necessary to maintain the HbA1c level at less than 7 percent. Sulfonylureas may be expected to lower the HbA1c by 0.8 to 2 percent and may increase body weight.",
"   </p>",
"   <p>",
"    Meglitinides, such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/21/11606?source=see_link\">",
"     nateglinide",
"    </a>",
"    (Starlix) or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/25/4503?source=see_link\">",
"     repaglinide",
"    </a>",
"    (Prandin) may be good alternatives for patients who cannot take sulfonylureas. One six month study found that repaglinide lowered mean HbA1c levels (7.6 to 5.8 percent) in 14 of 23 patients with NODAT, with the remainder eventually requiring insulin therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?25/40/26250/abstract/88\">",
"     88",
"    </a>",
"    ]. Meglitinides are not contraindicated in patients with renal or liver insufficiency and do not have adverse drug interactions [",
"    <a class=\"abstract\" href=\"UTD.htm?25/40/26250/abstract/1\">",
"     1",
"    </a>",
"    ]. However we generally do not use them as first-line agents because of their increased expense.",
"   </p>",
"   <p>",
"    Among patients who cannot take either sulfonylureas or meglitinides, some clinicians have used the dipeptidyl peptidase-4 inhibitor,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/31/5622?source=see_link\">",
"     sitagliptin",
"    </a>",
"    , or the incretin mimetic,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/2/14375?source=see_link\">",
"     exenatide",
"    </a>",
"    , although there are no published data to guide therapy.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/31/5622?source=see_link\">",
"     Sitagliptin",
"    </a>",
"    (Januvia) is an oral agent that inhibits dipeptidyl peptidase-4, the enzyme responsible for incretin degradation, which increases insulin synthesis and release and decreases glucagon levels. The dose must be adjusted for renal insufficiency. One report documented the safety and efficacy of sitagliptin for treatment of NODAT among 15 kidney transplant recipients [",
"    <a class=\"abstract\" href=\"UTD.htm?25/40/26250/abstract/89\">",
"     89",
"    </a>",
"    ]. Although sitagliptin does not cause hypoglycemia, it may prolong the QT interval especially if used with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    .",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/26/26022?source=see_link\">",
"     Saxagliptin",
"    </a>",
"    (Onglyza) does not prolong the QT interval.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/2/14375?source=see_link\">",
"     Exenatide",
"    </a>",
"    (Byetta), an incretin mimetic which is administered subcutaneously, increases the phase I response to oral glucose, and has been approved by the United States Food and Drug Administration as adjunctive therapy for patients with type 2 diabetes who are inadequately controlled on oral agents. This agent is discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/23/15734?source=see_link\">",
"     \"Amylin analogs for the treatment of diabetes mellitus\"",
"    </a>",
"    .) No data are yet available for use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/26/26022?source=see_link\">",
"     saxagliptin",
"    </a>",
"    or exenatide in kidney transplant recipients.",
"   </p>",
"   <p>",
"    Thiazolidinediones are generally not used among transplant recipients unless there are no other alternatives. We do not use",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/26/2472?source=see_link\">",
"     rosiglitazone",
"    </a>",
"    in any transplant recipient. The thiazolinediones may worsen immunosuppression-associated bone loss and are commonly associated with formation of edema, which may necessitate the use of diuretics and may predispose to calcineurin toxicity. Use of these agents is also contraindicated in hepatic dysfunction.",
"   </p>",
"   <p>",
"    <br/>",
"    We tend not to use",
"    <a class=\"drug drug_general\" href=\"UTD.htm?7/48/7944?source=see_link\">",
"     metformin",
"    </a>",
"    because renal insufficiency increases the risk of lactic acidosis. Alpha-glucosidase inhibitors such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?43/10/44197?source=see_link\">",
"     acarbose",
"    </a>",
"    (Precose) or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?3/0/3077?source=see_link\">",
"     miglitol",
"    </a>",
"    (Glyset) are not considered first- or second- line agents but may be considered if other options are not available. Alpha-glucosidase inhibitors slow carbohydrate ingestion and reduce postprandial blood sugar peaks. They are relatively less effective in lowering glycemia compared with other anti-diabetic medications but do not cause weight gain. These agents are relatively expensive and their use may be limited by gastrointestinal side effects, particularly in the setting of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/29/4569?source=see_link\">",
"     mycophenolate",
"    </a>",
"    mofetil treatment. There is a reduced risk of hypoglycemia [",
"    <a class=\"abstract\" href=\"UTD.htm?25/40/26250/abstract/86\">",
"     86",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h3\">",
"     Insulin therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Many patients will require institution of insulin, especially those with fasting blood sugars above 200",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?25/40/26250/abstract/86,90\">",
"     86,90",
"    </a>",
"    ]. We initiate insulin therapy if there has been metabolic decompensation, adverse side effects with oral therapy, or HbA1c levels that are consistently above 7 percent.",
"   </p>",
"   <p>",
"    There are little data regarding insulin therapy among patients who are receiving glucocorticoids. It is recommended that patients requiring insulin be referred to an endocrinologist [",
"    <a class=\"abstract\" href=\"UTD.htm?25/40/26250/abstract/1\">",
"     1",
"    </a>",
"    ]. We have also found it useful to use a diabetic nurse educator and advanced practice nurse to help manage these patients.",
"   </p>",
"   <p>",
"    Diurnal glucose patterns differ among patients who are receiving glucocorticoids compared with those who are not. Thus, even with small doses of steroids of 5 mg per day in the morning, we have typically observed a late afternoon or early evening peak in blood glucose concentration that is often much higher than the two-hour postprandial blood glucose concentrations.",
"   </p>",
"   <p>",
"    We use multiple agents and multiple-dose intensive insulin therapy. As an example, we typically use:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Medium-acting NPH in the morning, adjusted to control the late afternoon or early evening glucose increases. Morning NPH is particularly useful in controlling the hyperglycemia associated with steroids given in the morning.",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?33/30/34279?source=see_link\">",
"       Insulin glargine",
"      </a>",
"      (Lantus) at night, adjusted to control the morning fasting glucose.",
"     </li>",
"     <li>",
"      Premeal short-acting",
"      <a class=\"drug drug_general\" href=\"UTD.htm?10/42/10920?source=see_link\">",
"       insulin aspart",
"      </a>",
"      (Novolog), or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/48/17160?source=see_link\">",
"       insulin lispro",
"      </a>",
"      (Humalog), based on premeal glucose and anticipated carbohydrate ingestion.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Although insulin-pump therapy may be used in this setting, it is rarely necessary or indicated. A detailed discussion of insulin therapy is available in separate topic reviews. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/24/30089?source=see_link\">",
"     \"Insulin therapy in type 2 diabetes mellitus\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/35/43577?source=see_link\">",
"     \"Initial management of blood glucose in type 2 diabetes mellitus\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/20/24906?source=see_link\">",
"     \"Insulin therapy in adults with type 1 diabetes mellitus\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H35235334\">",
"    <span class=\"h3\">",
"     Monitoring patients with NODAT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hemoglobin A1c should be checked every three months with a target &lt;6.5 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?25/40/26250/abstract/1\">",
"     1",
"    </a>",
"    ]. The HbA1c assay will not reliably measure average glucose levels in the setting of anemia, especially if erythropoietin replacement is being used. Patients should be instructed in glucose self-monitoring. Patients should have regular screening for retinopathy and neuropathy [",
"    <a class=\"abstract\" href=\"UTD.htm?25/40/26250/abstract/1\">",
"     1",
"    </a>",
"    ]. Regular foot care is also indicated.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Approximately one-third of non-diabetic kidney transplant recipients develop persistently impaired glucose metabolism by six months posttransplantation. New onset diabetes after transplantation (NODAT) adversely affects patients and allograft survival. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Incidence'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H18\">",
"       'Clinical impact'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      NODAT may be diagnosed at any time after transplantation by symptoms plus a random plasma glucose &ge;200",
"      <span class=\"nowrap\">",
"       mg/dl",
"      </span>",
"      (11.1",
"      <span class=\"nowrap\">",
"       mmol/l),",
"      </span>",
"      fasting plasma glucose &ge;126",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (7.0",
"      <span class=\"nowrap\">",
"       mmol/L)",
"      </span>",
"      or a two-hour plasma glucose &ge;200",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (11.1",
"      <span class=\"nowrap\">",
"       mmol/L)",
"      </span>",
"      during an oral glucose tolerance test. Subdiabetic hyperglycemia (&ldquo;prediabetes&rdquo;) is diagnosed by a fasting plasma glucose between 100 and 125",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (5.6 and 6.9",
"      <span class=\"nowrap\">",
"       mmol/L)",
"      </span>",
"      or a two-hour plasma glucose between 140 and 199",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (7.8 and 11.0",
"      <span class=\"nowrap\">",
"       mmol/L)",
"      </span>",
"      during an oral glucose tolerance test according to ADA guidelines. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Definition'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Glucocorticoids, calcineurin inhibitors and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?5/39/5753?source=see_link\">",
"       sirolimus",
"      </a>",
"      increase the risk of NODAT. Compared with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"       cyclosporine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/14/32992?source=see_link\">",
"       tacrolimus",
"      </a>",
"      is more diabetogenic.",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/3/38967?source=see_link\">",
"       Azathioprine",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?4/29/4569?source=see_link\">",
"       mycophenolate",
"      </a>",
"      mofetil (MMF) are not diabetogenic. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Medications'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Pretransplant assessment should include screening for risk factors for NODAT, and for a history of gestational diabetes. All patients should be screened with a fasting plasma glucose, for other evidence of the metabolic syndrome, and for other cardiovascular risk factors. All patients should be counseled regarding their risk of NODAT and lifestyle modifications aimed at decreasing this risk. Individuals at high risk should be referred to a dietitian. (See",
"      <a class=\"local\" href=\"#H35235261\">",
"       'Pretransplant screening'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      All transplant recipients should have a fasting blood glucose measured weekly during the first four weeks posttransplant, then at three and six months post-transplant, and then yearly. A hemoglobin A1c can be checked after three months post-transplant, particularly if it is difficult to obtain fasting plasma-glucose levels. (See",
"      <a class=\"local\" href=\"#H35235284\">",
"       'Posttransplant screening'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Adjustment of immunosuppression therapy aimed at improving glucose tolerance must be weighed against the risk of allograft rejection. We suggest the following approach:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Among all patients with NODAT, we suggest that the glucocorticoid dose be decreased as soon as possible. We recommend NOT withdrawing glucocorticoids completely.",
"     </li>",
"     <li>",
"      Among all patients with NODAT, we suggest NOT switching",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/14/32992?source=see_link\">",
"       tacrolimus",
"      </a>",
"      to",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"       cyclosporine",
"      </a>",
"      unless other unless other tacrolimus-related side effects are present. The tacrolimus dose may be reduced if possible. Among patients with poorly controlled diabetes despite a reduction in tacrolimus dose, switching to cyclosporine may be considered.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A stepwise approach is recommended for the management of NODAT, starting with non-pharmacologic therapy, followed by oral monotherapy, oral combination therapy, and finally insulin providing metabolic decompensation has not occurred.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Among most patients with NODAT we initiate oral therapy with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?39/28/40391?source=see_link\">",
"       glipizide",
"      </a>",
"      at a dose of 2.5 to 5 mg per day and then advance to 10 mg twice per day as necessary to maintain the HbA1c level at &lt;7 percent. However, some experts would choose meglitinides such as",
"      <a class=\"drug drug_general\" href=\"UTD.htm?4/25/4503?source=see_link\">",
"       repaglinide",
"      </a>",
"      (Prandin) before sulfonylureas are used, since sulfonylureas may have potential toxicity in the setting of renal dysfunction. Thiazolinediones are generally avoided among transplantation due to adverse side effects.",
"     </li>",
"     <li>",
"      We initiate insulin therapy if there has been metabolic decompensation, adverse side effects with oral therapy, or HbA1c levels that are consistently &ge;7 percent. We may use multiple agents",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      multiple-dose intensive insulin therapy or insulin-pump therapy. It is recommended that patients requiring insulin be referred to an endocrinologist.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A detailed discussion of the management of type 2 diabetes is available in separate topic reviews. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/35/43577?source=see_link\">",
"     \"Initial management of blood glucose in type 2 diabetes mellitus\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/19/28986?source=see_link\">",
"     \"Management of persistent hyperglycemia in type 2 diabetes mellitus\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/24/30089?source=see_link\">",
"     \"Insulin therapy in type 2 diabetes mellitus\"",
"    </a>",
"    .)",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/40/26250/abstract/1\">",
"      Davidson J, Wilkinson A, Dantal J, et al. New-onset diabetes after transplantation: 2003 International consensus guidelines. Proceedings of an international expert panel meeting. Barcelona, Spain, 19 February 2003. Transplantation 2003; 75:SS3.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/40/26250/abstract/2\">",
"      Wilkinson A, Davidson J, Dotta F, et al. Guidelines for the treatment and management of new-onset diabetes after transplantation. Clin Transplant 2005; 19:291.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/40/26250/abstract/3\">",
"      American Diabetes Association. Standards of medical care in diabetes--2011. Diabetes Care 2011; 34 Suppl 1:S11.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/40/26250/abstract/4\">",
"      Valderhaug TG, Jenssen T, Hartmann A, et al. Fasting plasma glucose and glycosylated hemoglobin in the screening for diabetes mellitus after renal transplantation. Transplantation 2009; 88:429.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/40/26250/abstract/5\">",
"      David-Neto E, Lemos FC, Fadel LM, et al. The dynamics of glucose metabolism under calcineurin inhibitors in the first year after renal transplantation in nonobese patients. Transplantation 2007; 84:50.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/40/26250/abstract/6\">",
"      Is fasting glucose sufficient to define diabetes? Epidemiological data from 20 European studies. The DECODE-study group. European Diabetes Epidemiology Group. Diabetes Epidemiology: Collaborative analysis of Diagnostic Criteria in Europe. Diabetologia 1999; 42:647.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/40/26250/abstract/7\">",
"      Gunnarsson R, Arner P, Lundgren G, et al. Diabetes mellitus--a more-common-than-believed complication of renal transplantation. Transplant Proc 1979; 11:1280.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/40/26250/abstract/8\">",
"      Heisel O, Heisel R, Balshaw R, Keown P. New onset diabetes mellitus in patients receiving calcineurin inhibitors: a systematic review and meta-analysis. Am J Transplant 2004; 4:583.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/40/26250/abstract/9\">",
"      Kasiske BL, Snyder JJ, Gilbertson D, Matas AJ. Diabetes mellitus after kidney transplantation in the United States. Am J Transplant 2003; 3:178.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/40/26250/abstract/10\">",
"      Cosio FG, Pesavento TE, Osei K, et al. Post-transplant diabetes mellitus: increasing incidence in renal allograft recipients transplanted in recent years. Kidney Int 2001; 59:732.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/40/26250/abstract/11\">",
"      Sulanc E, Lane JT, Puumala SE, et al. New-onset diabetes after kidney transplantation: an application of 2003 International Guidelines. Transplantation 2005; 80:945.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/40/26250/abstract/12\">",
"      Vincenti F, Friman S, Scheuermann E, et al. Results of an international, randomized trial comparing glucose metabolism disorders and outcome with cyclosporine versus tacrolimus. Am J Transplant 2007; 7:1506.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/40/26250/abstract/13\">",
"      Porrini E, Moreno JM, Osuna A, et al. Prediabetes in patients receiving tacrolimus in the first year after kidney transplantation: a prospective and multicenter study. Transplantation 2008; 85:1133.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/40/26250/abstract/14\">",
"      Woodward RS, Schnitzler MA, Baty J, et al. Incidence and cost of new onset diabetes mellitus among U.S. wait-listed and transplanted renal allograft recipients. Am J Transplant 2003; 3:590.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/40/26250/abstract/15\">",
"      Gaston RS, Basadonna G, Cosio FG, et al. Transplantation in the diabetic patient with advanced chronic kidney disease: a task force report. Am J Kidney Dis 2004; 44:529.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/40/26250/abstract/16\">",
"      Caillard S, Eprinchard L, Perrin P, et al. Incidence and risk factors of glucose metabolism disorders in kidney transplant recipients: role of systematic screening by oral glucose tolerance test. Transplantation 2011; 91:757.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/40/26250/abstract/17\">",
"      Chakkera HA, Knowler WC, Devarapalli Y, et al. Relationship between inpatient hyperglycemia and insulin treatment after kidney transplantation and future new onset diabetes mellitus. Clin J Am Soc Nephrol 2010; 5:1669.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/40/26250/abstract/18\">",
"      Boudreaux JP, McHugh L, Canafax DM, et al. The impact of cyclosporine and combination immunosuppression on the incidence of posttransplant diabetes in renal allograft recipients. Transplantation 1987; 44:376.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/40/26250/abstract/19\">",
"      Cosio FG, Pesavento TE, Kim S, et al. Patient survival after renal transplantation: IV. Impact of post-transplant diabetes. Kidney Int 2002; 62:1440.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/40/26250/abstract/20\">",
"      Roth D, Milgrom M, Esquenazi V, et al. Posttransplant hyperglycemia. Increased incidence in cyclosporine-treated renal allograft recipients. Transplantation 1989; 47:278.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/40/26250/abstract/21\">",
"      Sumrani N, Delaney V, Ding Z, et al. Posttransplant diabetes mellitus in cyclosporine-treated renal transplant recipients. Transplant Proc 1991; 23:1249.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/40/26250/abstract/22\">",
"      Mathew JT, Rao M, Job V, et al. Post-transplant hyperglycaemia: a study of risk factors. Nephrol Dial Transplant 2003; 18:164.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/40/26250/abstract/23\">",
"      Maes BD, Kuypers D, Messiaen T, et al. Posttransplantation diabetes mellitus in FK-506-treated renal transplant recipients: analysis of incidence and risk factors. Transplantation 2001; 72:1655.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/40/26250/abstract/24\">",
"      Gourishankar S, Jhangri GS, Tonelli M, et al. Development of diabetes mellitus following kidney transplantation: a Canadian experience. Am J Transplant 2004; 4:1876.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/40/26250/abstract/25\">",
"      Shah T, Kasravi A, Huang E, et al. Risk factors for development of new-onset diabetes mellitus after kidney transplantation. Transplantation 2006; 82:1673.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/40/26250/abstract/26\">",
"      Luan FL, Steffick DE, Ojo AO. New-onset diabetes mellitus in kidney transplant recipients discharged on steroid-free immunosuppression. Transplantation 2011; 91:334.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/40/26250/abstract/27\">",
"      Bloom RD, Crutchlow MF. New-onset diabetes mellitus in the kidney recipient: diagnosis and management strategies. Clin J Am Soc Nephrol 2008; 3 Suppl 2:S38.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/40/26250/abstract/28\">",
"      Araki M, Flechner SM, Ismail HR, et al. Posttransplant diabetes mellitus in kidney transplant recipients receiving calcineurin or mTOR inhibitor drugs. Transplantation 2006; 81:335.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/40/26250/abstract/29\">",
"      Hur KY, Kim MS, Kim YS, et al. Risk factors associated with the onset and progression of posttransplantation diabetes in renal allograft recipients. Diabetes Care 2007; 30:609.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/40/26250/abstract/30\">",
"      Friedman AN, Miskulin DC, Rosenberg IH, Levey AS. Demographics and trends in overweight and obesity in patients at time of kidney transplantation. Am J Kidney Dis 2003; 41:480.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/40/26250/abstract/31\">",
"      Walczak DA, Calvert D, Jarzembowski TM, et al. Increased risk of post-transplant diabetes mellitus despite early steroid discontinuation in Hispanic kidney transplant recipients. Clin Transplant 2005; 19:527.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/40/26250/abstract/32\">",
"      Neylan JF. Racial differences in renal transplantation after immunosuppression with tacrolimus versus cyclosporine. FK506 Kidney Transplant Study Group. Transplantation 1998; 65:515.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/40/26250/abstract/33\">",
"      Hjelmesaeth J, Hartmann A, Kofstad J, et al. Glucose intolerance after renal transplantation depends upon prednisolone dose and recipient age. Transplantation 1997; 64:979.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/40/26250/abstract/34\">",
"      Bloom RD, Rao V, Weng F, et al. Association of hepatitis C with posttransplant diabetes in renal transplant patients on tacrolimus. J Am Soc Nephrol 2002; 13:1374.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/40/26250/abstract/35\">",
"      Abbott KC, Lentine KL, Bucci JR, et al. Impact of diabetes and hepatitis after kidney transplantation on patients who are affected by hepatitis C virus. J Am Soc Nephrol 2004; 15:3166.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/40/26250/abstract/36\">",
"      Fabrizi F, Martin P, Dixit V, et al. Post-transplant diabetes mellitus and HCV seropositive status after renal transplantation: meta-analysis of clinical studies. Am J Transplant 2005; 5:2433.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/40/26250/abstract/37\">",
"      Bloom RD, Lake JR. Emerging issues in hepatitis C virus-positive liver and kidney transplant recipients. Am J Transplant 2006; 6:2232.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/40/26250/abstract/38\">",
"      G&uuml;rsoy M, K&ouml;ksal R, Karavelio��lu D, et al. Pretransplantation alpha-interferon therapy and the effect of hepatitis C virus infection on kidney allograft recipients. Transplant Proc 2000; 32:580.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/40/26250/abstract/39\">",
"      Markell M. New-onset diabetes mellitus in transplant patients: pathogenesis, complications, and management. Am J Kidney Dis 2004; 43:953.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/40/26250/abstract/40\">",
"      Hjelmesaeth J, Midtvedt K, Jenssen T, Hartmann A. Insulin resistance after renal transplantation: impact of immunosuppressive and antihypertensive therapy. Diabetes Care 2001; 24:2121.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/40/26250/abstract/41\">",
"      Helmesaeth, J, Sagedal, S, Hartmann, A, et al. Asymptomatic cytomegalovirus infection is associated with increased risk of new-onset diabetes mellitus and impaired insulin release after renal transplantation. Daibetologia 2004; 47:1550.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/40/26250/abstract/42\">",
"      Gurwitz JH, Bohn RL, Glynn RJ, et al. Glucocorticoids and the risk for initiation of hypoglycemic therapy. Arch Intern Med 1994; 154:97.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/40/26250/abstract/43\">",
"      Boots JM, Christiaans MH, Van Duijnhoven EM, et al. Early steroid withdrawal in renal transplantation with tacrolimus dual therapy: a pilot study. Transplantation 2002; 74:1703.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/40/26250/abstract/44\">",
"      Hjelmesaeth J, Hartmann A, Kofstad J, et al. Tapering off prednisolone and cyclosporin the first year after renal transplantation: the effect on glucose tolerance. Nephrol Dial Transplant 2001; 16:829.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/40/26250/abstract/45\">",
"      Midtvedt K, Hjelmesaeth J, Hartmann A, et al. Insulin resistance after renal transplantation: the effect of steroid dose reduction and withdrawal. J Am Soc Nephrol 2004; 15:3233.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/40/26250/abstract/46\">",
"      Woodle ES, First MR, Pirsch J, et al. A prospective, randomized, double-blind, placebo-controlled multicenter trial comparing early (7 day) corticosteroid cessation versus long-term, low-dose corticosteroid therapy. Ann Surg 2008; 248:564.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/40/26250/abstract/47\">",
"      Vesco L, Busson M, Bedrossian J, et al. Diabetes mellitus after renal transplantation: characteristics, outcome, and risk factors. Transplantation 1996; 61:1475.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/40/26250/abstract/48\">",
"      Kr&auml;mer BK, Z&uuml;lke C, Kammerl MC, et al. Cardiovascular risk factors and estimated risk for CAD in a randomized trial comparing calcineurin inhibitors in renal transplantation. Am J Transplant 2003; 3:982.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/40/26250/abstract/49\">",
"      van Hooff JP, Christiaans MH, van Duijnhoven EM. Tacrolimus and posttransplant diabetes mellitus in renal transplantation. Transplantation 2005; 79:1465.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/40/26250/abstract/50\">",
"      Ekberg H, Tedesco-Silva H, Demirbas A, et al. Reduced exposure to calcineurin inhibitors in renal transplantation. N Engl J Med 2007; 357:2562.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/40/26250/abstract/51\">",
"      Burroughs TE, Lentine KL, Takemoto SK, et al. Influence of early posttransplantation prednisone and calcineurin inhibitor dosages on the incidence of new-onset diabetes. Clin J Am Soc Nephrol 2007; 2:517.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/40/26250/abstract/52\">",
"      Johnson C, Ahsan N, Gonwa T, et al. Randomized trial of tacrolimus (Prograf) in combination with azathioprine or mycophenolate mofetil versus cyclosporine (Neoral) with mycophenolate mofetil after cadaveric kidney transplantation. Transplantation 2000; 69:834.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/40/26250/abstract/53\">",
"      Weir MR, Fink JC. Risk for posttransplant Diabetes mellitus with current immunosuppressive medications. Am J Kidney Dis 1999; 34:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/40/26250/abstract/54\">",
"      Drachenberg CB, Klassen DK, Weir MR, et al. Islet cell damage associated with tacrolimus and cyclosporine: morphological features in pancreas allograft biopsies and clinical correlation. Transplantation 1999; 68:396.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/40/26250/abstract/55\">",
"      Schold JD, Kaplan B, Chumbler NR, et al. Access to quality: evaluation of the allocation of deceased donor kidneys for transplantation. J Am Soc Nephrol 2005; 16:3121.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/40/26250/abstract/56\">",
"      Johnston O, Rose CL, Webster AC, Gill JS. Sirolimus is associated with new-onset diabetes in kidney transplant recipients. J Am Soc Nephrol 2008; 19:1411.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/40/26250/abstract/57\">",
"      Prasad GV, Kim SJ, Huang M, et al. Reduced incidence of new-onset diabetes mellitus after renal transplantation with 3-hydroxy-3-methylglutaryl-coenzyme a reductase inhibitors (statins). Am J Transplant 2004; 4:1897.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/40/26250/abstract/58\">",
"      Miller J, Mendez R, Pirsch JD, Jensik SC. Safety and efficacy of tacrolimus in combination with mycophenolate mofetil (MMF) in cadaveric renal transplant recipients. FK506/MMF Dose-Ranging Kidney Transplant Study Group. Transplantation 2000; 69:875.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/40/26250/abstract/59\">",
"      Ciancio G, Burke GW, Gaynor JJ, et al. A randomized long-term trial of tacrolimus/sirolimus versus tacrolimus/mycophenolate mofetil versus cyclosporine (NEORAL)/sirolimus in renal transplantation. II. Survival, function, and protocol compliance at 1 year. Transplantation 2004; 77:252.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/40/26250/abstract/60\">",
"      Hjelmesaeth J, Hartmann A. Insulin resistance in patients with adult polycystic kidney disease. Nephrol Dial Transplant 1999; 14:2521.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/40/26250/abstract/61\">",
"      Ducloux D, Motte G, Vautrin P, et al. Polycystic kidney disease as a risk factor for post-transplant diabetes mellitus. Nephrol Dial Transplant 1999; 14:1244.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/40/26250/abstract/62\">",
"      de Mattos AM, Olyaei AJ, Prather JC, et al. Autosomal-dominant polycystic kidney disease as a risk factor for diabetes mellitus following renal transplantation. Kidney Int 2005; 67:714.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/40/26250/abstract/63\">",
"      Hamer RA, Chow CL, Ong AC, McKane WS. Polycystic kidney disease is a risk factor for new-onset diabetes after transplantation. Transplantation 2007; 83:36.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/40/26250/abstract/64\">",
"      Cosio FG, Kudva Y, van der Velde M, et al. New onset hyperglycemia and diabetes are associated with increased cardiovascular risk after kidney transplantation. Kidney Int 2005; 67:2415.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/40/26250/abstract/65\">",
"      Revanur VK, Jardine AG, Kingsmore DB, et al. Influence of diabetes mellitus on patient and graft survival in recipients of kidney transplantation. Clin Transplant 2001; 15:89.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/40/26250/abstract/66\">",
"      Jindal RM, Hjelmesaeth J. Impact and management of posttransplant diabetes mellitus. Transplantation 2000; 70:SS58.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/40/26250/abstract/67\">",
"      Friedman EA, Shyh TP, Beyer MM, et al. Posttransplant diabetes in kidney transplant recipients. Am J Nephrol 1985; 5:196.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/40/26250/abstract/68\">",
"      Cole EH, Johnston O, Rose CL, Gill JS. Impact of acute rejection and new-onset diabetes on long-term transplant graft and patient survival. Clin J Am Soc Nephrol 2008; 3:814.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/40/26250/abstract/69\">",
"      Wauters RP, Cosio FG, Suarez Fernandez ML, et al. Cardiovascular consequences of new-onset hyperglycemia after kidney transplantation. Transplantation 2012; 94:377.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/40/26250/abstract/70\">",
"      Lindholm A, Albrechtsen D, Fr&ouml;din L, et al. Ischemic heart disease--major cause of death and graft loss after renal transplantation in Scandinavia. Transplantation 1995; 60:451.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/40/26250/abstract/71\">",
"      Foley RN, Parfrey PS, Sarnak MJ. Epidemiology of cardiovascular disease in chronic renal disease. J Am Soc Nephrol 1998; 9:S16.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/40/26250/abstract/72\">",
"      Fern&aacute;ndez-Fresnedo G, Escallada R, de Francisco AL, et al. Posttransplant diabetes is a cardiovascular risk factor in renal transplant patients. Transplant Proc 2003; 35:700.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/40/26250/abstract/73\">",
"      Ducloux D, Kazory A, Chalopin JM. Posttransplant diabetes mellitus and atherosclerotic events in renal transplant recipients: a prospective study. Transplantation 2005; 79:438.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/40/26250/abstract/74\">",
"      Lentine KL, Brennan DC, Schnitzler MA. Incidence and predictors of myocardial infarction after kidney transplantation. J Am Soc Nephrol 2005; 16:496.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/40/26250/abstract/75\">",
"      Kuo HT, Sampaio MS, Vincenti F, Bunnapradist S. Associations of pretransplant diabetes mellitus, new-onset diabetes after transplant, and acute rejection with transplant outcomes: an analysis of the Organ Procurement and Transplant Network/United Network for Organ Sharing (OPTN/UNOS) database. Am J Kidney Dis 2010; 56:1127.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/40/26250/abstract/76\">",
"      Klein CL, Brennan DC. The tradeoff between the risks of acute rejection and new-onset diabetes after kidney transplant. Am J Kidney Dis 2010; 56:1026.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/40/26250/abstract/77\">",
"      Miles AM, Sumrani N, Horowitz R, et al. Diabetes mellitus after renal transplantation: as deleterious as non-transplant-associated diabetes? Transplantation 1998; 65:380.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/40/26250/abstract/78\">",
"      Owda AK, Abdallah AH, Haleem A, et al. De novo diabetes mellitus in kidney allografts: nodular sclerosis and diffuse glomerulosclerosis leading to graft failure. Nephrol Dial Transplant 1999; 14:2004.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/40/26250/abstract/79\">",
"      Markell M. Clinical impact of posttransplant diabetes mellitus. Transplant Proc 2001; 33:19S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/40/26250/abstract/80\">",
"      Burroughs TE, Swindle J, Takemoto S, et al. Diabetic complications associated with new-onset diabetes mellitus in renal transplant recipients. Transplantation 2007; 83:1027.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/40/26250/abstract/81\">",
"      Bergrem HA, Valderhaug TG, Hartmann A, et al. Undiagnosed diabetes in kidney transplant candidates: a case-finding strategy. Clin J Am Soc Nephrol 2010; 5:616.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/40/26250/abstract/82\">",
"      Schiel R, Heinrich S, Steiner T, et al. Long-term prognosis of patients after kidney transplantation: a comparison of those with or without diabetes mellitus. Nephrol Dial Transplant 2005; 20:611.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/40/26250/abstract/83\">",
"      Hollander AA, Hene RJ, Hermans J, et al. Late prednisone withdrawal in cyclosporine-treated kidney transplant patients: a randomized study. J Am Soc Nephrol 1997; 8:294.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/40/26250/abstract/84\">",
"      Woodward RS, Flore MC, Machnicki G, Brennan DC. The long-term outcomes and costs of diabetes mellitus among renal transplant recipients: tacrolimus versus cyclosporine. Value Health 2011; 14:443.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/40/26250/abstract/85\">",
"      Emre S, Genyk Y, Schluger LK, et al. Treatment of tacrolimus-related adverse effects by conversion to cyclosporine in liver transplant recipients. Transpl Int 2000; 13:73.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/40/26250/abstract/86\">",
"      Hoogwerf B, Danese RD. Drug selection and the management of corticosteroid-related diabetes mellitus. Rheum Dis Clin North Am 1999; 25:489.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/40/26250/abstract/87\">",
"      Kasayama S, Tanaka T, Hashimoto K, et al. Efficacy of glimepiride for the treatment of diabetes occurring during glucocorticoid therapy. Diabetes Care 2002; 25:2359.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/40/26250/abstract/88\">",
"      T&uuml;rk T, Pietruck F, Dolff S, et al. Repaglinide in the management of new-onset diabetes mellitus after renal transplantation. Am J Transplant 2006; 6:842.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/40/26250/abstract/89\">",
"      Lane JT, Odegaard DE, Haire CE, et al. Sitagliptin therapy in kidney transplant recipients with new-onset diabetes after transplantation. Transplantation 2011; 92:e56.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/40/26250/abstract/90\">",
"      Hirsch IB, Paauw DS. Diabetes management in special situations. Endocrinol Metab Clin North Am 1997; 26:631.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7327 Version 8.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-125.39.66.147-E2FE460E4C-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_40_26250=[""].join("\n");
var outline_f25_40_26250=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H28\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      DEFINITION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      INCIDENCE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      RISK FACTORS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Increased age",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Obesity",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Race and ethnicity",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Family history",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      HLA matching and donor characteristics",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Infection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Medications",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Glucocorticoids",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Calcineurin inhibitors",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Sirolimus",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Other agents",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Immunosuppressive combination regimens",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2159061289\">",
"      Underlying renal disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5971847\">",
"      Impaired glucose tolerance and perioperative hyperglycemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      CLINICAL IMPACT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Patient survival",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Allograft survival",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Infections",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Diabetic complications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H35235261\">",
"      Pretransplant screening",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H35235284\">",
"      Posttransplant screening",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Treatment",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      - Adjustment of immunosuppression",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H216879\">",
"      Glucocorticoids",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H216886\">",
"      Tacrolimus",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      - Oral therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      - Insulin therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H35235334\">",
"      - Monitoring patients with NODAT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/0/3078?source=related_link\">",
"      Alpha-glucosidase inhibitors and lipase inhibitors for treatment of diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/23/15734?source=related_link\">",
"      Amylin analogs for the treatment of diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/19/41272?source=related_link\">",
"      Benefits and complications associated with kidney-pancreas transplantation in diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/54/38758?source=related_link\">",
"      Diagnosis of diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/8/39048?source=related_link\">",
"      Estimation of cardiovascular risk in an individual patient without known cardiovascular disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/23/16761?source=related_link\">",
"      Hypertension after renal transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/35/43577?source=related_link\">",
"      Initial management of blood glucose in type 2 diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/20/24906?source=related_link\">",
"      Insulin therapy in adults with type 1 diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/24/30089?source=related_link\">",
"      Insulin therapy in type 2 diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/54/29546?source=related_link\">",
"      Lipid abnormalities after renal transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/47/27386?source=related_link\">",
"      Major side effects of systemic glucocorticoids",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/19/28986?source=related_link\">",
"      Management of persistent hyperglycemia in type 2 diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/26/38312?source=related_link\">",
"      Metformin in the treatment of diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/16/7434?source=related_link\">",
"      Patient selection for and immunologic issues relating to kidney-pancreas transplantation in diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/39/36472?source=related_link\">",
"      Renal transplantation in diabetic nephropathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/24/9610?source=related_link\">",
"      Risk factors for type 2 diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/46/35559?source=related_link\">",
"      Sulfonylureas and meglitinides in the treatment of diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/11/32954?source=related_link\">",
"      The metabolic syndrome (insulin resistance syndrome or syndrome X)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/50/21290?source=related_link\">",
"      Thiazolidinediones in the treatment of diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/4/21577?source=related_link\">",
"      Withdrawal or avoidance of glucocorticoids after renal transplantation",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f25_40_26251="Drug psychosis";
var content_f25_40_26251=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F50275&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F50275&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Drug toxicity and acute psychosis in children",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1\">",
"       Type of toxicity",
"      </td>",
"      <td class=\"subtitle1\">",
"       Substance",
"      </td>",
"     </tr>",
"     <tr>",
"      <td rowspan=\"5\">",
"       Drug overdose or abuse*",
"      </td>",
"      <td>",
"       Anticholinergic agents (eg, atropine, diphenhydramine, scopolamine)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Hallucinogens (eg, LSD, PCP, dextromethorphan, ketamine)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Marijuana",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Salvia divinorum",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Sympathomimetic agents (eg, cocaine, metamphetamine, ecstasy)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td rowspan=\"4\">",
"       Drug related syndrome",
"      </td>",
"      <td>",
"       Baclofen withdrawal",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Benzodiazepine (sedative) withdrawal",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Neuroleptic malignant syndrome (typical and atypical antipsychotic agents)&bull;",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Serotonergic agents (serotonin syndrome)&bull;",
"      </td>",
"     </tr>",
"     <tr>",
"      <td rowspan=\"4\">",
"       Drug induced psychosis&bull;",
"      </td>",
"      <td>",
"       Antibiotic-induced mania (amoxicillin, clarithromycin, erythromycin)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Anticonvulsants",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Corticosteroids",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Isoniazid",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     LSD: lysergic acid diethylamide; PCP: phencyclidine.",
"     <br>",
"      * Most common.",
"      <br>",
"       &bull; Psychosis associated with regular daily dosing of medication or medication class.",
"      </br>",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_40_26251=[""].join("\n");
var outline_f25_40_26251=null;
var title_f25_40_26252="Charlson risk index";
var content_f25_40_26252=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F72047&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F72047&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Charlson risk index",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Condition",
"       </td>",
"       <td class=\"subtitle1\">",
"        Assigned weights for diseases",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Myocardial infarct",
"       </td>",
"       <td>",
"        1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Heart failure",
"       </td>",
"       <td>",
"        1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Peripheral vascular disease",
"       </td>",
"       <td>",
"        1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cerebrovascular disease",
"       </td>",
"       <td>",
"        1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Dementia",
"       </td>",
"       <td>",
"        1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Chronic pulmonary disease",
"       </td>",
"       <td>",
"        1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Connective tissue disease",
"       </td>",
"       <td>",
"        1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Ulcer disease",
"       </td>",
"       <td>",
"        1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Mild liver disease",
"       </td>",
"       <td>",
"        1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Diabetes",
"       </td>",
"       <td>",
"        1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hemiplegia",
"       </td>",
"       <td>",
"        2",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Moderate or severe renal disease",
"       </td>",
"       <td>",
"        2",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Diabetes with end organ damage",
"       </td>",
"       <td>",
"        2",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Any tumor",
"       </td>",
"       <td>",
"        2",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Leukemia",
"       </td>",
"       <td>",
"        2",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Lymphoma",
"       </td>",
"       <td>",
"        2",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Moderate or severe liver disease",
"       </td>",
"       <td>",
"        3",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Metastatic solid tumor",
"       </td>",
"       <td>",
"        6",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        AIDS",
"       </td>",
"       <td>",
"        6",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_left\" colspan=\"2\" rowspan=\"1\">",
"        Weighted comorbidity classes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Low",
"       </td>",
"       <td>",
"        0 points",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Medium",
"       </td>",
"       <td>",
"        1 to 2 points",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        High",
"       </td>",
"       <td>",
"        3 to 4 points",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Very high",
"       </td>",
"       <td>",
"        &ge;5 points",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from: Charlson ME, Pompei P, Ales KL, et al. J Chron Dis 1987; 40:373.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_40_26252=[""].join("\n");
var outline_f25_40_26252=null;
var title_f25_40_26253="Chlamydial infection by gender";
var content_f25_40_26253=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F55053&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F55053&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Chlamydia - rates by gender: United States, 1984-1997",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 375px; height: 275px; background-image: url(data:image/gif;base64,R0lGODlhdwETAdUAAP///4CAgAAAAMDAwEBAQDAwMBAQEP8AACAgINDQ0PDw8ODg4KCgoICZ/1BQULCwsHBwcJCQkP8QEP+goGBgYMDN/0Bm/wAz//9AQP/w8P8wMP/Q0P+AgP9gYP/AwBBA//9wcP+wsP/g4P8gIP+QkDBZ/6Cz//Dz//9QULDA/+Dm/2CA/9DZ/3CN/1Bz/yBN/5Cm/3A8r7+MvwAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAACH5BAAAAAAALAAAAAB3ARMBAAb/QIBwSCwaj8ikcslsOp/QqHRKrVqv2Kx2y+16v+CweEwum8/otHrNbrvf8Lh8Tq/b7/i8fs/v+/+AgYKDhIWGh4iJiouMjY6PkJGSk5SVlpeYmZqbnJ2elgkRAQwKQgOnp0MPARELn6+whAKzAgRCtLNCEAIFBgauscHCeQwAC7kAs6gACgIGABECEKYB1QEDw9naagO7Abe1DtgDtQDktubWBN/b7e5gDATSQg4BFM4L5+blRdXv/wC1yMM2ZGACXgAeCHBgxF/AhxCZDCgQYJeAfBTvGSiFQMADBwKK9WMXsaRJIQsKzELwwJhKXgmEJFBpYFpDkidLbvCQAUAG/w8ihHjwkJOJw6IRQRzgAGDCARQAPBzQgFTJ0aoBQxzAAKDDAQkAOBwA4RMEhg4bhEzgEAIDiAwdMKSNisJtTw4TSJztCesqVoBfAUjQcGADhgNENUjgoDjo4REjvj4GoBWFUqgHpkbuEMvv33eHnWolIeEAgA1jKR8gAeBw1KWtTaNYyiEygK0+cffF+RlWiBBISBywrSEyVKlMkcd+zdT1YQ7QmerW/cpzb04iMEgAfgT107CZWQse4WF2WtfKXQtH4SEE5+lcd19/xUHCWyWlWXufu4HwiAlCoAeba2FF9h18nfE2HyYeaKABUQtaYV2EkmQAwmIUXjFhho6EIP8BBkFxWMWGIiaS3XbZKCBKNSK1QWKJhtR3Xzby0IKOiwrCeEiDD7bDCyoxufGijl6EAEJ0QyWZJBUWYugORXMMSeQWF0ZnFgZYZklYZlxmluWXGERXH4j/QICANS2yIeWUV4jgYIhR/KTkUCFYyd0/Nc5yo5o5srmFh2T5WUQCqAwQJI6CfnHhnYkOkQArwAjZZ6NTuKkBnJQCwAAtBhzKZ6ZYAAoqEQaI80ABDEk6ahWLrjqEAAQFsOcaa1KY11xRWIrpqgWcCUFNb9R6XQb1aYDCCB9yACETorpKRAIGzFJAKVSEMgq1CjBwrSqQHiHsXxt4xd4QIkzQAWFuhcD/lxGtOmuEoVfggo5K8hSgCy++RDrEt0i1Zd+uRGRg5GEadDBBiLq6O8QAChAKZBXFHCNAQgsBANIDzTwTjU0DqDNpbxmQABkJ6zbhAQfajYCCfQoTAWue/FDRjQDfBEAzADZfU44+6VSzDociXIgBo1NswFbLRASwgLZoWhHPPDnjTLM+PCf9MVLlHYAW0mEwQNADLV0x0MYA7BLBQfYqlKrVC06gGAclc+3Fz2XP+sREFc2ywDEIDNCRKx19FNJN820ggXhyg0EOLhVPkdJKYTPQEQIizeSMTSNdZziAiYeRAAEGIEAAAQ54SuvVEW3eORleR4n6Q6qvPoaKTauK/1UGI3Am+xgg2Rjs6/9kUPDuZEjzMvBh8JuN8LoTLwasv8j6O1LMO0+GAQw4gIABdqehvDAYUGX9GAwwAG2n0+d0btzjT/I9LOu3H8bo9I+O+acmxS8/GIzrmX5SEmDf/iTxvk5MQAK4GiA8rDGK/wXkgAlU4Bdg1j00FFATEJTgGBw2AOw58B1OiaAGxUC6D7oDA4gb4QLzVsEzXPASGTgAwFTIBZiFDVEACYH4aAgGDuoLf//oQAp56IVVtAIOL7QEAokIBos4w3RQWIAoIkCtQhEkId0i3D88MAIm8s9UpapCnuyVDFzcqxe/0OI7QBAoL3ahALFqIRMwpoCOYP9DGanIGDTm0TNZIc8TIxChG7EAgXXIah1pksLfyki6ceyMHx3z2R85YbhBzq1/clwC2SxmD3xQLWb7muQmONA8S2qBgw+bwi4oYASDIERtamyHBohmSiw86ohVAMmZroE3jXDEIyBJJM5EmQkRmKaWW9jULNBHBcYp7SUFCJLlgBVLbZAAKsjUQqkGcKq1AXEbKOBcNrEAKyFIz3bbiKEAxymFXlWEmjjchtvYmQVoSYta8dSGEOmpBXghkZiXkMAM+QkFBRTSATfM5zBC0EWCWsGGJgwGGx1qhZspoACZJEMSIRFIiuYybAHw5um2sYGGenQKFBAdARAguvt5D6D/lABBKU8KBZj575vCmCVNEbHRRogALDs9RE8Zcc2gChWmksCAOI06iKEqQp1MjeIpfohTWEwgPlFlggIoiM+qvgIFQ8wqEnah0o64VA1OTYRAxcoEAtyvkBH1hA7ZygQHFMBrA2AAquLaiQ60ka5IUAjjEjpSYXQUsEoYAAVGR4ErOm6K2NIWKbiFy8wFo6SIPcMYhUAvhJQNX2m0bCwmmtkkBKAjAjiTFehoR1heTI+bjKQfDUvL0gohGoyLABb+FrWcfRIdsqUbLH5qWySQDhgLcEBGNQm1m/n2kXZLayFIMNPiCuG4KFGuFVZ523mYDW0UE+kwg6GBpVq3u7nN/2VqqzEAvvntIgAIXDCr2QmonrcfqFVtFZypqclVjiZnHa9VsXlfPUh3EGAtMH5XglQtHFgQMlTwEHCLC92iU647lDB2jaHdC/eVKRK+rgOQ22GFcmKJId5jej28Ccym2Jz5bXAWHvwH0r7YDjT2A3luPKjJsjgTleQxEchhgAB09aWfoK6Qi9Ax4aJVxofQqZDz0d445HgPxlznfbcqryM/2RN6ETJZR2dWvlLCKeYNsVuJANcfVwLNS7YrXvUqXiRj8ABpTrFgcUHYL2cCzks2xWIJ0Nh//hnPgc7DlekA6ETjLMaGtkSjE01hWljYxJCYdKI3nNzlJvZQVqQsVf8FPAlNb3rE2fX0ER4VM8adMV/0dYSpKd2/S0uhRjfCIzZgy0e2SWLWjj4tg69QNT2JYx+24FlwoZwHYDu6C1Wrh0byAV1qSDISzn42ERgQ4LuB8rqwAi8sRduIbCeayqhYbBVC8SMF9NIZvxScMBetBnMn2maMU3UrcdFeaEoTwN5iNqMRrW0kdJB7ZNb3F+iNBg2EteBsvtE5MW2In2oZ4gs4VMbNPAiZQhwQDDcDij/eh5CTYZ4k94PJx6DUlKtc4HCwuMuNq3AxrDwMHp+5t2qePJi/YeQ6Z3Mt7MfxP0zApEEnAgWL7ocEJ93APmdDlp9eBIMSIAEIZTofSEn/9SL0TrF1tmDU17Djrr8qAgRostb1wFCzu+wBaS+hmwHhdLcDgAK+6Igw7VyIqdudGSCBJ8X/wPW/43jsaBhBbak+zW6L3RBtN3x8a6ESxD/h5lvoAIgN7xF68HzIh8rWtoRgxFFjPgsxHCjVG4gzVlbLZjfqLBl3gUaqnh4LRZU8AGz6bSfgmvQVe60z9njW219B8bqvW/3WPAWe9XZq1e6jkwHBxeRDmx/P11myIekxQmje+lzgGdm++8rG+ToQqQf/KaMBRwW4d5HyHRy5/5B79WMBZtiQXGr/e7mAD6K89mcMo8Z3fxBk9ncOjuVngOBXAcgMsiIAtkaAfZAB/2vVgEMwgGVgfFJwVfZnOX4TgQroBwCofmjUDZ+3BRoIBQYIfh6RdhPnVXnAgPZnAGj3AAjgeoNnBxSoen+Hb8qwdnBAAhmmfmiXdUDoBvbWORVQAScgBCxQASrgCK2TEH0mgXiQQQp0ARcAAwCgAlrYAI5AN22Wg3KAhVl4AS8AAC3whUJgAhZgAVyoAg2QAi1gAWDoB4uDC2HnQpanBR0AdIlzAiZQAUmAhheQAh/wAhcAhmvYAi6whRWghRbwARdgAn7wOaEzOqVzhGnQAYfVOSywAh9QAoSIBBdgAS7wAR/QAIsIAInYAKxoAZEIhinQin8whVbWh1egP3IjiP8l8AErwAJLcIq12AKsCIZoCIsNMIitOIuAQDsswollABcacHGjEoqjaAJNyASnCABMeIwA8IgNUAEmMI7NaIt+0Ds3RYZrIDzVyDW+CIzC+ATdKATgeAKieAGr6IzO+AfGMwDTF4JxIDwoYI2Ngo0loI3bAD0L8IKFJQfVMyoqsIQVkAKw+IvB+A7Yoz3cI41g0B/VdR0TuYQWqYxv+IaUqIUfcJJ2uIzb+A7lcz5QZIVsYDghCRAjWQHK2AAsmZL6yJI7mQIUGYXXMZMyUyhCIHo+FmtqYDgPJwgnUAEwAItCuYTzKAUUWY6w6AJvWAJa+JNvaIxUOZRT0jEEMYb/5GRGACB7SKCBsTMI5MiTlGgBKwCLLKmIX1kCJ+kCyliHKJmXb8iXsDiIS9gyBzELAUAvW6Br4WUxnceUZ3BAeZYHKmCRLuCVJcCXKUCUTECRcamMZNk+AVBk/raY4YAN2bcw3dcGSQgHKcCVP7mMpRhU0kMOjkcF0oYPqWlts8UGZqgHDfABMMCEdDWaBEAvzFdDsDJ+EOh/a/CbeHACFlACV1mcmNRPGQFv7wdfkCkGfyhIdcACL7ACLwlY6JZKWPA4MCEE+kc5bamLR+CJ4EkHJiCcFmha8FkEvJgHojib99mdXUCNBvkGJ1ACJVCe/zl/YeCOA+oGFQCMCWoV//lJkA3aBjDwAZYYofhJBhFZBuUolJzJBPj4AtWpoQCKBSBZBnI4ijw5iWA5liEKACyglwhqogrKBTZJBhWwAhewAv4pBBNZkn+5kna4ija6BA/mlGNgAr/YADHKBEHaAilwpEiKeG/pBSuakFQ6BtIlmWCwoz36o1u6cD53IpNJBUHaAE36pGNKplwgIxVaBGnaopRIpMvYpnyoBTyyLCJajkP6hjCKpzAIBU2yeUyAkHMIhYJKBxfkIWTSpxhZoovqOlVwIotXBAipkJOKB98Dp0sQjxm5qVAnBXu6BJlao6J6eIRaJUgQlRYZqan6ck/gqEHhqg1Qh155AXrZAv+aGqtvoJReFkpPIAMxMJ1auKuJiqq++gZs+Z5PoJNCqazLSgeu9ZgnOq1N5Vw3o5o+Y0gM9K3gGq7iOq7kWq7meq7omq7quq7s2q7u+q7omoAPsZu8qa6jk673eq75aq77Wq79Sq7/Oq4BK7De6q8FC7AHS7DoOrDhyrANm7DiKq8BwZwgKAW1siYYCzwZ6wQXq7Eey7Ef2wQdyyHbiYGXhzwbK7IhaxQry7Ig+7IqC7MuK7MU0p57Z7Eo27ISSrM7G7M8u6E+O7NCW6Un6zwjG7REi7Q9O7RJy7RA67TOqrRLKzup4ARVKxESewRXuwRbm1hZ+y5fC7ZWG7ZDRrb/C2O2poC25qC2a4utbvu2cDtOFOB6q6A0z8JeUDC3pFcNkXJLJnsEeotFS/koAWCUShC4q7CUdcu2QoC4o5eUXcsEjruUAEC4jLsq/sQM2pJQdasv+WC4zDA499AL5XR3qRWQSdAMxTC60ZJ/qQVrTqC6pqsSZKQQLGWtTSC7o+tZeYi7S6C7vOBZjYsMsSu6wUtGpis6+dkbrIYOFxW8NsG6pfu8cvQAG1FGChA1m7KHSWC9pTAL2Xsz0ZItAoCDc7QR4HUPxaASCQBeT+C96Ts4+bBHqga/CKG+wEe8TWC/9oK/2zs+v0d8k+cK4Bs1n9V7RLBxyVsA0+KY8mAA/2yrwPeAAAz8vQLgbgiMBBtHDvYSNcigv0ywwQhhwOxZvk8gwh1sUUUGwkuAwlLzDSDxwJcLKs43DwOxwA1MDrDnBOz3RLsHgdGAAFPQw+gzwYqpSLzQEd/wwRMzBR3RK9vKDNvzt0jwxEpsMfbCwk5gxTcjDxEQxM7DMxIDOuVExAlQRxBQNUpwELYQDbYAEnfUxFDAxvSrudUQxVH0xXAMAOOrR48VAXtcudsDukogRYBcTv3zx3u8x1osN1XzKPpXueXgxr2bwQnsDA9wD6y0vW4sBcdgAJlswqfAALAbBQ/QMZ51D3dsvlBwyjZDRh1Uvsrjyrx7Cj8oBbRMRv+cbMmGyX4MoykDABLT8MmhTAHuNgDsR8js2REGYMy6EC0EEKxMoH/NXAr4tolT8MDODHiz4ADS3FbOsM0+2MhLoM1HRs7lHM749Cu18M0tg39lpF/9pc4Lw8txe8/4nM/6vM/83M/+/M8AHdACPdAEXdDLOlUyUWUGLQg7rAC+4M4LjQd15BE2o1vZSzphU0iEFhMdkwC4GNFtYLue1QuJKQAx4SuhIzXRsrwgrQQ1EhNs3EnfYILRIjVV2NLcAEm1YA3ctBCnMjE2M8M47QVV4wteEwHaQjM2CNSlO9Rt8Mi9wxLPe7tSI9ROfdVYndVavdVc3dVe/dVgHdZiPdYOZF3WZn3WaJ3Wat11QQAAOw==);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This graph shows the increase in reported rates of chlamydial infection in the United States from 1984 through 1996.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from the Centers for Disease Control and Prevention (CDC).",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_40_26253=[""].join("\n");
var outline_f25_40_26253=null;
var title_f25_40_26254="Oxygen delivery in inspiration";
var content_f25_40_26254=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F79819&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F79819&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Oxygen delivery in inspiration",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 362px; height: 332px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Relation between oxygen delivery and dead space during tidal inspiration. Panel A) With a tidal volume of 450 mL, the first gas to arrive at the alveoli is the 150 mL of oxygen poor gas already occupying the dead space in the airways. This is followed by the first 300 mL of inspired gas expected to reach the alveoli. Panel B) The final 150 mL of inspired gas will fill the dead space at the end of inspiration but not reach the alveoli. Ideally, all oxygen delivery should occur prior to this last 150 mL.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Tiep BL. Continuous flow oxygen therapy and basis for improving the efficiency of oxygen delivery. In: Portable Oxygen Therapy: Including Oxygen Conserving Methodology, Tiep BL (Ed), Futura Publishing, Mt Kisco, New York, 1991.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_40_26254=[""].join("\n");
var outline_f25_40_26254=null;
var title_f25_40_26255="Generalized morphea - legs";
var content_f25_40_26255=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F68904&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F68904&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Generalized morphea on the legs",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 270px; height: 360px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Symmetric, hypopigmented, sclerotic plaques are present on the legs of this patient with generalized morphea.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_40_26255=[""].join("\n");
var outline_f25_40_26255=null;
